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Almost every woman will experience dysmenorrhoea at some time in her life, although the 
severity, duration and persistence of dysmenorrhoea vary widely. This thesis investigates 
the lived experience of women with severe dysmenorrhoea through observational studies 
of women’s symptoms, through laboratory studies investigating aetiologies for 
dysmenorrhoea, and by linking these studies to develop conclusions with strong 
translational relevance. While dysmenorrhoea may be associated with the more 
extensively researched medical condition endometriosis, this thesis is intentionally pain-
focused rather than endometriosis lesion-focused to ensure maximal translational 
potential to address the unmet needs of women with pain.  
 
In summary, this thesis addresses the differences between the one in five young women 
who suffer severe menstrual pain, and those women who are unaffected by pain. It 
investigates whether there is evidence for activation of the innate immune system in pelvic 
pain, and specifically Toll-Like Receptors (TLRs), and whether the hormonal environment 
influences this immune activation. It concludes with the novel hypothesis that a common 
aetiological factor linked to activation of Toll-Like Receptors within the uterus underlies the 
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PERSONAL STATEMENT  
 
Twenty years working as a gynaecologist caring for young women with endometriosis and 
pelvic pain have left me with one burning question: 
 
What is different about the one in five young women with severe 
dysmenorrhoea that sets them apart from unaffected women, and puts them 
at risk of a life of pain?  
 
In 1996 I completed my specialist training in Gynaecology with the primary aim of honing 
my surgical skills and becoming the best laparoscopic surgeon I could be. In those days, 
major advances in surgical technique were made frequently, and we had the naive idea 
that if we could just improve our surgery sufficiently, we could thereby cure pelvic pain. 
Over the following twenty years I realised that despite high quality surgery, many of my 
patients still had pain, with suffering that involved multiple symptoms both within and 
outside the pelvis. The gap between what was found during a laparoscopic examination 
and the symptoms women described was obvious. Girls who started their lives with severe 
dysmenorrhoea often progressed to a life of educational, personal, and financial 
disadvantage, in addition to their continued pain.  
 
Pain in women has been under-researched when compared to its life impact on those 
affected. This thesis seeks to advance knowledge of the mechanisms behind a hidden 






CHAPTER 1: INTRODUCTION 
 
In the middle of the flanks of women lies the womb, a female viscus resembling an animal; for 
it is moved of itself hither and thither in the flanks, also upward in direct line to below the 
cartilage of the thorax and also obliquely to right or left, either to the liver or spleen; and it 
likewise is subject to prolapses downwards, and, in a word, is altogether erratic. It delights 
also in fragrant smells and advances towards them; and it has an aversion to foetid smells 
and flees from them and, on the whole the womb is like an animal, within an animal. 
Arateus of Cappadocia. 2nd century AD 
Jenks EW. (1877) pp.10 
 
Menstrual difficulties, including dysmenorrhoea of varying severity, have been a woman’s lot 
through the ages. Metaphors for menstruation, such as ‘the curse’, aptly describe both the 
pain experience for a proportion of women, and the negative social and religious views of 
menstruation throughout history.  
 
The word pain derives from the Latin word poena i.e. punishment. This association between 
pain and wrongdoing has been the view across many societies for centuries, as outlined in 
the book ‘The story of pain: From prayer to painkillers’ by Joanna Bourke (2014). Pain was 
heaven sent and a punishment to accept. While the symptoms originally ascribed to the 
condition hysteria by the Ancient Greeks (Merskey, 1997), and now variably ascribed to the 
modern day Somatic Symptom Disorder (Diagnostic and statistical manual of mental 
disorders, 2013) do include non-pain symptoms, pain and menstrual maladies feature 
prominently. Indeed, the term hysteria derives from the Greek word hysteros meaning womb, 
and somatic symptom disorder (SSD) is a DSM-5 diagnosis that describes a cluster of patients 
who have distressing somatic symptoms along with abnormal thoughts, feelings, and 
behaviours in response to these symptoms. 
 
Consistent with this association of pain with wrongdoing has been the shame associated with 
menstrual bleeding. The Abrahamic Holy books (Bible, Torah and Qur’an) describe 
menstruating women as unclean: 
 
When a woman has her regular flow of blood, the impurity of her monthly period 
will last seven days, and anyone who touches her will be unclean till evening. 
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Anything she lies on during her period will be unclean, and anything she sits on 
will be unclean.  (Holy Bible, King James Version, Leviticus: 15:19) 
 
The combination of pain and bleeding in women has attracted only modest research interest 
over the years. Despite its severity, long history, and high prevalence, dysmenorrhoea has 
been under-researched, under-resourced and under-recognised when compared with many 
other medical or pain conditions (Coco, 1999; Proctor & Farquhar, 2007). The issues behind 
the lack of attention to pain conditions in women have been elegantly outlined in the recently 
published book Pain and prejudice by Gabrielle Jackson ( 2019). Jackson concludes that: 
 
Chronic pain works differently in male versus female brains, which is a problem 
because almost all of the pain research has traditionally been done using male 
cell lines, and male rodent and human participants (Jackson, 2009, p9) 
 
Jackson then quotes Janine Austin Clayton, associate director for women’s health research 
at the United States National Institutes of Health, in an interview for the New York Times 
(Rabin, 2014):  
 
The result is that we literally know less about every aspect of female biology 
compared to male biology (Rabin, 2014, p14) 
 
The present thesis seeks to address this large unmet human need by investigating the lived 
experience and aetiological mechanisms behind dysmenorrhoea and pelvic pain. It does so 
by considering the patient’s presenting symptom profile, the role of Toll-Like Receptor 4 
(TLR4) activation of the innate immune system, and the role of the hormonal milieu of women 
with dysmenorrhoea and chronic pelvic pain. While the interplay of pain with the closely 
associated, and more thoroughly researched, medical condition endometriosis is considered, 
this thesis specifically investigates dysmenorrhoea from a pain-based, rather than an 
endometriosis lesion-based, perspective. The majority of the current literature in this field 
describes the experience of women with surgically demonstrated endometriosis lesions. 
However, as dysmenorrhoea and pelvic pain may also be present in women without 
endometriosis lesions, this has limited application to the clinical management of women with 
pelvic pain in primary care settings.  
 
The topic is approached from a clinically relevant, pain-based perspective that is designed to 
provide the information required to support clinicians in their day-to-day management of girls 
and women with dysmenorrhoea in the real world. It addresses clinically relevant gaps in 
 13 
current knowledge that can prevent one in five young women reaching their full life potential. 
Although chronic pelvic pain may also occur in the absence of dysmenorrhoea, in pregnant 
women, or rarely even in men (Al-Obaidy & Idrees, 2019), this thesis will consider only pelvic 
pain associated with dysmenorrhoea in non-pregnant women. The laboratory research within 
this thesis considers girls aged 16-17 years and women aged 18-35 years, to ensure its 
relevance to the needs of young women.  
 
The present chapter defines dysmenorrhoea and chronic pelvic pain, provides a summary of 
the epidemiological data available, a description of the human and fiscal burden of 
dysmenorrhoea-related pelvic pain to individuals and society, and outlines the current theories 
for the mechanisms behind dysmenorrhoea and chronic pelvic pain. It justifies the need for 
research into the causes and implications of dysmenorrhoea in our society and throughout the 






1.1.1 THE DEFINITION AND CLASSIFICATION OF DYSMENORRHOEA 
Dysmenorrhoea is defined as pain associated with menstruation. Where no underlying 
medical condition has been diagnosed, it typically presents as painful spasmodic cramping in 
the lower abdomen at the time of menstruation, and is classified as primary dysmenorrhoea 
(Dysmenorrhea: Painful periods - ACOG, 2019). Where an underlying medical condition such 
as endometriosis has been diagnosed, pain symptoms are classified as secondary 
dysmenorrhoea (Figure 1.1, Figure 1.2). In particular, secondary causes of dysmenorrhoea 
include the medical condition endometriosis, where tissue similar to endometrium is present 
outside the uterus, and the related condition adenomyosis, where endometrial glands and 
stroma invade the myometrium of the uterus (Figure 1.3).  
 
However, in clinical practice, the differentiation between primary and secondary 
dysmenorrhoea is less useful. Dysmenorrhoea is a subjective symptom, and the pain 
symptom profiles associated with the different causes of secondary dysmenorrhoea may 
overlap within an individual. For example, a woman with uterine dysmenorrhoea may develop 
endometriosis lesions close to the rectum, resulting in pain on defecation during menstruation. 
In addition, the comprehensive exclusion of secondary causes of dysmenorrhoea requires 
assessment and examination by a skilled clinician, high quality imaging of the uterus to 
exclude adenomyosis, and visualisation or exclusion of endometriosis at a laparoscopic 
surgical intervention requiring general anaesthesia (Figure 1.4). This approach may not be 
available or acceptable to a young woman or her family. Consequently, clinical management 
when offered and where available for women is generally initiated empirically without 
knowledge of the presence or absence of underlying conditions. For the purpose of this thesis, 






Figure 1.3: Illustration of adenomyosis with endometrial glands and stroma sited within the 




Fig 1.4: Illustration of a laparoscopic surgical procedure where a telescope (laparoscope) is 
inserted through the umbilicus to view the pelvic organs.  
Reproduced with permission Ms K Skelsey 
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1.1.2 THE DEFINITION OF CHRONIC PELVIC PAIN 
 
Chronic pelvic pain (CPP) is variably defined as pain in the pelvis that has been either 
continuous or recurrent for longer than either three (Royal Australian College of 
Obstetrics and Gynaecology, 2020) or six months (European Association of Urology, 
2015). In particular, there is disagreement in the literature as to whether or not pain 
that is experienced exclusively during menstruation (dysmenorrhoea) should be 
included within the classifications of chronic pain conditions. For example, in 2012, 
The Royal College of Obstetricians and Gynaecologists (RCOG), in their Green-top 
guideline No.41 (RCOG, 2012), specifically excludes pain felt exclusively with 
menstruation from classification as a chronic pelvic pain. However, while the American 
College of Obstetricians and Gynaecologists (ACOG Committee, 2004) initially 
excluded pain experienced exclusively during menstruation from classification as a 
chronic pain, this guideline was later withdrawn and has yet to be replaced.  The 
current ACOG online consumer information, first published in 2011, includes 
dysmenorrhoea as a chronic pelvic pain condition (Chronic pelvic pain - ACOG, 2018).  
 
For the purpose of this thesis, CPP is defined as pain perceived in structures related 
to the pelvis, which has been continuous or recurrent for more than six months, 
including pain experienced exclusively during menstruation. 
 
Multiple medical conditions in both men and women are associated with the 
development of chronic pelvic pain. However, this thesis will consider only chronic 
pelvic pain in women where the symptom profile includes dysmenorrhoea, and where 
pain has been present on most days for more than 6 months. For convenience, this 




Insert Fig 1.5 and Fig 1.7  
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1.1.3 THE DEFINITION AND CLASSIFICATION OF ENDOMETRIOSIS 
Endometriosis is an estrogen-dependent, common, chronic inflammatory condition 
characterised by the presence of tissue displaying the histological features of endometrial 
glands and stroma outside the uterus. It is frequently, but not consistently, associated with 
symptoms of dysmenorrhoea and pelvic pain (Moen & Stokstad, 2002). When visualised at a 
laparoscopic surgical procedure, endometriosis lesions may appear clear, white, pink, red, 
yellow, brown or bluish-black (Donnez et al., 2003). The American Society of Reproductive 
Medicine (ASRM) describes 4 stages of endometriosis according to the severity and extent of 
lesions present (American Society for Reproductive Medicine, 1997), with Stage 1-2 being 
relatively mild, and Stages 3-4 more severe (Figure 1.5). However, this classification was 
developed for the purpose of estimating the chance of subsequent pregnancy, rather than as 
a way to determine the presence or severity of pain experienced by the women affected. 
 
Endometriosis lesions display a wide range of appearances (Figures 1.6a,1.6b and 1.6c).  
More recent studies have suggested that multiple aetiologies may contribute to variations in 
endometriosis phenotype with peritoneal lesions, deeply infiltrating lesions, and ovarian cystic 
lesions, potentially representing three separate disease processes (Gordts et al., 2017; 











1.1.4 CLINICAL IMPLICATIONS 
 
In clinical practice, dysmenorrhoea and chronic pelvic pain have traditionally been associated 
with the presence of endometriosis. However, the association of endometriosis with 
dysmenorrhoea and pelvic pain is inconsistent. Women may have endometriosis without pain, 
or may have pain without endometriosis (Fauconnier & Chapron, 2005). The American Society 
for Reproductive Medicine classification for the staging of endometriotic lesions during surgical 
procedures (American Society for Reproductive Medicine, 1997) correlates poorly with the 
severity of pain experienced (Vercellini et al., 2006). In addition, the removal of endometriosis 
lesions does not reliably reduce pain symptoms (Abbott et al., 2003). The lack of correlation 
between the presence of endometriosis and the experience of pain is further discussed in 
section 1.4. For these reasons, the association of endometriosis with dysmenorrhoea should 
not be considered to imply causation.  
 
While an endometriosis lesion-based approach to pelvic pain in women has made it easier to 
achieve consensus among researchers and clinicians, and has facilitated the development of 
management guidelines, this is of little use to a primary care clinician, caring for a girl or 
woman with dysmenorrhoea-related pelvic pain in medical practice. Laparoscopic surgery to 
diagnose or exclude endometriosis may or may not have been performed, and may or may 
not relieve symptoms (Abbott et al., 2003). In addition, there is currently no sufficiently reliable 
clinical or non-surgical biomarker to indicate which women may have endometriosis and might 
benefit most from surgery (Nisenblat et al., 2016), and which women would best be managed 
without surgery. Initial studies suggest that multiple symptomatology may be common in 
women with dysmenorrhoea (Ju et al., 2014b; Saidi et al., 2020; Smorgick et al., 2013; 
Zondervan et al., 2001). The subjective nature of dysmenorrhoea, the variation in presenting 
symptoms, and the lack of a clinical pain biomarker for endometriosis have hampered 
research into novel treatment options. Knowledge of the mechanisms behind her symptoms 
is incomplete. Grace and Zondervan found that 29% of 1160 women with chronic pelvic pain 
in a community-based study had received no diagnosis for their pain (Grace & Zondervan, 
2006). 
 
There is substantial overlap between the clinical presentations of dysmenorrhoea, chronic 
pelvic pain and endometriosis (Figure 1.7). Dysmenorrhoea may be present as a sole 
symptom in an otherwise well woman, as one of many symptoms in a woman with chronic 
pelvic pain, or may be present in association with endometriosis lesions. This thesis has 
chosen a pain-focused approach to dysmenorrhoea-related pelvic pain to better address gaps 
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1.2 THE EPIDEMIOLOGY OF DYSMENORRHOEA, CHRONIC PELVIC PAIN AND 
ENDOMETRIOSIS 
 
1.2.1 THE PREVALENCE OF DYSMENORRHOEA 
 
Dysmenorrhoea is the commonest gynaecological condition in young women (Coco, 1999). A 
meta-analysis of 15 community-based studies by Ju found the prevalence of dysmenorrhoea 
to be between 16% and 91% in women of reproductive age, with severe pain in between 2% 
and 29% of the populations studied (Ju et al., 2014a). Populations studied included women 
from Japan, China, the United States of America, Canada, Hungary, India, Mexico, Australia, 
the United Kingdom, Iran and Turkey. Societal, familial, medical and religious attitudes to 
menstruation mean that dysmenorrhoea may be disregarded or considered as normal, 
contributing to the above variations in reported prevalence. These attitudes may also have 
contributed to the scarcity of research to support the delivery of health care to women with 
dysmenorrhoea that is informed by basic science and clinical trials. Within an Australian 
setting, a study of 1051 girls aged 16-18 showed that while 93% of these girls experienced 
some pain with menstruation, 21% experienced severe pain, frequently associated with 
disruption of life activities and school absence (Parker et al., 2010). This prevalence far 
exceeds the prevalence of certain common health conditions for which there are long running 
and substantial government policy initiatives. For example, the frequency of asthma in 
Australia is 11%, and the frequency of diabetes is approximately 7% (Diabetes in Australia, 
2019).  
 
Dysmenorrhoea is more common where there is a family history of the condition, and less 
common with increasing years towards menopause (Sundell et al., 1990), increasing parity 
and increased use of the oral contraceptive pill (Andersch & Milsom, 1982; Ju et al., 2014a). 
 
1.2.2 THE PREVALENCE OF CHRONIC PELVIC PAIN 
 
The prevalence of chronic pelvic pain in women is unknown. International community-based 
estimates vary between 15% of 5,263 women aged 18-50 years in the USA (Mathias et al., 
1996), to 25.4% of women aged 18-50 years in New Zealand (Grace & Zondervan, 2006). 
This difference may reflect variation in the cohorts studied. Mathias et al. contacted potential 
participants through a Gallup Organisation telephone survey, whereas Grace and Zondervan 
used a questionnaire posted to a random sample of women on the New Zealand electoral roll, 
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with a 66% response rate. Saunders et al. (2007) investigated chronic pain conditions among 
2,466 children aged 11-17 years, and found that both the presence of multiple pain sites, and 
the presence of abdominal pain in a mother to be positive predictors for these symptoms in a 
child. This suggests that common genetic, environmental or socio-cultural factors may 
influence the prevalence of chronic pain. While chronic pelvic pain may be associated with a 
wide range of medical conditions, this thesis investigates only chronic pelvic pain (CPP) in 
non-pregnant women where the symptom profile includes dysmenorrhoea.  
 
1.2.3 THE PREVALENCE OF ENDOMETRIOSIS 
 
A definitive diagnosis of endometriosis requires visualisation of endometriosis lesions at a 
laparoscopic surgical intervention. The invasive nature, requirement for general anaesthesia, 
and variable availability of this intervention throughout the world, mean that prevalence 
estimates for endometriosis vary according to the population studied, their access to 
laparoscopic surgery, and their presenting symptoms. Data obtained through the Australian 
Longitudinal Study on Women’s Health found that 11% of women born between 1973 and 
1978 were diagnosed with endometriosis by the age of 40-44 years (Endometriosis in 
Australia: Prevalence and hospitalisations, Table of Contents - Australian Institute of Health 
and Welfare, 2019). In a study of 1,418 women undergoing their first laparoscopic surgical 
procedure for a variety of indications across ten countries and 19 centres, Nnoahem et al. 
(2009) found an incidence of endometriosis ranging from 35% in Oxford, England to 100% in 
Siena, Italy. Mueleman et al. (2009) diagnosed endometriosis in 47% of 221 women 
undergoing laparoscopy for infertility, where ovulatory function was normal and their partner 
had a normal semen analysis. Overall, estimates suggest that endometriosis affects 
approximately 5%-10% of girls and women during their reproductive years, which in 2011 
translated to represent 176 million women worldwide (Eskenazi & Warner, 1997). In a study 
of particular relevance to the pain focus of this thesis, Janssen found endometriosis lesions to 
be present in 62% of adolescent girls undergoing laparoscopy for the investigation of pain 
symptoms: 75% of 314 girls with chronic pelvic pain resistant to medical treatments, 70% of 
146 girls with dysmenorrhoea alone and 49% of 420 girls with chronic pelvic pain who had yet 
to try all medical management options (Janssen et al., 2013). 
 
While knowledge of the presence or absence of endometriosis can assist medical 
management, it does not necessarily result in interventions that resolve pain in an individual. 
High quality laparoscopic care may not be available or acceptable to young women and their 
families. In many parts of the world, clinicians are required to manage dysmenorrhoea and 
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pelvic pain without the potential benefits of easily accessible surgical interventions, or under 
circumstances where access to surgery is affected by a patient’s socioeconomic status 
(Fourquet et al., 2019). Where surgery is available, clinicians are required to advise on 
whether surgery is applicable in each individual’s case. The lack of an indicative symptom 
profile for endometriosis, and a reliable laboratory biomarker for either endometriosis (Gupta 
et al., 2016; Liu et al., 2015; Nisenblat et al., 2016a; Nisenblat et al., 2016b Nisenblat et al., 
2016c) or visceral pain, hampers clinical management of girls and women with 




1.3 HUMAN AND FISCAL BURDENS OF PELVIC PAIN 
 
1.3.1 THE HUMAN BURDEN 
 
Multiple studies have documented the dramatic effect of severe dysmenorrhoea on the lives 
of the girls and women affected, their families, their partners, their children, and their societies 
(Bajalan et al., 2018; Patel et al., 2006). The communities studied include girls and women 
from Europe, the United States, China, Japan, Australia, Iran, Saudi Arabia, Turkey, India, 
South Korea, Switzerland, Ethiopia, Israel and Italy. These effects include reduced school 
attendance, reduced quality-of-life, impaired daily functioning, an increased prevalence of 
mental health conditions, socio-economic disadvantage, and disrupted sleep. To date, there 
has been limited documentation of the long-term implications of dysmenorrhoea on wellbeing, 
and the potential for dysmenorrhoea to precede the development of chronic pain conditions.  
 
The severity of the pain experienced by women with dysmenorrhoea should not be under-
estimated. Zannoni  found that girls with dysmenorrhoea were 28 times as likely to miss school 
during menses than girls without dysmenorrhoea. 
 
Grandi et al. (2012) investigated the prevalence of dysmenorrhoea and its impact on daily 
functioning in a cross-sectional study of 408 Italian students. Their study found that 84.1% of 
these female students reported dysmenorrhoea, 55.2% reported dysmenorrhoea that required 
medication, 31.9% reported dysmenorrhoea resulting in absenteeism, and 25.3% reported 
dysmenorrhoea requiring both medication and school absenteeism. Estimated rates of school 
absenteeism at the time of menstruation range from 20% to 50% (Andersch & Milsom, 1982; 
Parker et al., 2010; Sundell et al., 1990). 
 
A strong and complex association between dysmenorrhoea and anxiety, stress and 
depression has also been found (Barnard et al., 2003; Chen & Chen, 2005; Dorn et al., 2009; 
Iacovides et al., 2015b; Reynolds, 1969). It has yet to be determined whether the mood 
disorder pre-dates dysmenorrhoea or is consequent upon the pain experience and its impact 
on quality-of-life. Facchin et al. (2015) used psychometric scoring to assess the quality-of-life, 
anxiety and depression scores of 110 women with endometriosis and 61 healthy controls. Of 
the women with endometriosis, 78 had pelvic pain, and 32 had no pain. Facchin et al. 
determined that it is the presence of pain rather than the presence of mental health issues 
that determines the impact of endometriosis on quality-of-life measures. 
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Similarly, the relationships between dysmenorrhoea, sleep and fatigue are multi-faceted. 
Woosley and Lichstein (2013) investigated the sleep patterns of 89 women aged 18-24 years 
using daily sleep diaries, and found that reduced sleep efficiency, as measured by a longer 
waking time after sleep onset and increased number of awakenings, was common both during 
menstruation and throughout the menstrual cycle in women with dysmenorrhoea. They found 
that those women with the most severe dysmenorrhoea suffered significantly higher Insomnia 
Severity Index scores (p<0.001) (Morin et al., 2011), when compared to women with mild 
dysmenorrhoea. Through its effect on absenteeism, sleep, and mood disorders, 
dysmenorrhoea may confer a profound educational disadvantage on those girls and women 
affected. Interestingly, despite these demonstrated dramatic reductions in quality-of-life, the 
perception of society that dysmenorrhoea is normal results in under-reporting of the condition 
in young women (Coco, 1999; Wong & Khoo, 2010). Wong studied 1,295 Malaysian female 
students and found that 76.1% of students believed that dysmenorrhoea was a normal part of 
the menstrual cycle. For 62.3% of these students, their mother was the primary source of 
information on menstruation.  
 
The severe clinical situation of chronic pelvic pain is also common and of long duration, as 
shown in the New Zealand study by Grace and Zondervan (2006). Chronic pain from any 
cause has a major effect on an individual’s quality-of-life, with wellbeing indicators 
progressively diminishing as the  duration of pain increases, and with increasing pain severity 
(Laursen et al., 2005). Sleep disturbance was present in 80% of 157 women with pelvic pain 
in a study by Cosar et al. (2014). 
 
In contrast to its high impact on individuals and society, dysmenorrhoea has only recently 
begun to come to the attention of health policy makers. Australia’s National Women’s Health 
Policy (2010) was developed as “a guide for the next 20 years to improving the health and 
wellbeing of all women in Australia, especially those at risk of poor health”.  It makes 
recommendations on eight specific areas, including five areas of direct relevance to 
dysmenorrhoea and pelvic pain: sexual and reproductive health, mental health, chronic 
conditions, risk factors for depression and anxiety, and the impact of comorbid conditions on 
physical and psychological health and social function. However, this Policy does not include 
the words dysmenorrhoea or period pain, and mentions pelvic pain only as a potential 
consequence of chlamydial pelvic infection (National Women’s Health Policy 2010).  This 
discrepancy between impact and health policy attention has been partially addressed in 2018 
with the development of Australia’s National Action Plan for Endometriosis (National Action 
Plan for Endometriosis, 2018). In 2019 Australia’s National Womens Health Strategy 2020-
2030 was released, with the inclusion of the stated objective “to reduce the prevalence and 
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impact of endometriosis and chronic pelvic pain” (National Australian Womens Health 
Strategy, 2020) 
 
When considering the qualitative experiences of 18 women after a diagnosis of endometriosis 
in their article “A life shaped by pain”, Huntington and Gilmour (2005) describe impacts 
affecting a woman’s ability to work, her family relationships and her self-esteem. The 
diagnostic process had typically taken five to ten years, and there had been no formal pain 
management follow up after the diagnosis was made, and treatment was undertaken.   
 
Gallagher compared Short Form-36 (SF-36) (Ware & Sherbourne, 1992) survey responses 
from 360 adolescents with endometriosis, and 207 healthy controls within the Women’s Health 
Study (Gallagher, DiVasta, et al., 2018). They found significantly lower physical health (43.4 
vs 53.8, p<0.0001) and mental health scores (43.3 vs 46.3, p=0.008) in the adolescents with 
endometriosis. Affected girls reported increased rates of mental health diagnoses, use of pain 
medication and avoiding exercise during menstruation.  
 
Pelvic symptoms associated with endometriosis include recurrent painful periods, painful 
intercourse, painful defecation during menstruation, chronic lower abdominal pain and 
hypersensitivity, chronic lower back pain, and infertility (Proctor & Farquhar, 2007). However, 
the symptoms experienced extend beyond the pelvis. Increasingly, the presence of extra-
pelvic symptoms such as migraine, fatigue and mental health in women with endometriosis 
have been recognised (Tietjen et al., 2007; Yosef et al., 2016). Simoens et al. (2014) estimated 
a 0.81 reduction in quality adjusted life years in 909 European women with endometriosis 
treated at tertiary referral centres. 
 
Predictors of depression, anxiety and stress in women with pelvic pain have been investigated 
in 168 Australian women by Brooks et al. (2020). Higher depression scores were associated 
with a higher current pain severity score, a history of stabbing pain, the prior experience of a 
sexually distressing event, having experienced pain as a child, and being nulliparous. Higher 
anxiety scores were associated with a higher current pain severity score, younger age, a 
history of stabbing pelvic pain, the prior experience of a sexually distressing event, and a 
younger age at menarche. Higher stress scores were predicted by a higher current pain 
severity, a younger age, a history of stabbing pains, and prior experience of a sexually 
distressing event.  
 
In summary, dysmenorrhoea and pelvic pain, regardless of the presence or absence of 
endometriosis, are associated with a reduced quality-of-life, increased prevalence of mental 
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health conditions, and severe sleep disruption. Section 1.4.4 will discuss the growing evidence 
that recurrent episodes of dysmenorrhoea may predispose women to the future development 
of chronic pain conditions, potentially through the mechanism of increased central pain 
sensitisation. If proven, this argues against the presence of dysmenorrhoea as a benign 
condition. 
 
1.3.2 THE FISCAL BURDEN 
 
The fiscal burden of dysmenorrhoea and pelvic pain affects both individuals and society as a 
whole. As outlined below, affected individuals suffer losses in educational achievement, incur 
direct health related expenses, and underachieve in workplace participation. Absolute costs 
are dependent on the inclusion criteria of the study, and whether or not both the direct medical 
costs, and the indirect personal costs borne by the individual, are included.  
 
In 1988, Dawood estimated that with an estimated 10%–30% of all working or studying women 
in the USA losing 1–2 working days per month due to dysmenorrhoea, this equated to an 
annual loss of 600 million working hours, or up to $US2 billion in business revenue (Dawood, 
1988). Personal costs borne by the individual include the impact on family income through 
reduced workplace participation, the direct costs of health care, impaired personal 
relationships, and reduced physical and emotional wellbeing (De Graaff et al., 2013). A US-
based study in 1996 estimated that annual direct medical costs for outpatient visits for chronic 
pelvic pain in women aged 18-50 years was $US881.5 million. Among 548 employed 
respondents, 15% reported time lost from paid work and 45% reported reduced workplace 
productivity (Mathias et al., 1996). 
 
In addition to the direct costs for providing health care to those affected, society suffers 
economic losses due to lost workplace productivity, lost caregiver workplace participation, and 
increased reliance of the individual on living assistance programs. The 2011 study by Bush, 
Evans and Vancaillie entitled The $6 billion woman and the $600 million girl: The Pelvic pain 
report estimated that pelvic pain costs the Australian economy $6.6 Billion annually (Bush et 
al., 2011).   
 
Pelvic pain is a frequent cause of emergency department presentation and hospital admission. 
However, accurate information regarding the utilisation of inpatient and emergency health 
services by girls and women with pelvic pain is hampered by poor data collection. For 
example, the justification for hospital admission recorded in health records may be for the 
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exclusion of pelvic inflammatory disease, or for the management of menstrual disorders, 
uterine fibroids, or ovarian cysts, rather than for the management of CPP (Velebil et al., 1995; 
Whiteman et al., 2010). Once in hospital, the reason for admission may be categorised 
according to the surgical procedure undertaken, rather than the medical condition diagnosed. 
 
In a 2011 European study of 909 women attending an endometriosis referral centre, Simoens 
et al. (2014) found that a diagnosis of endometriosis is associated with an average of 11 hours 
of lost workplace productivity per week. This study estimated an average annual cost per 
woman with endometriosis of €9,579 which included €6,298 in lost productivity and €3,113 in 
health care costs. Health care costs included surgery (29%), monitoring tests (19%), 
hospitalisation (18%) and physician visits (16%). In a 2017 US-based prospective study of 
113,506 women with endometriosis and 927,599 controls, the direct and indirect costs 
associated with a diagnosis of endometriosis were assessed. This study showed that in the 
12 months following study enrolment, costs associated with endometriosis patients ($16,573) 
were over three times higher than for matched non-endometriosis patients ($4,733) (Soliman 
et al., 2018). 
 
With regard to the direct costs for endometriosis-related inpatient hospital care in Australia, 
Medicare records reveal that over the 2016-2017 financial year, there were 34,200 
endometriosis-related hospital admissions (Endometriosis in Australia: Australian Institute of 
Health and Welfare, 2018). Seventy-nine percent of these inpatient care episodes were 
among girls and women aged 15-44 years. In 2019, accounting firm Ernst and Young released 
the comprehensive report entitled The cost of endometriosis in Australia (2019.), prepared in 
collaboration with endometriosis advocacy group EndoActive. This estimated the cost of 
endometriosis in Australia for the 2017/2018 financial year at AUD 7.4 Billion. 
 
In summary, dysmenorrhoea, pelvic pain and endometriosis are conditions with substantial 
worldwide economic impact, both on the individual affected and society as a whole (Hofmeyr, 
1996; Jones, 2004). When considering the age of those affected and the potential impact that 
health policy changes might achieve, the effective management of dysmenorrhoea-related 
pelvic pain offers an extraordinary opportunity to improve a country’s economy and workplace 
productivity.  
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1.4 THE AETIOLOGY OF DYSMENORRHOEA, CHRONIC PELVIC PAIN AND 
ENDOMETRIOSIS 
 
Overlapping, yet distinct, aetiologies have been advanced for the development of 
dysmenorrhoea, chronic pelvic pain and endometriosis.  
 
1.4.1 THE AETIOLOGY OF DYSMENORRHOEA 
 
The pain of dysmenorrhoea is commonly believed to be due to contraction of the uterine 
myometrium causing pain associated with ischaemia. Moir (1934)  demonstrated that an 
increase in intrauterine pressure to 120mm of mercury triggered feelings of heaviness and 
discomfort, with a loss of uterine vascular pulsations, while an increase in intrauterine pressure 
to 150mm of mercury was associated with severe pain. The discovery of prostaglandins in 
1935, and the subsequent research by Dawood et al. (1988), provided a mechanism for these 
contractions. Subsequent research has refined this concept. The enzyme cyclo-oxygenase 
that catalyses the formation of prostaglandins within the endometrium is inhibited by 
progesterone during the secretory phase of the menstrual cycle (Evans and Salamonsen, 
2012). Progesterone withdrawal following the resolution of the corpus luteum allows levels of 
cyclo-oxygenase to rise, enhancing prostaglandin production from its precursors. The release 
of prostaglandins and the closely related leukotrienes from within the uterus stimulates uterine 
contractions, myometrial ischaemia and pain.  
 
Ample clinical evidence supports this theory. Firstly, women with dysmenorrhoea have higher 
levels of prostaglandins in both the endometrium and their systemic circulation than women 
without dysmenorrhoea (Lundström et al., 1979). Secondly, women with dysmenorrhoea 
display higher levels of uterine contractility, and an increased number of uncoordinated 
contractions at menstruation, than women without dysmenorrhoea (Åkerlund, 1979; Dawood, 
1990).  Thirdly, these uncoordinated uterine contractions are associated with reduced 
myometrial blood flow and ischaemia (Altunyurt et al., 2005).  Fourthly, the release of 
prostaglandins at menstruation is consistent with additional systemic symptoms commonly 
reported by women during menstruation, including an elevated body temperature, diarrhoea, 
headaches, and sleep disruption (Hayaishi & Matsumura, 1995). Fifthly, the administration of 
prostaglandins vaginally or systemically induces uterine contractions, and systemic symptoms 
such as nausea, diarrhoea and vomiting (Coco, 1999; Dawood & Huang, 1998; Proctor & 
Farquhar, 2006). Finally, drugs known to block the conversion of arachidonic acid to 
prostaglandins, by inhibiting the enzyme cyclo-oxygenase, are effective in reducing menstrual 
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fluid prostaglandin levels (Dawood & Khan-Dawood, 2007), menstrual pain (Marjoribanks et 
al., 2015), and sleep disruption (Iacovides et al., 2009). These commonly prescribed non-
steroidal anti-inflammatory drugs (NSAIDs) include ibuprofen, naproxen, diclofenac, 
mefenamic acid, and celecoxib amongst others (Chantler et al., 2008, 2009). While NSAIDs 
are effective treatments for dysmenorrhoea in some, but not all, women with dysmenorrhoea, 
they may be associated with adverse effects including gastrointestinal bleeding (Campbell & 
Mcgrath, 1999; Oladosu et al., 2018; Owen, 1984). 
 
1.4.2 THE AETIOLOGY OF CHRONIC PELVIC PAIN 
 
Multiple medical conditions, some present in men as well as women, may pre-date CPP 
(Moore & Kennedy, 2000). This thesis investigates only those women with pelvic pain where 
dysmenorrhoea is a symptom. In a study of 3,916 women from the United Kingdom, 
Zondervan compared the rate of dysmenorrhoea among women who menstruated. 
Dysmenorrhoea was present in 81% of women with CPP, compared with only 58% of women 
without CPP (Zondervan et al., 2001). Anecdotally, women with CPP frequently describe a 
progression of symptoms over their menstrual life, with increasing days per month of pain, an 
increasing complexity of pain symptoms, and with dysmenorrhoea as their first pain symptom. 
The potential for severe dysmenorrhoea to progress to chronic pelvic pain over time has been 
considered by Hardi et al. (2014) using a retrospective questionnaire. One hundred women 
with CPP, where dysmenorrhoea was a symptom, were asked to report their age at menarche, 
their age when dysmenorrhoea began, and their age when pain transitioned from pain 
exclusively with menstruation (dysmenorrhoea alone) to pain on most days (CPP). Their study 
found that 16% of women transitioned from dysmenorrhoea to CPP within 12 months of 
developing severe dysmenorrhoea, while over 50% had transitioned within 12 years (Figures 
1.8a and 1.8b).   
 
In a survey questionnaire of 1,012 reproductive-aged women, Westling et al. (2013) 
considered a range of pain-related symptoms including dysmenorrhoea, non-cyclic pelvic 
pain, mood, fatigue and somatic complaints. They concluded that dysmenorrhoea is an 













Figure 1.8b: Time in years from menarche to transition to chronic pelvic pain 
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The mechanism by which dysmenorrhoea predisposes women to chronic pelvic pain 
remains unknown. The combination of abnormal visceral sensations across a range of pelvic 
viscera is consistent with viscero-visceral hyperalgesia, a phenomenon of central 
sensitisation (Giamberardino et al., 2010), and is discussed further in section 1.4.4. 
However, the mechanism by which this occurs requires further investigation. Jarrell and 
Arendt-Nielsen (2016) considered the development of CPP following dysmenorrhoea from 
an evolutionary perspective as a consequence of reduced fertility and recurrent 
menstruation. The increase in menstrual cycles experienced by women in the modern era is 
presented in Figure 1.9. Anecdotally, girls with severe dysmenorrhoea often report severe 






Figure 1.9: Estimation of total number of menstrual cycles and additional menstrual 
parameters experienced by women in modern and ancient times. Reproduced with permission 
(Jarrell & Arendt-Nielsen, 2016).   
 
In medical practice, dysmenorrhoea may be present as a primary condition, or in association 
with a range of diagnosable medical conditions, including endometriosis, adenomyosis, pelvic 
inflammatory disease, cervical stenosis, sub-mucosal uterine fibroids, and the use of intra-
uterine contraceptive devices. The clinical overlap of symptoms between these causes of 
secondary dysmenorrhoea is common. For example, adenomyosis, a condition where 
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endometrial glands and stroma are found within the myometrium of the uterus, shares similar 
symptomatology with endometriosis (Bird et al., 1972). In practice, despite the desirability of 
full clinical assessment, many women currently receive no diagnosis for their pain despite 
attending multiple medical consultations (Grace & Zondervan, 2006). Their management is 
empirical, based on their presenting symptoms, clinical examination, and the preference of 
their treating doctor.  
 
Of particular interest for the current thesis is the possibility that prolonged, repeated 
episodes of dysmenorrhoea, often with associated sleep disturbance, may have important 
long-term implications for the development of chronic pain symptoms in the future. Hunter et 
al. (2001) demonstrated that repeated episodes of pain are predictive of future pain 
experiences, and may predispose the patient to a range of pain conditions, including post-
surgical pain, over the individual’s lifetime (Katz & Seltzer, 2009). Schuh-Hofer et al. (2013), 
found that one night of sleep deprivation in healthy volunteers was sufficient to induce 
generalised hyperalgesia and increased anxiety scores, a finding confirmed by Moldofsky, 
Scarisbrick, and McBeth (McBeth et al., 2015; Moldofsky & Scarisbrick, 1976).  
  
1.4.3 THE AETIOLOGY OF ENDOMETRIOSIS 
 
Endometriosis is an ancient disease, and one which was described in European texts as early 
as 300 years ago (Knapp, 1999). It may also represent one of the medical conditions 
underlying the symptoms of hysteria, first described in the second millennium BC, the first 
mental health condition solely attributed to women (Tasca et al., 2012). 
 
Retrograde menstruation, where menstrual blood passes in a retrograde fashion along the 
fallopian tubes carrying viable endometrial cells to the peritoneal cavity, has been considered 
an important factor in the development of endometriosis since it was first described by 
Sampson in 1927 (Sampson, 1927).  “Sampson’s Theory” postulates that endometrial cells 
that reach the peritoneal cavity are deposited, implant, and develop into endometriotic lesions. 
This theory is supported by the higher prevalence of endometriosis in women with increased 
peritoneal exposure to menstrual fluid, through heavier menstrual loss, shorter menstrual 
cycles, or earlier menarche (Missmer & Cramer, 2003). However, retrograde menstruation 
does not fully explain the presence of endometriosis in all women. Retrograde menstruation 
occurs in up to 90% of women (Halme et al., 1984), yet endometriosis affects only an 
estimated 5%-10% of women. In addition, retrograde menstruation does not explain the rare 
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finding of endometriosis lesions present outside the abdominal cavity (Goldberg & Davis, 
2016).  
 
As a variant of Sampson’s theory, it has recently been suggested that pluripotent endometrial 
stem cells may spread to the peritoneal cavity following retrograde bleeding in the neonatal 
period with the withdrawal of maternal steroid hormones (Brosens et al., 2013; Gargett et al., 
2014).  While only 5% of female neonates exhibit vaginal bleeding, the presence of a cervical 
mucus plug may result in occult bleeding, with endometrial cells passed in a retrograde fashion 
to the peritoneal cavity without the passage of blood from the vagina. This potentially explains 
the uncommon situation of premenarchal endometriosis in girls with a normal reproductive 
tract, as documented by Marsh and Laufer (2005).  
 
An alternative “Theory of Coelomic Metaplasia” postulates that pluripotent mesenchymal cells 
present in the abdominal peritoneum exhibit endometrial differentiation. This theory, first 
proposed by Meyer (1924), has been further investigated by Ferguson and Figueira et al. 
(Ferguson et al., 1969; Figueira et al., 2011).  This theory provides an explanation for the 
development of endometriosis lesions outside the abdominal cavity, within the rectovaginal 
septum, in women with congenital absence of the uterus, and in the rare situation of 
endometriosis in men (Taguchi et al., 2012).  
 
The “Theory of Metastatic Lymphatic Spread”, where viable endometrial cells spread to distant 
sites via lymphatic channels, was first proposed by Halban in 1925, and discussed together 
with other theories in an article published by the Journal of the American Medical Association 
(1929) soon afterwards. It is supported by the finding of endometriotic tissue in lymph nodes 
by Mechsner and Berbic (Berbic et al., 2013; Mechsner et al., 2008). Intriguingly, the potential 
for lymphatic spread offers a rich opportunity for interaction between the endometrium and the 
innate immune system. The relationship between endometriosis and immune function is 
further outlined in Section 1.4.5.  
 
Genome-wide association studies have identified a large number of potential genetic loci 
associated with the presence of endometriosis (Borghese et al., 2017; Rahmioglu et al., 2015; 
Treloar et al., 2005), with the largest meta-analysis identifying 14 common genetic loci of 
particular interest (Sapkota et al., 2017). Associated processes implicate cell adhesion, 
angiogenesis, inflammation and hormonal pathways in endometriosis development, with the 




Epigenetic mechanisms acting via methylation may promote epithelial-mesenchymal 
transition (EMT) in endometrial lesions (Hsiao et al., 2017), which is further discussed below 
in section 1.5.3.  However, current studies suggest that a large number of genetic loci may 
predispose women to endometriosis, with each genetic locus affecting risk to a small degree, 
but with no single gene responsible. Unfortunately, genetic studies have rarely been correlated 
with reported symptoms, including pain (Sapkota et al., 2017). Gao et al. (2019a) investigated 
a cohort of 3,406 Swedish women born between 1933 and 1972, and found a lower birth 
weight for gestational age among the 111 women subsequently diagnosed with endometriosis 
(hazard ratio 1.35 per standard deviation decrease; 95% CI 1.08 to 1.67), providing support 
for the presence of developmental aetiological factors. 
 
Irrespective of the origin of endometrial cells, the presence of other factors appears necessary 
to allow endometriosis lesions to develop in individual women. Other factors potentially of 
importance include a favourable endocrine, immune or inflammatory environment, or reduced 
clearance and increased persistence of endometrial cells within the peritoneal cavity. 
 
Environmental factors, including increased levels of organochlorines, have been proposed to 
increase the prevalence of endometriosis lesions. Heilier et al. (2005) investigated 25 women 
with peritoneal endometriosis, 25 women with deep endometriotic nodules and 21 control 
women. They found increased levels of polychlorinated dibenzo-p-dioxin (PCDD), 
polychlorinated dibenzofuran (PCDF), and polychlorinated biphenyl (PCB) serum 
concentrations in women with endometriosis than controls, with an odds ratio of 3.3. However, 
other studies have reported conflicting results, as summarised by Heilier et al. (2007). They 
observe that the presence of these organochlorines is not sufficient for the development of 
endometriosis, as endometriosis was present through history prior to the development of these 
chemicals, and that not all women exposed to high levels of organochlorines develop 
endometriosis. 
 
In summary, while mechanisms for each condition have been proposed, much remains 
unknown regarding the aetiology of dysmenorrhoea, chronic pelvic pain, and endometriosis, 






1.4.4 THE ROLE OF PERIPHERAL AND CENTRAL PAIN SENSITISATION IN 
DYSMENORRHOEA, CHRONIC PELVIC PAIN AND ENDOMETRIOSIS 
 
Central sensitisation represents a heightened responsiveness to normal peripheral inputs 
(Woolf & Salter, 2000; Woolf, 2007), presenting as an amplified pain response. It may develop 
in the absence of peripheral tissue injury or inflammation, as in the central pain sensitisation 
of fibromyalgia or tension headache syndromes (Yunus, 2007, 2008), or develop following 
repeated episodes of peripheral pain (Apkarian et al., 2005; Bajaj et al., 2002; Hermann et al., 
2008). The repeated monthly experience of dysmenorrhoea, with peripheral prostaglandin 
release, severe stress, disrupted sleep, and reduced quality-of-life, provides a potent 
environment for the development of central sensitisation, and the evidence that this occurs is 
compelling.  
 
Women with dysmenorrhoea display increased pain perception throughout the menstrual 
cycle at sites both within and outside the pelvis, to a variety of stimuli, when compared with 
controls (Bajaj et al., 2002; Granot et al., 2001; Iacovides et al., 2013; Jarrell & Arendt-Nielsen, 
2016; Slater et al., 2015; Smorgick et al., 2013). The central nature of pain in women with 
dysmenorrhoea has also been suggested by initial functional magnetic resonance imaging 
(fMRI) studies, where changes to gray matter within the brain of women affected by pain were 
noted (Vincent et al., 2011).  
 
Vincent et al. investigated 10 women with dysmenorrhoea and 10 pain-free controls. During 
menstruation, deactivation of brain regions in response to noxious stimulation was observed 
in control women but not in women with dysmenorrhoea (Figures 1.10a and 1.10b). When the 
women were not menstruating, activity in the entorhinal cortex appeared to mediate increased 





Figure 1.10a: Comparison of response to a noxious thermal 
stimulus of the left arm and midline lower abdomen during 
menstruation in women with dysmenorrhoea and control 
women with no pain. Areas of activation are shown in yellow, 
and areas of deactivation are shown in blue. Reproduced with 












Figure 1.10b: Summary of regions deactivated by noxious thermal stimulation of the left arm 
and midline lower abdomen in women with and without dysmenorrhoea during the menstrual 






Jarrell & Arendt-Nielsen (2016) considered that evolutionary human reproductive factors 
associated with increased menstrual exposure, including early menarche and delayed 
childbearing, may predispose women with dysmenorrhoea to transition to chronic pelvic pain 
through the repeated experience of menstrual pain. Sinaii et al. (2002) found a higher 
prevalence of both fibromyalgia symptoms and chronic fatigue syndrome in women with 
endometriosis when compared with controls. Fibromyalgia and chronic fatigue syndrome are 
both medical conditions that are associated with central pain sensitisation (Fleming & 
Volcheck, 2015; Woolf, 2011). 
 
Clinically, the presence of central sensitisation provides a rationale for multiple and complex 
symptom profiles, possibly via the twin mechanisms of viscero-visceral and viscero-somatic 
hyperalgesia. Viscero-visceral hyperalgesia occurs where pain conditions in one visceral 
organ enhance the likelihood of pain symptoms in a second visceral organ with which it shares 
a common central projection pathway in the spinal cord (viscera-visceral convergent neurons). 
The uterus, colon and bladder share central projection pathways via the dorsal horn of T10-
L1 spinal segments (Giamberardino et al., 2006), and an association between pain symptoms 
in these organs has been demonstrated. Hellman found significantly more urinary symptoms 
and bladder filling pain in women with severe dysmenorrhoea when compared with 
dysmenorrhoea-free controls (Hellman et al., 2018). Brinkert et al. (2007) used anal 
manometry to demonstrate significantly lower colonic distension volume pain thresholds in 
women with severe dysmenorrhoea when compared with dysmenorrhoea-free controls In 
addition, Chaban et al. (2012) used retrograde labelling of sensory afferent nerves in a rat 
model to demonstrate that in a proportion of cases, a single sensory afferent nerve may 
innervate both the uterus and the bowel, providing even more opportunity for trans-visceral 
sensitisation (Figure 1.11). 
 
Viscero-somatic hyperalgesia occurs where pain conditions in a visceral organ are associated 
with pain symptoms in the somatic tissues (skin, muscle, tendon or joint) with which it shares 
a common central projection pathway in the spinal cord (viscera-somatic convergent neurons). 
Long-lasting somatic pain sensitisation has been demonstrated in women with severe 
dysmenorrhoea by Iacovides et al. (2015a). Women experienced a significantly increased 







Figure 1.11: Models of alternative possibilities for viscero-visceral cross-sensitisation in the 
DRG neuron. (a) ATP released by a neuron innervating the inflamed uterus acts on a 
neighbouring neuron sensitising its responses to colonic distention. (b) The same neuron 




Viscero-visceral and viscera-somatic hyperalgesia fit well with the potential for additional pain, 
or pain-related, symptoms in women with dysmenorrhoea (Chaban, 2013, 2015; 
Giamberardino, 1999, 2003; Giamberardino et al., 2010). Researchers have sought to 
elucidate whether sensitisation predates the transition from dysmenorrhoea alone to chronic 
pain, or develops during the transition period. Dysmenorrhoea alone is variably classified or 
excluded as a chronic pain condition in clinical practice, due to variable interpretations of the 
definitions of chronic pain. Despite the clinical ambiguity, somatic muscle pressure testing (Tu 
et al., 2009; Tu et al., 2012), and fMRI (Vincent et al., 2011) support the presence of central 
sensitisation in women with dysmenorrhoea who are otherwise well. Tu et al. compared 19 
women with CPP and 12 pain-free controls, and demonstrated a reduced pressure pain 
threshold at external sites such as hip, knee or shoulder, in women with pelvic pain. Vincent 
(2011) found that control women, but not those with dysmenorrhoea, displayed deactivation 
of areas of the brain during menstruation that may be protective from dysmenorrhoea. These 
fMRI findings suggest that women with dysmenorrhoea have both amplified pain facilitation 
and impaired pain inhibition. Similar fMRI findings have been found in patients with Irritable 
Bowel Syndrome by Chen et al. (2011) and Blackstein et al. (2010), and by  Woodworth et al. 
(2018) in patients with urologically-based chronic pelvic pain. These studies further support a 
role for central sensitisation in visceral pain syndromes. In an elegant study of cutaneous 
temporal pain summation in 18 women with chronic pelvic pain and 18 pain free controls, 
Thompson et al. (2019) assessed the pain scores reported following 3 strokes of a cotton tip 
swab on the abdomen. Women with pelvic pain and allodynia showed significantly increasing 
pain with successive strokes of the cotton tip swab: (p = 0.012 for strokes 1 vs. 2, p = 0.026 for 
strokes 2 vs. 3, and p = 0.005 for strokes 1 vs. 3). This effect is consistent with the wind-up 
phenomenon found in association with central pain sensitization, where there is an increase 
in pain intensity over time when a given stimulus is delivered repeatedly above a critical rate. 
 
With regard to the presence of central sensitisation in women with endometriosis, As-Sanie et 
al. (2012) used functional MRI to investigate the relationship between the presence of 
endometriosis lesions and the experience of chronic pelvic pain in 61 women divided into four 
groups: 17 with endometriosis and CPP, 15 with endometriosis but no CPP, 6 with CPP but 
no endometriosis, and 23 healthy controls. When the volumetric assessment of brain gray 
matter was compared between the groups, women with CPP showed decreases in gray matter 
volume in the left thalamus, regardless of whether or not endometriosis was present. Women 
with endometriosis but without CPP showed similar gray matter volumes when compared with 
normal controls. This finding further dissociates the presence of endometriosis lesions with 
the experience of chronic pelvic pain. While the conditions are commonly associated, they 
should not be considered as causal in nature.  
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At the level of peripheral tissues, there are several mechanisms by which chronic peripheral 
nociceptive input (e.g. dysmenorrhoea) may increase responsiveness of dorsal horn neurons 
and promote peripheral or central sensitisation. Normally present nociceptors may become 
activated, silent nociceptors may be sensitised by inflammation, or there may be a sprouting 
of new nociceptors resulting in a greater total number of nociceptors (Evans et al., 2007; 
Mckinnon et al., 2015).  
 
The central mechanisms contributing to central sensitisation are less easy to assess. 
Extensive investigation of pain thresholds to a variety of painful stimuli in women with 
dysmenorrhoea have been inconclusive. Iacovides (2015b) summarised these studies and 
the possible reasons for their inconsistent outcomes. Variations were seen in menstrual cycle 
phase, the measurement of gonadal hormones, the presence or absence of dysmenorrhoea 
at the time of testing, and the choice of pain stimuli used. Despite the difficulties encountered, 
Iacovides concludes that: 
 
When taken together, the majority of recent studies that have considered tissue 
depth, areas within and outside of the referred area of pain and controlled for 
menstrual cycle phase, have shown that across the menstrual cycle, 
dysmenorrheic women are hypersensitive to experimental pain compared with 
controls (Iacovides et al., 2015b, p766) 
 
Whether sleep disruption pre-dates the development of dysmenorrhoea or chronic pain is yet 
to be determined. While pain may disrupt sleep, it is also recognised that a poor night’s sleep 
may pre-date a day of increased pain (Cosar et al., 2014; Gupta et al., 2014; Harrison et al., 
2016), and that the relationship of pain to sleep may be bi-directional. Schwertner found a 
39% reduction in daily pain scores and a 38% reduction in dysmenorrhoea in women with 
endometriosis treated with melatonin to improve sleep quality, when compared with untreated 
controls (Schwertner et al., 2013).  
 
Despite the compelling evidence for central and peripheral sensitisation of pain and the 
beginnings of a multi-disciplinary approach (Jarrell et al., 2005, 2018), clinical practice 
continues to rely almost exclusively on either the surgical excision of endometriosis lesions, 
or hormonal suppression when managing dysmenorrhoea or pelvic pain (Johnson et al., 2013; 
Leyland et al., 2010; Taylor et al., 2012). 
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1.4.5 THE ROLE OF INFLAMMATION AND THE IMMUNE SYSTEM IN 
DYSMENORRHOEA, CHRONIC PELVIC PAIN AND ENDOMETRIOSIS 
 
This thesis seeks to describe and understand new mechanisms for dysmenorrhoea and pelvic 
pain. The role of inflammation offers a potential new approach to our understanding of these 
conditions, with an evolving, but not yet established, evidence base. Normal menstruation has 
been described as an inflammatory event (Evans & Salamonsen, 2012), due to the 
endometrial edema, influx of leukocytes (Berbic et al., 2014), and subsequent breakdown of 
tissue that occurs prior to and during menstruation. The leukocytes found within the 
endometrium include macrophages, mast cells, dendritic cells, neutrophils, eosinophils and 
regulatory T-cells (Berbic et al., 2014): all cells of the innate or adaptive immune system with 
the ability to secrete neurostimulatory factors that may sensitise neurons and modulate the 
experience of pain (Evans & Salamonsen, 2012). Following extensive research, Evans and 
Salamonsen conclude that with normal menstruation: 
 
A cascade of events is initiated by progesterone withdrawal achieving a threshold 
of inflammation after which tissue destruction is inevitable. Progesterone 
withdrawal sits at the summit of this cascade leading to removal of protective 
mechanisms, induction of cytotoxic signals, activation of inflammatory signaling 
pathways (NF-κB) proceeding to production of inflammatory factors (chemokines, 
cytokines and prostaglandins), recruitment of inflammatory leukocytes and 
protease activity (Evans & Salamonsen, 2012, pp284-285) 
 
However, while all women menstruate, and therefore experience a certain degree of 
inflammation within the uterus on a monthly basis, only a proportion of women suffer severe 
pain. The potential for excessive inflammation to cause menstrual dysfunction, including 
dysmenorrhoea, must involve additional factors.  
 
Human studies consistently demonstrate evidence of an association between inflammation, 
immune factors, and the presence of dysmenorrhoea, pelvic pain or endometriosis. Clinically, 
this is reflected in the ubiquitous use of non-steroidal anti-inflammatory medications for the 
clinical management of symptoms. In a Cochrane meta-analysis of 80 randomised controlled 
trials with 5,820 women, Marjoribanks et al. (2015) found that between 38% and 45% of 
women using a non-steroidal anti-inflammatory drug (NSAID) received moderate or excellent 
relief of dysmenorrhoea, compared with only 18% of women taking placebo. 
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Inflammation acts via the increased cell secretion of cytokines, small peptides or proteins that 
affect the function of other cells. Cells able to secrete cytokines include, among others, the 
glandular cells of the endometrium (Hannan et al., 2011), glial cells of the central nervous 
system, and the macrophages found in peritoneal fluid and peripheral blood.  Cytokines 
regulate T-cell functions including the initiation and maintenance of pain (Scholz & Woolf, 
2007; Sommer et al., 2018; Sommer & Kress, 2004). Altered cytokine production in peripheral 
tissues, infiltrating leukocytes, and non-neuronal (glial) components of the CNS can become 
drivers for activation of the immune system (Bayas et al., 2002; Ledeboer et al. 2005; Cao & 
DeLeo 2008; Milligan & Watkins 2009). Ma et al. (2013) studied monocytes in the peripheral 
blood of women with dysmenorrhoea, and found up-regulation of genes coding for pro-
inflammatory cytokines, and down-regulation of genes coding for anti-inflammatory 
responses. These changes were present throughout the menstrual cycle, and not only at 
menstruation. 
 
Immune system changes in women with endometriosis were first considered in the 1980s, 
when abnormal polyclonal B-cell activation (Gleicher et al., 1987), and increased numbers of 
T- and B- lymphocytes in peritoneal fluid and peripheral blood compared with controls, were 
discovered (Badawy et al., 1987). High serum concentrations of IgG and IgM autoantibodies 
to endometrial cells (Wild & Shivers, 1985) in women with endometriosis were described. 
Epidemiologically, women with endometriosis are known to have a higher risk of developing 
auto-immune inflammatory disorders including systemic lupus erythematosis (SLE), Sjögren’s 
syndrome, multiple sclerosis, and rheumatoid arthritis (Harris et al., 2016; Nielsen et al., 2011). 
These autoimmune conditions are all associated with the presence of pain and elevated levels 
of cytokines (Nothnick, 2001).  
 
Trabert et al. (2011) found a 22% reduction in a subsequent diagnosis of endometriosis over 
the next ten years in women who ate a diet high in anti-inflammatory omega-3 fatty acids, 
when compared with a diet low in omega-3 fatty acids. However, inflammation and pain may 
be present without endometriosis lesions. Thomson and Redwine (2005a) investigated the 
histological findings from peritoneal biopsies in 3,238 women undergoing laparoscopy. In the 
24% of women where no endometriosis was found, chronic peritoneal inflammation was 
present in 15.7% of women with pain, compared with 0.0% of women without pain. Thomson 
further described the clinical findings in a subsequent group of 40 women with chronic pain, 
endometriosis excluded and either histological or serological evidence of inflammation Of 
these women, eleven women were treated with the immune-modulator medication 
hydroxychloroquine, with 9 describing a resolution of pain symptoms, and 2 describing an 
80% reduction in pain symptoms.  
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Endometriosis is now described as a chronic inflammatory disorder (Lousse et al., 2012). 
Endometriosis is associated with an increased presence of macrophages within the peritoneal 
cavity of affected women, higher levels of macrophage derived cytokines, and impaired 
macrophage phagocytic activity (Wu et al., 2005). In a further association between 
endometriosis and inflammation, Cicinelli found a higher prevalence of chronic endometritis in 
women with endometriosis compared to healthy controls. Thirty-three of 78 (42.3%) affected 
women vs. 12 of 78 (15.4%) healthy controls showed signs of endometritis according to 
hysteroscopy. Thirty of 78 (38.5%) affected women vs. 11 of 78 (14.1%) healthy controls 
showed signs of endometritis according to histology (Cicinelli et al., 2017).  
 
The cytokines and neurotrophic factors that have been most researched and associated with 
dysmenorrhoea, pelvic pain and endometriosis include Interleukin 1-beta (IL-1β), tumour 
necrosis factor-alpha (TNF-α), and Nerve Growth Factor (NGF). Interleukin 1-beta (IL-1β) is 
an acute phase inflammatory cytokine released by mononuclear and epithelial cells in 
response to injury that leads to inflammation. Scholl et al. (2009) investigated peritoneal fluid 
sampled at laparoscopy, and found a correlation between levels of IL-1β and both the severity 
of endometriosis lesions present, and the severity of pain reported. Sikora et al. (2012, 2015)  
found higher levels of IL-1β in the peritoneal fluid and the blood of women with endometriosis.  
 
Tumour necrosis factor alpha (TNF-α) is produced by activated macrophages, natural killer 
(NK) cells, and T-helper-1 (Th1) cells (Cameron & Kelvin, 2003). It acts synergistically with IL-
1β to activate the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
inflammatory pathway. The ability of TNF-α to induce neuropathic hyperalgesia (Sommer & 
Kress, 2004) and to contribute to chronic inflammatory pain (Pezet & McMahon, 2006) is well 
established. It has been suggested that TNF-α is one of the essential factors for the 
pathogenesis and maintenance of endometriosis (Bullimore, 2003). Consistently raised levels 
of TNF-α have been found in the peritoneal fluid and eutopic endometrium of women with 
endometriosis (Eisermann et al., 1988; Pizzo et al., 2003; Salmeri et al., 2015).  
 
Nerve Growth Factor (NGF) is a neuropeptide involved in the growth and survival of neurons. 
Alterations in NGF expression are known to contribute to chronic inflammatory pain (Pezet & 
McMahon, 2006). An increase in NGF expression has been demonstrated in patients with 
painful bladder symptoms (Jacobs et al., 2009), and intense immune-reactivity for NGF has 
been reported in both eutopic endometrium and peritoneal endometriotic lesions (Tokushige 
et al., 2006; 2007; 2008; 2010; 2011; Wang et al., 2009).  
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In a further potential mechanism associating cytokines with dysmenorrhoea, both TNF-α and 
IL-1β are capable of inducing cyclooxygenase-2 (COX-2) expression, with potential for 
increased prostaglandin E2 (PGE2) production (Wu et al., 2010). A positive feedback cycle 
then results, with increasing PGE2 inducing COX-2 expression, resulting in further increases 
in PGE2 with inflammation and pain. Despite the consistent findings relating IL-1β, TNF-α and 
NGF to both pain and endometriosis, levels of these cytokines in blood have not reliably 
correlated with the severity of pain symptoms or the severity of endometriosis (Overton et al., 
1996).  
 
In summary, studies to date have investigated inflammation and immunity in the periphery by 
investigating peripheral blood, peritoneal fluid, eutopic endometrium, and endometriotic 
lesions. Measurable changes have been found. However, these do not reliably correlate with 
a woman’s experience of pain, nor provide a reliable way of predicting the presence or 
absence of endometriosis. Additional factors apart from the presence or absence of 
endometriosis appear to drive a woman’s lived experience of pain. Research has been 
endometriosis lesion-focused rather than pain-focused, and new treatments specifically 
targeting inflammation in pelvic pain are yet to be developed. The potential for novel clinical 
management discoveries to modulate inflammation and reduce the impact of pain on a 
woman’s quality-of-life remains under-researched. 
 
1.4.6 THE RELATIONSHIP BETWEEN DYSMENORRHOEA, PELVIC PAIN AND 
ENDOMETRIOSIS 
 
Traditionally, dysmenorrhoea and pelvic pain have been linked to the presence or absence of 
visible abnormalities found at laparoscopy, most commonly endometriosis lesions. Where no 
visible cause for pain was found during laparoscopic examination, pain was considered 
unexplained. Certainly, as explained in Section 1.2.3, the prevalence of endometriosis lesions 
in women undergoing laparoscopy for the investigation of pain is high. In a study of 4,334 
members of the United States-based Endometriosis Association who completed a 
questionnaire on their experience of diagnosis, 98.4% reported pain. Of these women, 84% 
reported menstrual pain and 67% reported non-menstrual pain (Greene et al., 2009). 
However, while this visual explanation for pain is convenient and easily accepted by patients 
and clinicians alike, the relationship between endometriosis and pain is far from clear. Many 
factors argue against a direct causal relationship between endometriosis lesions and pain. 
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Firstly, women may have endometriosis without pain. In a study of fertile women undergoing 
laparoscopy for tubal sterilisation purposes, 4% were found to have endometriosis (Eskenazi 
& Warner, 1997). Abbott et al. (2003) found that of 254 women with pelvic pain, only 176 had 
histologically proven endometriosis at laparoscopy.  Even where endometriosis lesions are 
present, the severity of the condition according to the American Society of Reproductive 
Medicine classification illustrated in Figure 1.5 correlates poorly with the severity of pain 
(Vercellini et al., 2006; Vercellini, 1996).  
 
Secondly, women may have pain without endometriosis. The studies of Eskenazi, Abbott, and 
Vercellini equally demonstrate that not all women with pain have endometriosis found at 
laparoscopic surgical assessment (Abbott et al., 2003; Eskenazi & Warner, 1997; Fauconnier 
& Chapron, 2005; Vercellini, 1996). This has been demonstrated previously in large studies, 
including those of Redwine and Janssen. Redwine studied 3,238 women undergoing 
laparoscopy for chronic pain, and found no endometriosis in 17.9% of women (Thomson & 
Redwine, 2005b). Janssen collated 15 studies of adolescent girls with dysmenorrhoea 
undergoing laparoscopy, and found no endometriosis in 38% of 880 girls (Janssen et al., 
2013). 
 
Thirdly, the site of endometriosis lesions correlates poorly with the site of pain. Among patients 
with endometriosis, the site and severity of pain are variably correlated with laparoscopic 
findings. Most consistently, deep infiltrating endometriosis (DIE) lesions of the uterosacral 
ligaments is associated with more severe pain, and DIE Lesions within the rectovaginal 
septum are associated with dyspareunia and dyschezia (Chapron et al., 2012). Roman found 
no correlation between the site of endometriosis and the presence of bowel symptoms in a 
study of 116 women (Roman et al., 2012). 
 
Fourthly, both dysmenorrhoea and endometriosis are associated with extra-pelvic symptoms. 
Dysmenorrhoea is over-represented in women with chronic pain conditions outside the pelvis 
when compared to controls. These conditions include fibromyalgia, tension-type headaches 
(Yunus, 2007; 2008), migraine (Tietjen, 2007),  Irritable Bowel Syndrome (Olafsdottir et al., 
2012), and Painful Bladder Syndrome (PBS). Olafsdottir used a postal survey to investigate 
the frequency of dysmenorrhoea and irritable bowel syndrome in the Icelandic population. 
While the prevalence of IBS is estimated at between 10% and 15% in western societies, 
(Hungin et al., 2005; Müller-Lissner et al., 2001), Olafsdottir found a prevalence of 42% for 
IBS in women with dysmenorrhoea using the Manning criteria (Manning et al., 1978) in a 
random sample of 2000 participants. 
 
 49 
Fifthly, pelvic pain may occur in men in the absence of dysmenorrhoea or endometriosis. In 
possibly the ultimate evidence that the presence of pain need not be associated with 
endometriosis, Clemens et al. (2014) of the Multidisciplinary Approach to the Study of Chronic 
Pelvic Pain (MAPP) Research Network, describes pelvic pain in men, where menstruation, 
and hormonal cycles do not exist. Despite these observations, Fauconnier and Chapron state 
that: 
 
Based on randomized trials against placebo, endometriosis appears to be 
responsible for chronic pelvic pain symptoms in more than half of confirmed cases. 
A causal association between severe dysmenorrhoea and endometriosis is very 
probable (Fauconnier & Chapron, 2005, p595) 
 
However, based on the information provided in this thesis, the relationship between 
dysmenorrhoea, chronic pelvic pain and endometriosis should be considered as an 





1.5 THE ROLE OF HORMONAL FACTORS IN DYSMENORRHOEA, CHRONIC PELVIC 
PAIN AND ENDOMETRIOSIS 
 
1.5.1 GENDER AND PAIN 
 
Ample evidence, as summarised by Mogil et al. (2012) describes the higher prevalence of 
chronic pain conditions in women when compared to men. This gender pain disadvantage 
begins with puberty and persists throughout a woman’s life. Perquin et al. (2000) studied the 
prevalence of chronic pain in 5,336 Dutch children aged 4-18 years. Before puberty the 
prevalence of chronic pain conditions in their study was approximately equal between boys 
and girls. However, by the age of 12-14 years girls were over-represented, and by the age of 
16-18 years girls were four times more likely to report a chronic pain condition than boys 




Figure 1.12: Three-month prevalence rates of severe chronic pain (chronic pain with 
intensities of more than 50 mm on the VAS and occurring weekly) by age groups and gender. 
Data were based on one pain report per child (Perquin et al., 2000). 
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The most frequently reported chronic pain grouping was a combination of abdominal pain and 
headache in 16-18-year-old girls. Girls reported multiple pain sites twice as commonly as 
boys. In further evidence for an association between hormonal factors and the experience of 
pain, LeResche studied 3,101 children aged 11-17 years, and showed that it is the stage of 
puberty rather than the chronological age of children that most accurately predicts the 
presence of a chronic pain condition in children (LeResche, 1995).  
 
The increased prevalence of chronic pain in women includes medical conditions both within 
and outside the gynaecological sphere. Greenspan et al. (2007) studied 54 non-
gynaecological chronic pain conditions and found a higher female prevalence in 39 of 54 pain 
conditions, and a higher male prevalence in only 19 of 54 pain conditions.  Interestingly, for 
both sexes, the presence of chronic pain is also associated with the potential for altered 
gender identity perceptions. Bernardes et al. found a public perception of men with chronic 
pain as being less masculine, and a public perception of women with chronic pain as being 
less feminine, when considering a list of 33 personality traits (Bernardes & Lima, 2010).  
 
Research into the implications of sex on medical conditions and pharmaceutical development 
was hampered by the 1977 US Food and Drug Administration (FDA) guidelines (Greenspan 
et al., 2007; Houghton et al., 2016), advising that women of childbearing potential should be 
excluded from drug trials. While these guidelines sought to avoid the potential for adverse 
drug effects on the foetus in the event of unrecognised pregnancy, they resulted in the 
inadequate representation of women in clinical trials, and the development of pharmaceutical 
products and dosing regimens best suited to males. Since the 1990s, the FDA and the 
National Institutes of Health (NIH) in the USA, have recommended that clinical trials should 
include female subjects. However, while it is now common for trials to consider whether 
outcomes differ between females and males, this trial analysis is not required. In 2015 the US 
Government Accountability Office (GAO) found that 8 out of 10 drugs withdrawn from the US 
market from 1997-2000 had greater adverse effects in women.  While the NIH does not ensure 
that current studies are designed to identify differences between men and women in disease 
processes and responses to treatment, new guidelines require that chromosomal sex is 
considered as a biological variable in preclinical research (Fish, 2008). 
 
Despite the evident effect of chromosomal sex, and substantial effort on the part of 
researchers since the 1990s (Geller et al., 2011), research to date has not provided an 
adequate mechanism for the increased prevalence of chronic pain in women. While both 
sexes produce estrogen and testosterone, estrogen is dominant in females and testosterone 
is dominant in males. As outlined by Geller, research to date has investigated whether the 
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relative dominance of estrogen may predispose women to pain. This research has proved 
inconclusive. An alternative theory might consider the potential for testosterone to protect 
males from pain, and will be considered further in Chapter 5.  
 
Approaches have considered biological differences between men and women (Mogil, 2012; 
Sorge et al., 2015), the differences in the way that men and women describe pain (Strong et 
al., 2009), and the different psychological responses to pain in males and females (Archey et 
al., 2018).  
 
1.5.2 HORMONAL FACTORS AFFECTING DYSMENORRHOEA 
 
As was discussed in section 1.4.1, it is prostaglandin release within the uterus that has been 
most consistently associated with dysmenorrhoea. Hormonal factors are well placed to affect 
the release of prostaglandins from the endometrium, with the potential to either aggravate or 
ameliorate menstrual pain. Arachidonic acid, the precursor of prostaglandins (Evans and 
Salamonsen, 2012), is formed from endometrial cell membrane phospholipids following the 
release of the enzyme phospholipase A from endometrial cell lysosomes. The stability of 
lysosomes is regulated by several factors, particularly the levels of progesterone: high 
progesterone levels tend to stabilise, while falling levels tend to destabilise, endometrial 
lysosomes (Dawood, 1995; Hofmeyr, 1996). In the high progesterone, luteal phase of the 
menstrual cycle, lysosomes are stable, phospholipase A is not released, and arachidonic acid 
production is low. As menstruation approaches, progesterone levels fall, lysosomes become 
unstable, phospholipase A is released, and arachidonic acid is formed (Chan et al., 1981; 
Dawood & Huang, 1998).  
 
Clinically, use of the combined oral contraceptive pill (OC), which includes both estrogenic 
and progestogenic components, reduces both prostaglandin levels and dysmenorrhoea in a 
proportion of women (Hauksson et al., 1989; Lindh & Milsom, 2013). In an evaluation of 
contraceptive options, Lindh followed a random sample of 656 19-year-old Swedish women 
over 5 years, and found a significant reduction in dysmenorrhoea among users of the OC, or 
a levonorgestrel-releasing intra-uterine device, but not among users of a non-hormonal intra-
uterine device or other non-hormonal contraceptive methods that included barrier methods, 
sterilisation, withdrawal or natural family planning (Lindh & Milsom, 2013). Although not 
evaluated in the Swedish study, the continuous use of an oral progestogen medication, with 
induction of endometrial atrophy, has been shown to be equally effective as the oral 
contraceptive pill at reducing dysmenorrhoea in a group of 38 Jordanian women (Al-Jefout & 
 53 
Nawaiseh, 2016). That the effect of the progestogen on dysmenorrhoea is predominantly 
uterine is demonstrated by the effectiveness of the levonorgestrel-releasing intra-uterine 
device for reducing dysmenorrhoea, despite the lack of suppression of ovarian function, and 
the low systemic dose of levonorgestrel delivered (Backman, 2004). 
 
The hormonal environment may also impact on chronic pain through its association with 
impaired sleep quality. Baker et al. (1999) found both self-reported sleep disturbance during 
the pre-menstrual phases of the cycle, and higher morning levels of estrogen, in women with 
dysmenorrhoea. Sleep disruption has been shown to increase pain sensitivity the following 
day, even in healthy, young, normally pain-free women (Iacovides et al., 2017), so whether 
sleep disruption precedes or follows the development of dysmenorrhoea is yet to be 
determined (Baker et al., 1999, 2008; Baker & Lee, 2018). 
 
1.5.3 HORMONAL FACTORS AFFECTING CHRONIC PAIN 
 
A woman’s experience of pelvic pain may include pain associated with pelvic viscera beyond 
the uterus, such as the bladder or bowel. The assertion that pelvic visceral afferent nerves are 
sensitised by estrogen is supported by several factors. Firstly, functional disorders of the pelvic 
viscera are more common in women than men  (Greenspan et al., 2007). A meta-analysis of 
139 research articles found a frequency of between 7% and 21% for Irritable Bowel Syndrome, 
with 2 in 3 of those affected being female (Canavan et al., 2014).  Painful Bladder Syndrome 
is estimated to affect between 3 million and 8 million women in the United States, depending 
on the diagnostic criteria used. It is estimated that 5 in 6 of those affected are women (Berry 
et al., 2011). Gender differences in patient presentation, societal attitudes, and treatment 
outcomes are further explored from a clinician’s perspective by Houghton et al., and with 
regard to deep tissue pain perception by Traub and Ji (Houghton et al., 2016; Traub & Ji, 
2013). 
 
Secondly, clinical treatments that reduce systemic levels of estrogen, such as gonadotrophin-
releasing hormone analogues (GnRHa), are associated with a reduction in pain. Gallagher et 
al. (2018) followed 51 girls and women aged 15-22 years treated with a combination of GnRH 
analogue leuprolide and add-back hormonal therapy comprising norethisterone 5mg and 
conjugated equine estrogen 0.625mg daily. 63% of these women described an improvement 
in their pain, 28% described no improvement in their pain, and 8% described worse pain than 
pre-treatment Thirdly, visceral pain symptoms vary in pre-menopausal women across the 
menstrual cycle (Riley et al., 1999). Pain may be further modified by levels of progesterone, 
 54 
or the use of synthetic progestogens. In a trial considering the severity of pelvic pain in 111 
women with endometriosis over 12 months of use, the synthetic progestogen dienogest 
reduced the visual analogue score (VAS) for pelvic pain from 8.9 to 0.9 (Maiorana et al., 2017).  
 
Hormonal factors may influence the pain experience via peripheral or central effects, with 
central effects further divided between central neural mechanisms, and central effects 
following activation of the innate immune system. From a neural perspective, estrogens 
modulate the voltage-gated calcium channels (VGCCs) and purinoreceptors (P2Xs) 
associated with neuronal sensitivity of visceral afferents either directly, or via the enhanced 
expression of P2X receptors associated with inflammation (Chaban, 2013). The impact of 
hormonal factors on the innate immune system and the actions of glial cells will be discussed 
further in Section 1.6. 
 
1.5.4 HORMONAL FACTORS AFFECTING ENDOMETRIOSIS 
 
Endometriosis is a clinical condition rarely diagnosed outside the reproductive years, and 
ample evidence links the development or progression of endometriosis lesions with steroid 
hormones (Bulun et al., 2002; 2010; Monsivais et al., 2014). Modification of the hormonal 
environment with a reduction in estrogen effect is a major focus of medical management of 
the condition worldwide (Taylor et al., 2012), although its effectiveness in managing pain is 
variable. For example, a Cochrane analysis (Brown et al., 2010) investigated the effectiveness 
of estrogen suppression using GnRH analogues for pain management across 41 trials 
involving 4,935 women. Brown et al. confirmed that GnRH-a was more effective than placebo 
at reducing pain in women with endometriosis. However, GnRH analogues were no more 
effective than danazol (p=0.53) or levonorgestrel (p=0.46) for pain reduction. GnRH analogues 
carried a significant higher risk of adverse effects, including vaginal dryness (p<0.00001) and 
hot flushes (p<0.00001) than danazol, a synthetic steroid medication that combines anti-
estrogenic, weak androgenic and weak progestogenic activity.  
 
Estrogen affects the phenotype of endometrial cells present within the endometrium and their 
response to inflammation. This presents as an increase in the ratio of epithelial-mesenchymal 
transition (EMT) cells to mesenchymal-epithelial transition (MET) cells. EMT cells acquire an 
invasive phenotype in the presence of chronic inflammation. This change promotes cellular 
proliferation and fibrosis (Wu et al., 2007), with the potential to enhance endometriosis lesion 
formation. In contrast, MET cells promote the decidualisation of the endometrium (Yu et al., 
2016). The ratio of EMT to MET within the endometrium is also affected by the presence of 
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seminal plasma (Ibrahim et al., 2019).  McGuane et al. (2015) demonstrated that exposure to 
seminal plasma induces an eight-fold increase in the growth of endometrial xenografts in a 
mouse model of endometriosis. 
 
The ratio of the two estrogen receptors, ERα and ERβ, is altered in the presence of 
endometriosis. ERβ is more highly e pressed in ectopic endometriotic tissue than ERα, and 
has been shown to promote endometriosis lesion growth (Han et al., 2015). This mechanism 
is described further in Section 1.6.3. 
 
Since hormones are modulators of gene transcription, the pattern of modulated genes also 
depends on the additional signalling pathways currently active within the cell at the time of 
hormone exposure (Katzenellenbogen & Katzenellenbogen, 2002). The alteration of estrogen 
signalling also provides a potential mechanism for environmental factors, including toxins, to 
enhance the growth of endometriosis lesions (Smarr et al., 2016). 
 
Multiple enzyme mechanisms within endometriosis lesions further alter the intra-lesional 
hormonal equilibrium, providing an additional mechanism for lesion growth and development.  
Delvoux et al. described an increased expression of the enzyme 1 β-hydroxysteroid-
dehydrogenase ype 1 1 β-  ype 1), but not 1 β-HSD types 2, 4, 5, 7 or 12, within 
endometriosis lesions, compared with eutopic endometrium (Delvoux et al., 2009). This 
favours the production of the more potent 1 β-estradiol (E2) over two of its metabolites, 
estrone and estriol, which display weaker ER agonist activity. In further research Delvoux 
demonstrated that 1 β-HSD Type 1 could be selectively inhibited using 3-[15b-estronyl]-N-(5-
methyl-thiazol-2-yl)-propionamide in vitro (Delvoux et al., 2014). 
 
Zeitoun et al. demonstrated the increased expression of the enzyme aromatase within 
endometriosis lesions. Aromatase favours the conversion of androgens to estrogens (Zeitoun 
& Bulun, 1999) and is found in multiple tissues including the granulosa cells of the ovary, brain, 
adipose tissue, placenta, skin, and bone. It is also expressed in certain pathological conditions 
including uterine fibroids, breast cancer and endometrial cancer. Importantly, it is found in 
endometriosis lesions, but not in eutopic endometrium. The ability of aromatase inhibitors, 
such as letrozole, to reduce the size of endometriosis lesions has been demonstrated (Bulun 
et al., 2001), but their use is limited by adverse side effects associated with low estrogen, 
including hot flushes, dry vagina and reduced bone density.  
 
Importantly, positive feedback between inflammation and estrogen within the ectopic 
endometrial stromal cells of women with endometriosis results in increased expression of 
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PGE2, which is itself a potent inducer of aromatase (Noble et al., 1997). The subsequent 
conversion of androgens to estrogen results in increased estrogen levels, which stimulate the 
production of cyclo-oxygenase-2, resulting in an increase in PGE2 (Huang et al., 1998). 
Hormonal manipulation thus has the potential to act in multiple ways in women with 




1.6 THE INTERPLAY OF CHROMOSOMAL SEX AND HORMONAL FACTORS ON THE 
INNATE IMMUNE SYSTEM 
 
An area of increasing research interest since the 1990s is the role of the immune system in 
the initiation and maintenance of chronic pain in females. While Section 1.5 demonstrates the 
well supported belief that hormonal factors play a role in the experience of pain, chromosomal 
sex provides an additional mechanism for gender sex differences, particularly with regard to 
immune function.  
 
Immune differences between males and females present clinically as two broad scenarios: 
the sex differential in susceptibility to infectious disease, and the sex differential in 
inflammatory or autoimmune conditions, potentially including dysmenorrhoea, endometriosis 
or pelvic pain. Certain immune differences between the sexes are evident from birth and 
suggestive of a chromosomal sex mechanism.  Others, such as the increased frequency of 
chronic pain conditions in females post puberty are adaptive, and suggestive of a hormonal 
mechanism. Section 1.6.1 provides an overview of human immunity prior to the further 
discussion of the impact of chromosomal sex on immune function in Section 1.6.2. 
 
1.6.1 INTRODUCTION TO THE INNATE IMMUNE CELLS IN PERIPHERAL BLOOD 
 
The innate immune response is the body’s first line of defence against pathogens. Its purpose 
is to detect the presence of infectious agents and to initiate mechanisms to eliminate potential 
infectious threats. It achieves this through a flexible network of cells that travel via the 
circulation to tissues where the initiation of an inflammatory response is required. Prominent 
among immune cells are the haematopoietically-derived peripheral blood mononuclear cells 
(PBMCs). PBMCs are peripheral blood cells with a round nucleus that are found in the buffy 
coat of centrifuged blood. In contrast, erythrocytes and platelets have no nucleus, and 
neutrophils, basophils and eosinophils have a multi-lobed nucleus. The majority (70%-90%) 
of PBMCs are lymphocytes, which can be further subdivided into T-cells, B-cells and Natural 
Killer (NK) cells. Monocytes represent 5%-10% of PBMCs, and are further subdivided into 
macrophages and dendritic cells (DCs). Circulating macrophages respond to immune 
inflammatory challenges by infiltrating the affected tissue and differentiating to fulfil the 
immune response required (Ginhoux & Jung, 2014).  
 
Dendritic cells comprise 1%-2% of PBMCs, and are further divided into plasmacytoid DCs and 
myeloid DCs. Myeloid DCs are known for their role as antigen-presenting cells (Kleiveland, 
 58 
2015). They process antigen material and present it to T-cells (Ueno et al., 2007). DCs capture 
microbes, present their antigens, and provide signals necessary for the T-cell expansion and 
differentiation necessary to mount an immune response. They thus act as messengers 
between the innate and adaptive immune systems. DCs are found in blood and in tissues that 
are in contact with the external environment, such as the skin, intestines, and endometrium 
(Schulke et al., 2009). Once activated, DCs migrate to draining lymph nodes, where they 
initiate and modify the adaptive immune response through their interaction with T- and B- cells.  
 
T-cells are formed in the thymus and differentiate to multiple subtypes classified according to 
their surface receptor that include T-cell co-receptor cells (CD3+), T-helper cells (CD4+) and 
cytotoxic T-cells (CD8+). Females have higher numbers of CD3+, CD4+ and CD8+ expressing 
cells than males, and a different balance between subsets of T-helper (CD4+) Cells. T-helper 
cells differentiate into two major cell subtypes known as Th1 and Th2 cells (Villacres et al., 
2004). Th1 helper cells facilitate an increased cell-mediated immune response typically 
involving macrophages and cytotoxic T-Cells (CD8+), resulting in the secretion of pro-
inflammatory cytokines such as interferon gamma (IFN- ) and tumour necrosis factor alpha 
(TNF-α). h2 helper cells facilitate a humoral immune response typically involving B-Cells, 
resulting in the secretion of anti-inflammatory cytokines such as interleukin 4 (IL-4), IL-10, and 
IL-13 (Mosmann & Sad, 1996). An increase in the Th1/Th2 ratio is considered pro-
inflammatory, while a decrease in the Th1/Th2 ratio is considered anti-inflammatory.  During 
pregnancy a bias towards T-helper 2 (Th2) protects the foetus by inhibiting the production of 
proinflammatory cytokines (Sykes et al., 2012). Females exhibit upregulated expression of 
proinflammatory genes compared to males, with many of these genes incorporating estrogen 
response elements in their gene promoters (Hewagama et al., 2008).  
 
The cytokine interleukin-1beta (IL-1β) plays a pivotal role in the implementation of innate and 
adaptive immune responses. IL-1β is a pro-inflammatory cytokine and is expressed by many 
cells, including macrophages, NK cells, monocytes, and neutrophils. IL-1β is released in 
response to a wide variety of pathogen-associated molecular patterns (PAMPs). Under the 
influence of E2, monocytes differentiate into inflammatory DCs, with increased production of 
α and pro-inflammatory cytokines (Seillet et al., 2013). Importantly, PBMCs offer an easily 






1.6.2 CHROMOSOMAL SEX AND THE IMMUNE SYSTEM 
 
Males and females differ in their innate and adaptive immune responses, with adult females 
generally mounting stronger antibody and cell-mediated immune responses to antigenic 
stimulation, vaccination, and infection than males  (Fish, 2008; Jaillon et al., 2019; Klein & 
Flanagan, 2016a; Marriott & Huet-Hudson, 2006). This sexual dimorphism is associated with 
a well-documented survival advantage in females through reduced bacterial, viral, parasitic 
and fungal infections (Fish, 2008; Roberts et al., 2001; Steeg & Klein, 2016), and an enhanced 
response and benefit for females from public health vaccination programs (Klein et al., 2010). 
The increased immune response in females offers protection against infection during 
childbirth, and enhanced survival of offspring through the non-genetic passive transfer of 
immunity from mother to child during pregnancy and breast feeding. In contrast, the relatively 
reduced immune response in males is associated with a higher mortality rate from infections 
and cancer (Figure 1.13).  
 
 
Figure 1.13: Sex differences in the intensity (i.e., pathogen load), prevalence (i.e., proportion 
of population with disease), incidence (i.e., new cases of disease), and severity (i.e., 
hospitalisation or progression of disease state) of disease following microbial infections in 
humans (Steeg & Klein, 2016).  
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However, while a stronger inflammatory immune response may help women resist infections, 
this may come at the expense of an increased susceptibility to inflammatory and autoimmune 
disease conditions, potentially including dysmenorrhoea, endometriosis and pelvic pain. As 
an example, Cooper and Stroehla (2003) reviewed the prevalence of autoimmune disease in 
the United States of America, and found that 85% of Americans with thyroiditis, systemic 
sclerosis, systemic lupus erythematosis and Sjögren’s Disease were female. 
 
Hewagama et al. demonstrated that when T-cells are repeatedly stimulated, T-cells from 
women overexpressed a greater number of genes than T-cells from men.  Estrogen response 
elements were identified in the promoters of half of the overexpressed immune genes in 
women, but less than 10% of the overexpressed immune genes in males. The 
inflammatory/cytotoxic effector genes overexpressed in women, with effects 1.4-1.8 times 
higher in women than men, included interferon gamma (IFNG), lymphotoxin beta (LTB), 
granzyme A (GZMA), interleukin-12 receptor beta2 (IL12RB2), and granulysin (GNLY).  
 
In a further association between chromosomal sex and inflammatory disorders, Amadori et al. 
(1995) studied the CD4 (T Helper cells) /CD8 (T cytotoxic cells) ratio between males and 
females in 46 families. They confirmed the known sex-dependent ratio described by 
Hewagama, with the additional finding that the CD4/CD8 ratio of parents significantly 
influenced the CD4/CD8 ratio in offspring. This is consistent with either genetic factors or 
common environmental factors as a cause for the ratio difference between males and females. 
Many genes on the X chromosome regulate immune function (Libert et al., 2010), and skewed 
X chromosome activation has been proposed as a potential cause of the higher prevalence of 
autoimmune disease among females. While evidence for skewed activation has been found 
in Hashimoto’s Thyroiditis (Simmonds et al., 2014), none of the highly expressed gender-
biased genes detected in Hewagama’s study were encoded on the X chromosome.  
 
Despite the findings of Hewagama, the X chromosome is known to contain the largest number 
of immune-related genes within the human genome (Bianchi et al., 2012). Humans with 
chromosomal anomalies offer a unique opportunity to investigate the relative importance of 
chromosomal versus hormonal factors in the development of immune-mediated medical 
conditions. Males with Klinefelter syndrome (XXY) display lower testosterone levels, higher 
oestrogen levels, and respond immunologically more like females to immune challenges. They 
exhibit higher immunoglobulin concentrations, higher CD4+ T-cell numbers, higher CD4/CD8 
T-cell ratios and higher B-cell numbers than XY males. In comparison, females with Turner 
syndrome (XO) display lower immunoglobulin concentrations, lower T-cell and lower B-Cell 
numbers than XX females (Cacciari et al., 1981). Both males with Klinefelter syndrome and 
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females with Turner syndrome show an increased prevalence of  autoimmune disease 
(Bianchi et al., 2012). In showing that this effect could be reversed by treatment with 
testosterone, Kocar et al. (2000), provided evidence that both chromosomal sex, including the 
X chromosome, and hormonal factors are involved in immune function.   
 
Jarrell and Arendt-Nielsen (2016) have proposed that recurrent episodes of painful 
menstruation predispose women to the development of endometriosis and chronic pelvic pain 
through increased immune activation. Recurrent ovulatory cycles result in a repetitive cycle of 
hormonal fluctuations and menstruation inflammation, predispose females to a higher 
prevalence of autoimmune conditions, inflammatory conditions (including endometriosis), and 
the development of chronic pain. Multiple clinical studies support an association between 
endometriosis and immune-mediated medical conditions.  An increased prevalence of 
endometriosis has been found in women with multiple sclerosis, systemic lupus 
erythematosis, rheumatoid arthritis, Sjögren’s Syndrome, and fibromyalgia (Brandt et al., 
2015; Greenbaum et al., 2019; Harris et al., 2016; M. D. Lockshin, 2005; Miclea et al., 2019; 
Sinaii et al., 2002). Conversely, Porpora et al. (2019) found an increased prevalence of 
inflammatory bowel disease (p<0.07), coeliac disease (p<0.0001), autoimmune thyroiditis 
(p<0.0001), and systemic lupus erythematosis (p=0.01) among 148 women with 
endometriosis when compared with 150 controls. 
 
1.6.3 SEX STEROID HORMONES AND THE IMMUNE SYSTEM 
 
Endogenous estrogens include estrone E1), 1 β-estradiol (E2), and estriol (E3), with E2 
being the major form in females of reproductive age. E3 is produced in high levels during 
pregnancy. Immune cells express estrogen receptors (ERs), progesterone receptors (PRs), 
and androgen receptors (ARs), implying that endogenous sex hormones are directly involved 
in the activation, development or functional responses of immune cells (Whitacre et al., 1999).  
The enzymatic pathways of the precursors and metabolites of sex hormones are governed by 
complex enzyme interactions (Figure 1.14). 
 
Estrogen receptors display three distinct subtypes  ERα, ERβ, and G protein-coupled estrogen 
receptors ER). ERα and ERβ belong to the nuclear hormone receptor class of transcription 
factors that regulate gene transcription by translocating to the cell nucleus and binding to DNA. 
GPER is a member of the G protein-coupled receptor (GPCR) family, localised in the 
endoplasmic reticulum, which binds with high affinity to estradiol, and is responsible for the 
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Estrogens modify the function of macrophages, the differentiation of DCs, and the expression 
of cytokines (Bachy et al., 2008; Cunningham et al., 2014; Khan & Ahmed, 2016; Liu et al., 
2002; Liu et al., 2002; Papenfuss et al., 2011). While estrogen receptors are common across 
populations of immune cells, they are not ubiquitous. In the periphery, CD4+ T-cells express 
more ERα than ERβ, B-cells e press more ERβ than ERα, and CD8+ T-cells and monocytes 
express low amounts of ER (Phiel et al., 2005). owever, in general, ERα plays a larger role 
in immune processes than ERβ (Liu et al., 2002; Liu et al., 2002; Maret et al., 2003).  
 
Estrogen effects may be tissue specific, and display both agonist and antagonist functions 
within cells  (Heldring et al., 2007), or have effects which are estrogen level dependent. For 
example, low doses of E2 increase the production of pro-inflammatory cytokines including IL-
1β, IL-6, and TNF-α from monocytes and macrophages, whereas high concentrations reduce 
the production of these cytokines (Bouman et al., 2004). ER signalling may be anti-
inflammatory in certain cell types including monocytes and macrophages (Härkönen & 
Väänänen, 2006), as measured by the inhibition of NF-kB, yet be pro-inflammatory with an 
increase in NF-kB proteins in other tissues (Karpuzoglu et al., 2006). Notably, Karpuzoglu et 
al. investigated the response of splenocytes to T-cell stimulation with and without the presence 
of estrogen. Estrogen-treated mice were found to have an up-regulated expression of cyclo-
oxygenase 2 compared with controls. As COX-2 facilitates the production of PGE2, this has 
potential relevance for the severity of dysmenorrhoea. Estrogens modulate visceral 
nociception and opioid receptor function within minutes of administration (Gintzler & Liu, 
2012), consistent with a role for ER in addition to the nuclear estrogen receptors ERα and 
ERβ. In a study of 31 patients with IBS and 30 normal controls, Jacenik demonstrated a 
statistically significant overexpression of ERα in women with diarrhoea-predominant IBS 
under the age of 50 years (Jacenik et al., 2018).  
 
Multiple endocrine disruptors, both plant-based and pollutant in origin, can affect immune 
function through action on the ER. Ren described over 20 dietary phytoestrogens, including 
seasonings (garlic, aniseed, fennel, caraway, parsley), legumes (soybeans, chick peas, 
clover), grains (wheat, barley, rye, rice and oats), vegetables/herbs (carrots, potatoes, alfalfa, 
red clover), fruits (apples, pears, grapes, dates, pomegranates, cherries), and drinks (beer, 
coffee), which could act as either ER agonists or antagonists, with variable binding to either 
ERα or ERβ (Ren et al., 2001). Environmental pollutants with ER activity are found in plastics 
(bisphenol-A, phthalates), detergents and surfactants (octylphenol, nonylphenol), 
organochlorine pesticides (methoxychlor, dichlorodiphenyl-trichloroethane or DDT, 
hexachlorobenzene, and dieldrin), and industrial chemicals (polychlorinated biphenyls or 
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PCBs, 2,3,7,8-tetrachlorodibenzo-p-dioxin or TCDD) (Ahmed, 2000). Bisphenol-A (BPA) 
exposure increases pro-inflammatory cytokines and reduces anti-inflammatory cytokine 
secretion in rodents, and is immunotoxic to human macrophages (Chen et al., 2018). 
Bisphenol exposure has been associated with a higher prevalence of medical conditions, 
including endometriosis (Kim et al., 2019; Rashidi et al., 2017). Rashidi compared BPA levels 
in 50 women with ovarian endometriomata and 50 women with no endometriosis. While the 
percentage of urine samples containing BPA was similar in both groups (86% of cases and 
82.4% of controls), higher concentrations of BPA were significantly associated with the 
presence of endometriosis. The mean concentration of BPA was 5.53 ± 3.47 ng/mL in women 
with endometriosis, and 1.43 ± 1.57 ng/mL in women without endometriosis (p < 0.0001).  
 
Progesterone (P4) is a steroid hormone secreted primarily by the ovarian corpus luteum 
following ovulation, and by the adrenal cortex in non-pregnant women. Progesterone 
receptors (PR) bind the hormone progesterone, are found within cells, and display 2 main 
subtypes   Rα and Rβ. uman  levels are low in the follicular phase of the menstrual 
cycle (1-2nM), and rise following ovulation to a peak (20-40nM) in the late luteal phase. During 
pregnancy, placental production of P4 increases serum progesterone levels to 100–500nM 
(Stites & Siiteri, 1983). Rβ e erts the tissue effects of progesterone, while Rα regulates the 
activity of Rβ. Both -lymphocytes and macrophages express PR (Khan et al., 2005). 
Progesterone in blood is bound to transcortin (corticosteroid-binding globulin), and at 
physiological levels displays similar effects on leukocytes as glucocorticoids (Bamberger et 
al., 1999; Kontula et al., 1983). Reducing inflammatory responses may be an important role 
of P4. P4-exposed macrophages and DCs in rodents have a lower state of activation and 
produce lower amounts of IL-1β and TNF-α compared with untreated cells (Butts et al., 2007).  
 
Androgens are a family of sex steroid hormones that bind to the androgen receptor. The major 
androgen in both males and females is testosterone, which is around 50% formed in the 
periphery from its precursors (androstenedione, dehydroepiandrostenedione (DHEA) and the 
sulphated form DHEA-S), 25% secreted by the ovary, and 25% secreted by the adrenal gland. 
Testosterone is metabolised to the more potent dihydrotestosterone (DHT) within peripheral 
tissues under the influence of 5-alpha-reductase (Figure 1.14). Ovarian androgen production 
is suppressed by the use of the oral contraceptive pill (OC). Women with normal ovarian 
function have levels of testosterone that vary between 0.42 and 2.94nmol/l (Pesant et al., 
2012). ndrogen receptors Rs) bind with nuclear  and e ist in 2 forms  Rα and Rβ. 
Androgens are considered to be generally immunosuppressive, resulting in decreased T- and 
B-cell proliferation, and decreased immunoglobulin and cytokine production (Bebo et al., 1998; 
Miller & Hunt, 1996; Olsen & Kovacs, 2001). 
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In peripheral blood, estrogens and androgens are predominantly bound to either albumen or 
Sex Hormone Binding Globulin (SHBG), with only 1%-2% in the unbound or free form. Only 
the unbound fraction is biologically active and able to activate the nuclear receptor. SHBG 
levels are decreased by androgens, polycystic ovarian syndrome, hypothyroidism and obesity 
(Dunn et al., 1981; Grasa et al., 2017). SHBG levels are increased by estrogens, the oral 
contraceptive pill, pregnancy, and hyperthyroidism. Through hormone binding, a higher level 
of SHBG inhibits the actions of both androgens and estrogens. 
Importantly, androgens are converted to estrogens by the enzyme aromatase in a range of 
tissues, such as ovarian granulosa cells where aromatase is present, providing a secondary 
estrogen effect. Individuals with increased aromatase activity show accelerated estrogen 
conversion, and thus lower testosterone levels, within affected tissues. Capellino et al. and 
Folomeev et al. demonstrated that individuals with rheumatoid arthritis (Capellino et al., 2014; 
Castagnetta et al., 2003; Cutolo et al., 2004, 2006) and SLE (Folomeev et al., 1992) show 
increased aromatase, reduced testosterone, and an increase in the pro-inflammatory 
cytokines TNF-α, IL-1β and IL-6 in affected tissues. Interestingly, aromatase activity is 
downregulated by Vitamin D (Capellino et al., 2014), offering the potential for Vitamin D 
supplementation as an androgen-enhancing treatment option. 
 
As discussed in Section 1.5, the hormonal profile of endometriosis lesions differs substantially 
from the profile of eutopic endometrium. Firstly, endometriosis lesions contain abundant 
aromatase, allowing local androgen conversion to estradiol. Aromatase production is 
stimulated by prostaglandin E2 (PGE2), resulting in the local production of estrogen, which 
further stimulates the formation of  PGE2 inducing a positive feedback cycle (Bulun et al., 
2000; Noble et al., 1997; Zeitoun & Bulun, 1999). Secondly, low levels of PR in endometriotic 
stromal cells reduce the induction of the en yme 1 β-hydroxysteroid dehydrogenase, 
reducing the conversion of estradiol to the less potent estrone (Bulun et al., 2010; Cheng et 
al., 2007).  Thirdly, ERβ levels are significantly higher in endometriosis lesions than in eutopic 
endometrial tissue (Carli et al., 2008). Bulun has proposed that a dramatically higher ERβ-to-
ERα ratio in endometriotic stromal cells, combined with suppression of the PR progesterone 
receptor, increases cyclo-oxygenase-2 levels, contributing to progesterone resistance and 
inflammation (Bulun et al., 2012).  
 
These factors result in high levels of intra-lesion estradiol, relative progesterone resistance, 
and the ability of endometriosis lesions to maintain high estrogen concentrations, even 
following ovarian removal or suppression of circulating estrogen levels.  
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1.7 TOLL-LIKE RECEPTORS (TLRS) 
 
The complex interaction between the immune system, hormonal factors, and the presence of 
dysmenorrhoea, endometriosis or chronic pelvic pain has been described in Sections 1.5 and 
1.6. However, they do not provide a specific mechanism by which the immune system 
becomes activated in some, but not all, women. The discovery of the Toll gene by Christiane 
Nüsslein-Volhard and Eric Wieschaus in drosophila (fruit fly) in 1995, and the subsequent 
discovery of a human homologue of the drosophila toll protein now known as TLR4, offered a 
new mechanism for immune activation, with potential implications across a range of human 
conditions. TLR4 was found to induce genes involved in inflammatory responses (Medzhitov 
et al., 1997), and a multitude of research papers have since considered the role of TLR4 in 
inflammation, sepsis and chronic pain.  
 
TLRs are pattern-recognition receptors that respond to different components of invading 
microbes. Each TLR responds to a different component (Figure 1.15). To date, 13 TLRs have 
been described, with TLR 1-10 present in mammalian species, each responding to different 
components of potential invading pathogens. TLR4 is the quintessential, and most 
investigated TLR: a transmembrane protein encoded by the TLR4 gene. It is present on the 
surface of both circulating immune cells such as macrophages and monocytes, and glial cells 
such as astrocytes and microglia, within the brain and spinal cord.  
 
Recognised ligands for TLR4 include lipopolysaccharide (LPS), a component present in the 
cell wall of many gram-negative bacteria (e.g. Neisseria spp.), various gram-positive bacteria, 
certain viruses, polysaccharides, low-density lipoproteins, beta-defensins, and heat shock 
protein (Brubaker et al., 2015). TLR4 also recognizes components of pathogens and 
endogenous molecules produced during tissue damage (Vaure & Liu, 2014). The ability of 
TLR4 activation to enhance the circulating immune response has led to its development as a 








Figure 1.15: Pictorial representation of human TLRs and their specific ligands: triacylated 
lipoprotein for TLR1; peptidoglycan for TLR2; double-stranded RNA for TLR3; 
lipopolysaccharide (LPS) for TLR4; flagellin for TLR5; diacylated lipoprotein for TLR6; 
imidazoquinoline and its derivative R-848 for TLR7; and bacterial unmethylated CpG DNA for 
TLR9. MyD88 associates with the TIR domain of TLRs and transduces signals to induce 




Figure 1.16: Pictorial description TLR signalling pathways: MyD88-dependent pathway that 
leads to the production of pro-inflammatory cytokines with quick activation of NF-κB and 
MAPK; and MyD88-independent pathway associated with the induction of IFN-β and -
inducible genes, and maturation of dendritic cells with slow activation of NF-κB and . 




1.7.1 TLR4 AND ACTIVATION OF CIRCULATING IMMUNE CELLS 
 
Activation of TLR4 triggers one of two intracellular signalling pathways (Figure 1.16). The first 
pathway is mediated by myeloid differentiation primary response gene 88 adaptor protein 
(MyD88), and is termed the MyD88-dependent pathway. The importance of the MYD88 
pathway in LPS-induced inflammation has been illustrated by Kawaii et al. who found that 
MYD88-deficient macrophages in mice were unable to produce pro-inflammatory cytokines 
(Kawai & Akira, 2007). The second pathway is mediated by TIR-domain-containing adapter-
inducing interferon-β R ), and is termed the TRIF-dependent pathway (Takeda & Akira, 
2004). It acts via NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells) to 
control DNA transcription. Following LPS binding to TLR4, this pathway results in the 
production of interferon (IFN) and the development of antigen-specific adaptive immunity 
(Martin & Wesche, 2002).  
 
TLR4 is the only TLR currently described that can signal via both MYD88-dependent and 
MYD88-independent pathways. Both TLR2 and TLR4 are able to trigger the intracellular 
MYD88 pathway. Hoshino demonstrated that TLR4 deficient mice are hyporesponsive to LPS 
(Hoshino et al., 2016). LPS binds to the TLR4 receptor by collaborating at the cell surface with 
several molecules including CD14, a protein made by macrophages, and MD-2, a lymphocyte 
antigen that provides a link between the TLR4 receptor and LPS signalling (Figure 1.17). 
Further details regarding the binding of LPS to TLR4 are outlined in a comprehensive review 




Figure 1.17: TLR4 signaling through 
MYD88-dependent and TRIF-
dependent pathways. Reproduced 







1.7.2 TLR4 AND ACTIVATION OF GLIA WITHIN THE SPINAL CORD AND BRAIN 
 
Glial cells are non-neuronal cells of the brain and spinal cord that do not produce electrical 
impulses, but play a role in neurotransmission, synaptic connections, learning and memory 
(Fields et al., 2014). Until recently, glial cells were considered to be purely structural in 
function: the support for the neuronal conduction of pain impulses from the periphery to the 
brain. However, in the last decade, the recognition that glia of the spinal cord and brain 
express TLRs, including TLR4, and that TLR4 activation of glia contributes to both the initiation 
and maintenance of chronic pain, has provided a potential new mechanism with which to study 
female pelvic pain.  Glia play an active role within the innate immune system (Baaklini et al., 
2019; Lehnardt, 2010) with the formation of a wide range of cytokines including IL-1β following 
immune recognition of the presence of an infective pathogen or damaged tissues.  
 
There are three major glial cell types within the central nervous system (CNS): astrocytes, 
oligodendrocytes and microglia, which communicate with each other, and modulate the 
activity of neuronal synapses, using neurotransmitters including glutamate, ions including 
potassium and calcium, and small molecules. Astrocytes are derived from neuronal stem cells 
(Mujtaba et al., 1998). Their functions include the regulation of cerebral blood flow, which is 
believed to be the basis for changes observed during functional MRI imaging (Ogawa et al., 
1990). Oxygen delivery exceeds the rate of oxygen utilisation in areas of the brain with 
increased neuronal activity, which in turn increases the MRI signal. Glia can affect both the 
encoding and the consolidation of memory (Steadman et al., 2020). Interestingly, Han et al. 
who replaced forebrain mouse astrocytes in humanised chimeric mice with human astrocytes, 
demonstrated faster learning among these mice than controls (Han et al., 2013).  
 
The association of astrocytes with memory and learning has potential implications for the 
development of chronic pain. Microglia are the macrophages of the CNS. They invade the 
developing brain from the fetal yolk sac, the same tissue of origin as macrophages within the 
systemic circulation (Ginhoux et al., 2010; Li & Barres, 2018). Microglia are involved in 
neuronal pruning, the phagocytosis of pathogens and debris, and are the first glia activated 
following acute injury. Oligodendrocytes are derived from neuronal stem cells (Mujtaba et al., 
1998). They support and restore myelin sheath formation through the formation of synaptic 
proteins (Hughes & Appel, 2019). The transition from an early microglial activation response 
to a later astrocytic activation response has been suggested as the mechanism behind the 




1.7.3 TLR4 AGONISTS AND ANTAGONISTS IN CURRENT MEDICAL PRACTICE 
 
Multiple drugs in current clinical practice have demonstrated activity at TLR receptors, either 
as agonists or antagonists. TLR4 agonists include commonly prescribed medications such as 
opioids (morphine, buprenorphine, fentanyl, methadone, oxycodone, pethidine), 
carbamazepine, ethanol, and oxcarbazepine (Hutchinson et al., 2010; Hutchinson et al., 
2010). Tapentadol is a mixed agonist/antagonist. TLR4 antagonists include amitriptyline, 
cyclobenzaprine, ketotifen, imipramine, mianserin, ibudilast, naloxone, naltrexone, 
propentofylline, palmitoylethanolamide (Impellizzeri et al., 2015), (+)-naloxone (Hutchinson et 
al., 2008), melatonin, and eritoran (TAK-242).  
 
As an example of a drug affecting TLR activity, melatonin is an indolamine derived from the 
amino acid tryptophan that is formed in the pineal gland. It has multiple physiological effects, 
including anti-angiogenesis, anti-proliferation, and anti-inflammation, and acts through 
signalling pathways that include nuclear factor-κB -κB) (Shrestha et al., 2017; Yao et al., 
2019). Of relevance to this thesis, melatonin reduces both the activation and production of 
cyclo-oxygenase-2 from microglia (Yao et al., 2019). As described in section 1.4.3, levels of 
melatonin are lower in women with dysmenorrhoea than in normal controls (Schwertner et al., 
2013). In another study, Berkiks et al. (2018) showed that melatonin mediated significant 
protective effect against LPS-induced depression and anxiety, both common symptoms in 
humans with inflammatory conditions (Hardeland, 2019; Yao et al., 2019).  
 
As an example of foodstuffs affecting TLR activity, curcumin, the active ingredient in turmeric, 
has known TLR4 antagonist activity (Boozari et al., 2019; Gupta et al., 2012; Islam et al., 2019; 
Momtazi-Borojeni et al., 2019; Zhang & Zeng, 2019). Unitt and Hornigold (2011) demonstrated 
that phytohaemagglutin (in green beans) enhanced the release of inflammatory cytokines from 
peripheral blood mononuclear cells (PBMCs) through a pure TLR4 mechanism. TLR agonists 
have been proposed as adjuvants for vaccines against viruses or bacteria through their ability 
to enhance the inflammatory immune response (Behzad et al., 2012; Liu et al., 2006). 
Lipopolysaccharide (endotoxin) is a large molecule found in the outer membrane of gram-
negative bacteria, that induces a strong immune response via TLR2 and TLR4 receptors. LPS 
is widespread in the human environment, even present at low levels as a contaminant in 
intravenous saline, where LPS is acceptable provided its concentration does not exceed the 




1.7.4 TLR4 AND DYSMENORRHOEA, PELVIC PAIN AND ENDOMETRIOSIS 
 
Since their discovery, the role of Toll-Like Receptors, particularly TLR4, in infective and 
malignant conditions of the thoracoabdominal viscera, has been an intense research focus. 
Preclinical research has demonstrated a benefit of TLR4 inhibition in inflammatory or 
malignant conditions of the heart and lung (Wang et al., 2016), kidney (Fenhammar et al., 
2011; Zhang et al., 2015), liver (Yu et al., 2013), and pancreas (Pan et al., 2017). Toll-like 
receptor antagonists such as eritoran (TAK-242) have been developed and investigated in 
human trials of sepsis (Rice et al., 2010).  
 
However, the inflammatory role of TLR4 in female sex-specific pelvic pain and reproductive 
health has attracted less interest. A search of Pubmed (accessed 03/01/2020) found that while 
5,642 articles were available when combining the search terms TLR4 and infection, only 18 
were found when searching ‘TLR4’ with ‘Endometriosis’, 7 were available searching ‘TLR4’ 
with ‘pelvic pain’, and 2 were available when searching ‘TLR4’ with ‘dysmenorrhoea’, both 
utilising a rodent model.  
 
Despite this lack of prior research activity, multiple lines of evidence support a strong role for 
TLRs in female pain. TLR4 receptors may be activated following exposure to certain bacteria 
(presence of LPS) or where there are damaged or degenerating cells present (Gong et al., 
2020; Molteni et al., 2016). The process of menstruation involves cells undergoing tissue 
breakdown (Evans & Salamonsen, 2012; Salamonsen et al., 2002) and the potential for 
bacterial contamination of the endometrial cavity. The activation of TLR4 receptors triggers a 
cascade of cellular processes acting via the NF-kb signaling pathway, and resulting in the 
productions of COX-2, and cytokines IL-1β, -6 and TNF-α (Shih et al., 2018; Saito et al., 
2010; Uematsu et al., 2002) (Figure 1.19). With regard to dysmenorrhoea, a TLR4 -mediated 
rise in COX-2, and subsequent increase in PGE2 production offers a potential mechanism for 
increased myometrial contractions and an increase in the intensity of dysmenorrhoea. Seillet 
et al. demonstrated that estrogen enhanced the TLR4 response of human dendritic cells 
(Seillet et al., 2012a, 2013), providing a mechanism for an increase in symptoms as estrogen 
rises with puberty.  Seillet’s study found that DCs from premenopausal women exhibited 
increased TLR4 responses when compared to men, while DCs from postmenopausal women 






Figure 1.19. TLR4-mediated NF-κB signaling pathway with enhanced production of -2, 
IL-1β, IL-6 and TNF-α following  stimulation (Shih et al. 2018) 
 
 
The wide variation in hormonal levels across the menstrual cycle, and among individuals, 
offers addition ways in which activation of the immune system can impact female pain. Nicotra 
et al. used a graded severity model of sciatic nerve pain in rats (Nicotra et al., 2014), 
developed by Grace, to demonstrate its importance in chronic pain. Female rats were more 
allodynic than males following sciatic nerve injury, and female rats were more allodynic during 
the higher estrogenic phases of the rat oestrus cycle (Nicotra et al., 2014). This was further 
supported  by oucy et al. who determined that 1 β-estradiol E2) acting via ERα is required 
for a full microglial response to LPS in the brain of female mice (Soucy et al., 2005). Rettew 
et al. (2008) showed that  E2 enhanced the expression of TLR4 on the surface of peritoneal 
macrophages in rodents, while testosterone reduced TLR4 expression consistent with an 
immunosuppressive effect. Recent research has found sex-specific variation in glial cell 
response between males and females after acute injury, with microglial activation prominent 
in males but not females, and astrocytic activation common to both sexes (Chen et al., 2018).  
 
Use of the oral contraceptive pill (OC) substantially alters the inflammatory response, including 
the release of inflammatory cytokines. Sikora et al. (2015) measured levels of IL-1β and 
neopterin (a biomarker for systemic inflammation) in serum and monocyte culture in 4 groups 
of women: 25 women with a normal menstrual cycle, 25 women using the oral contraceptive 
pill, 25 women with endometriosis and 20 post-menopausal women where estrogen levels are 
low. Serum IL-1β levels were lowest in women on the oral contraceptive pill and highest in the 
women with endometriosis. Serum neopterin levels were lowest in women with normal 
menstrual cycles and highest in women with endometriosis.  
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With regard to endometriosis, TLR4 is expressed on macrophages, the cells associated with 
the clearance of menstrual debris from the peritoneal cavity.  Khan et al. have provided a solid 
and compelling body of work supporting a role for the immune system and TLR’s in 
endometriosis through a series of research projects. Their findings have demonstrated: 
 a. A higher prevalence of endotoxin in the peritoneal fluid of 54 women with 
endometriosis when compared with 25 healthy controls. Within this group, higher levels of 
E.Coli in the menstrual blood of women with endometriosis were observed, potentially 
contributing to the higher levels of E.coli within the peritoneal fluid samples. Macrophages 
from the fluid of women with endometriosis induced higher expression of IL-6 and TNF-α when 
treated with LPS (Khan et al., 2006) 
 b. The demonstration of more severe endometritis (p<0.0001), but no higher frequency 
of the condition in a histological study comparing the endometrium of 73 women with 
endometriosis and 55 healthy controls (Khan et al., 2014).  
 c. The additive effect of 1 β-estradiol and LPS on the in vitro production of IL-6 and 
TNF-α by macrophages and endometrial stromal cells obtained by women with endometriosis 
(Khan et al., 2015). The peritoneal fluid from 46 women with endometriosis and 30 control 
women was collected at laparoscopy. Macrophages and endometrial stromal cells isolated 
from women were then exposed to either 1 β-estradiol or LPS or a combination of E2 and 
LPS.  
 
Khan’s research culminated in the publication of the “bacterial contamination theory for the 
development of endometriosis” (Khan et al., 2018). However, the potential implications of 
these findings on the presence or severity of dysmenorrhoea or pelvic pain do not seem to 
have been further explored.  
 
In summary, these studies indicate that roles exist for genetic, hormonal and environmental 
factors to explain the increased immune activation in females compared to males. In addition, 





1.8 THE EVIDENCE FOR A COMMON AETIOLOGICAL MECHANISM ACROSS 
DYSMENORRHOEA, CHRONIC PELVIC PAIN AND ENDOMETRIOSIS  
 
As has been described in sections 1.1, 1.2, 1.3, 1.4, and 1.5, despite their varied clinical 
presentations, dysmenorrhoea, chronic pelvic pain and endometriosis display substantial 
overlap with regard to epidemiology, human and fiscal burdens, and potential aetiologies.  
 
1.8.1 THE COMMON ASSOCIATION WITH MENSTRUATION 
 
Exposure of an individual to menstruation is associated with the presence or progression of 
each of these conditions. While there are many causes of female pelvic pain, dysmenorrhoea 
is by far the most frequent symptom reported. In a study by Jarrell of 181 women with CPP, 
62% of women described dysmenorrhoea (Jarrell & Arendt-Nielsen, 2016).  Hardi described 
the transition from dysmenorrhoea alone to CPP in a retrospective study of 100 women, and 
found that transition occurred in 16% of women within 12 months of severe dysmenorrhoea, 
and in over 50% of women within 12 years (Hardi et al., 2014).  Risk factors for the 
development of endometriosis include an earlier age at menarche (Nnoaham et al., 2012), 
shorter menstrual cycles and fewer pregnancies (Missmer & Cramer, 2003; Treloar et al., 
2005).  
 
In 2016, Jarrell and Arendt-Nielsen (Jarrell & Arendt-Nielsen, 2016) proposed that the high 
frequency of chronic pelvic pain in modern communities may be due to the increased number 
of menstrual cycles experienced in modern times.  Girls and women now experience many 
more episodes of menstruation than women in previous generations (Figure 1.9). Menarche 
is earlier, pregnancy is delayed, fewer pregnancies occur and breast-feeding is reduced. They 
proposed that dysmenorrhoea may have developed to enhance reproduction in unknown 
ways, at a time where there were fewer menses experienced and therefore fewer implications 
of pain to the individual.  
 
However, while the transition from dysmenorrhoea to CPP may occur over time, as proposed 
by Jarrell and supported by Hardi et al (Hardi et al., 2014), severe dysmenorrhoea itself 
frequently presents at, or soon after, menarche. Adolescents with severe dysmenorrhoea 
display a high prevalence of laparoscopically-visualised endometriosis despite their brief 
exposure to menstruation (Harel, 2008; Janssen et al., 2013; Marsh & Laufer, 2005; Zannoni 
et al., 2014). This strongly suggests that other factors apart from the number of menstrual 
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cycles experienced are involved in the generation of dysmenorrhoea, endometriosis and 
chronic pelvic pain.  
 
With regard to endometriosis, suppression of menstruation reduces the likelihood of lesion 
recurrence following endometriosis excision when compared with women in whom 
menstruation is not suppressed (Unger & Laufer, 2011).  Vercellini (2003) found a lower 
frequency of dysmenorrhoea in women who suppressed menstrual bleeding using a 
levonorgestrel-releasing intra-uterine device following laparoscopic removal of endometriosis 
lesions when compared with women who underwent surgery alone. 
 
These factors confirm an association between dysmenorrhoea, pelvic pain, and endometriosis 
with menstruation, but do not imply causation.  
 
1.8.2 A COMMON EPIDEMIOLOGY AND EARLY AGE OF SYMPTOM ONSET 
 
Consistent with their association with menstruation, dysmenorrhoea, CPP and endometriosis 
are most frequently diagnosed during a woman’s reproductive years, beginning at or close to 
menarche. Jarrell & Arendt-Nielsen (2016) proposed an evolutionary aetiology that attributes 
much of the risk of dysmenorrhoea and endometriosis to the more numerous menstrual cycles 
experienced by first-world girls and women in the modern era. However, we know that 
dysmenorrhoea can be severe from menarche, which argues against this conclusion.  
 
Pain symptoms also present at an early age in women who are later diagnosed with 
endometriosis. In 1998, Ballweg et al. (2004) reviewed the histories of 3020 women in the 
1980s and 4000 women in 1998 with surgically confirmed endometriosis. Forty-one percent 
in the 1980s and 66% in the 1998 cohort described pain symptoms that began before the age 
of 20. A comparison of these two patient cohorts is presented in Figure 1.20.  
 
 
Figure 1.20: Age of first pelvic 
symptoms across two patient 
cohorts sampled 10 years apart 




Marsh & Laufer (2005) describe five premenarchal girls with unexplained pelvic pain and with 
histologically-confirmed endometriosis lesions visualised at laparoscopy and histologically 
confirmed despite an otherwise normal reproductive tract. This demonstrates that 
endometriosis lesions may be present from a young age, and in the absence of menstruation.  
 
The early age for the development of all three conditions suggests a common premenarchal 
mechanism predisposing to the development of one or more of dysmenorrhoea, chronic pelvic 
pain or endometriosis. These findings are inconsistent with a mechanism for endometriosis 
relying on the cumulative effect of retrograde menstruation over progressive menstrual cycles.  
 
 
1.8.3 A COMMON SYMPTOM PROFILE SUGGESTING CENTRAL PAIN SENSITISATION 
 
The presence of endometriosis lesions is increasingly associated with an increased 
prevalence of non-gynaecological pain symptoms within and beyond the pelvis that include 
migraine, Painful Bladder Syndrome, Irritable Bowel Syndrome, or pelvic muscle dysfunction 
(Tietjen, 2007; Smorgick et al., 2013; Surrey et al., 2018; Vannuccini et al., 2018). However, 
this should not be seen as implying causality between endometriosis lesions and these 
additional symptoms. The presence of pain is a common feature across these conditions, and 
central pain sensitisation provides a potential mechanism for this effect. 
 
The co-occurrence of dysmenorrhoea with additional pain symptoms within the pelvis may be 
ascribed to viscero-visceral hyperalgesia (Section 1.4.4), where pain from one visceral organ 
affects the pain reactivity in a second visceral organ (Giamberardino, 1999; Giamberardino et 
al., 2010).  This phenomenon is attributed to the convergence of afferent neurons from both 
visceral organs in the dorsal horn of the spinal cord. Inflammation in the first organ results in 
central pain sensitisation with amplification of pain sensations from the second organ 
(Brumovsky & Gebhart, 2010). Li et al. (2008) used retrograde tracing dyes to demonstrate 
that while some sensory afferent neurons of the dorsal root ganglion are specific to either the 
uterus or the colon, a proportion of sensory afferent neurons receive sensory input from both 
uterus and bowel (Li et al., 2008). Sensory afferent neurons innervating the bladder, uterus 





Figure 1.21: The common innervation pathways for pelvic viscera in women through the 
hypogastric nerve. Reproduced with permission (Jobling et al., 2014). 
 
Pain sensitisation also provides a mechanism for pain symptoms outside the pelvis, including 
migraine, through the release of systemic cytokines, or activation of glial immune cells within 
the CNS, as described in Section 1.7. In contrast to the traditional view that neurogenic 
inflammation, passes purely from periphery to central locations, Sorkin et al. (2018) have 
presented evidence that neuroinflammation within the CNS may travel in an antidromic 
direction to induce inflammation in the periphery. 
 
1.8.4 THE COMMON ASSOCIATION WITH INFLAMMATION, TLR4, AND THE IMMUNE 
SYSTEM 
 
Menstruation provides ample opportunity for activation of the immune system. Breakdown of 
the endometrium during menses is associated with edema, leukocyte infiltration (Salamonsen 
et al., 2002), activation of cytotoxic T-Cells of the endometrium (H. D. White et al., 1997), and 
an increase in intrauterine chemokines (Roomruangwong et al., 2020). 
 
The ability of endometrial cells to reach draining lymph nodes during menstruation, and thus 
present endometrial cells to T-Cells, has been confirmed in both a baboon (Papio anubis) 
model (Hey-Cunningham et al., 2011) and in humans (Berbic et al., 2013; Javert, 1950, 1952a, 
1952b). Berbic et al. reviewed the obturator lymph node histology of seven women with 
endometriosis and nine women without endometriosis at the time of hysterectomy for 
gynaecological malignancy (cervical or ovarian). CD10+ endometrial stromal cells were found 
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across the menstrual cycle, with numbers peaking during menstruation. Any situations where 
lymphocyte activation is impaired has the potential to result in the reduced clearing of 
menstrual debris from the peritoneal cavity, prolonged exposure to both endometrial cells and 
micro-organisms, and increased potential for immune activation.  
 
In women with endometriosis, the numbers of various immune cell populations, including 
macrophages, uterine NK cells and immature dendritic cells within the endometrium and 
peritoneal fluid, are chronically increased (Berbic et al., 2009; Schulke et al., 2009). 
Macrophages comprise 50% of peritoneal cavity leukocytes (Kubicka et al., 1996) and have a 
central role in the development of endometriosis (Hogg et al., 2020). Macrophages infiltrate 
endometriosis lesions (Greaves et al., 2014), and exhibit disrupted function with complex 
alterations in pro- and anti-inflammatory cytokines (Beste et al., 2014) associated with a 
transition from the classical M1 macrophage activity to the more pro-inflammatory M2 profile 
(Johan et al., 2019). 
 
The dysregulation of immune cells, including macrophages, has been demonstrated in women 
with endometriosis, and particularly in women where pain is a major symptom (Akoum et al., 
2005; Akoum et al., 2006; Berbic et al., 2009; Schulke et al., 2008; 2009; 2009). This disruption 
includes deficiencies in macrophage phagocytic activity (Sharpe-Timms et al., 1998), 
activation of macrophages, and increased synthesis of cytokines. Macrophages are present 
in almost all tissues, displaying varied physiology in response to their environment, and an 
ability to transition to an inflammatory phenotype with tissue infiltration in the presence of 
inflammation (Mosser & Edwards, 2010; Gordon & Taylor, 2005). 
 
Activation of the innate immune system within the uterus, potentially involving TLR4 
mechanisms, offers a unifying theory between the enhanced immune activation in females, 
the increased female exposure to infectious organisms via the reproductive tract, and 
inflammatory conditions including dysmenorrhoea, endometriosis and chronic pain.  
 
1.8.5 UNANSWERED QUESTIONS IN AN AREA OF UNMET NEED 
 
To date, medical practice has considered dysmenorrhoea to be due to either biochemical 
changes within a normal uterus, or to secondary pelvic conditions such as endometriosis. This 
‘peripheral’ approach to dysmenorrhoea provides the rationale for current medical 
management: drugs to reduce prostaglandin release, drugs to reduce estrogen levels, or 
surgery to remove endometriosis. While these techniques are successful in a proportion of 
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cases, there remain girls and women for whom these treatments are ineffective, unacceptable, 
or associated with adverse effects.  
 
This literature review has outlined substantial gaps in current knowledge regarding 
dysmenorrhoea and its relationship to chronic pelvic pain and endometriosis. Clinically, 
gynaecologists who care for girls and women with pain must do so without the benefit of high-
quality research to guide their recommendations. They offer laparoscopic investigation to 
remove endometriosis, without the benefit of reliable, non-invasive ways to predetermine 
whether endometriosis will be present, or evidence that the lesions are wholly responsible for 
their patient’s pain. They offer hormonal management and non-surgical treatments without the 
benefit of a clear knowledge of the underlying mechanisms underlying their patient’s pain.  
 
Dysmenorrhoea is clearly a condition with important educational, employment, quality-of-life, 
financial and health economic implications, worthy of further research. Many questions 
remain, despite convincing evidence that the end mechanism behind uterine dysmenorrhoea 
is prostaglandin-mediated, hormone-facilitated excessive contraction of the uterus, with 
resulting myometrial ischaemia. 
 
With approximately one in five young women throughout the world affected, dysmenorrhoea 
has been under-researched with regard to its frequency and human impact. Dysmenorrhoea 
dramatically affects a woman’s ability to live to her full potential, by affecting her ability to 
engage in educational, social, workplace and personal opportunities. 
 
This thesis has five aims, to address knowledge gaps that will support researchers, women 
and clinicians in their quest to lessen the impact of DRPP: 
 
Aim 1: To further knowledge of the symptoms associated with dysmenorrhoea-related pelvic 
pain, as described by women themselves.  This knowledge seeks to determine whether these 
experiences are consistent with a purely pelvic condition, or a systemic condition with 
symptoms both within and outside the pelvis. These findings will determine whether a specific 
symptom profile is associated with the presence or absence of endometriosis, to refine where 
surgical management is appropriate.  
 
Aim 2: To determine whether activation of the innate immune system, via Toll-Like Receptors, 
provides an explanation for the symptoms associated with DRPP. These findings will guide 
clinicians and researchers in their quest to develop new and effective non-surgical 
management options for women with DRPP.  
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Aim 3: To determine whether levels of high sensitivity C-Reactive Protein (hsCRP), an easily 
measurable blood test, may act as a biomarker for pain and immune activation in women with 
DRPP. These findings, if positive, will support researchers with a clinically objective endpoint 
for clinical trials of novel therapies. 
 
Aim 4: To determine whether levels of sex steroid hormones, or cortisol, influence activation 
of the innate immune system in women with DRPP. These findings will guide clinicians 
towards prescribing hormonal medication optimially suited to the minimisation of pain and 
pain-related symptoms.  
 
Aim 5: To determine whether it is possible to develop a Unifying Theory for the relationship 










This chapter aims to further knowledge in an area of medicine that has been under-researched 
with regard to its impact on the wellbeing of women, their families and our society: the lived 
experience of women with dysmenorrhoea, as described by women themselves. Through the 
use of a clinical symptom questionnaire developed over many years within a multi-disciplinary 
pelvic pain clinic, it has four aims, all of high translational importance for treating clinicians and 




This chapter has four aims: 
 
Aim 1: To investigate the frequency of 14 symptoms, both within and outside the pelvis, in a 
group of 168 women with dysmenorrhoea-related pelvic pain. This aim considers whether the 
range of symptoms present in women with dysmenorrhoea is consistent with purely peripheral 
mechanisms within the pelvis. A high prevalence of symptoms outside the pelvis would 
support the presence of central mechanisms, as a component of the pain experience in these 
women.   
 
Aim 2: To determine whether a specific profile of pain-related symptoms can differentiate 
between women with or without laparoscopically confirmed endometriosis. The development 
of an indicative symptom profile would dramatically improve the ability of health practitioners 
to target invasive surgical procedures, including laparoscopy, for those women most likely to 
obtain benefit from the procedure. This finding would have implications for health economics, 
through allowing the better targeting of health dollars and hospital resources. A comparison 
of the symptom profiles of women with and without endometriosis lesions, provides additional 
insights into whether the relationship between endometriosis lesions and pain is one of 
causation or association. A similar symptom profile for women both with and without 




Aim 3: To document the range of symptoms commonly experienced by women with 
dysmenorrhoea-related pelvic pain, and determine whether certain symptoms cluster with 
dysmenorrhoea. Where clustering of symptoms is found, this supports the presence of a 
common underlying mechanism. A clustering of certain symptoms would also form the basis 
for a new clinical syndrome: Dysmenorrhoea-Related Pelvic Pain Syndrome (DRPPS).  
 
Aim 4: To investigate whether a history of distressing sexual events alters the frequency, or 
severity of clinical symptoms in women with dysmenorrhoea and related symptoms. 
 
This chapter introduces the manuscript entitled “The co-morbidities of dysmenorrhoea: A 
clinical survey comparing symptom profile in women with and without endometriosis” which 




This chapter investigates four hypotheses: 
 
Hypothesis 1: That women with dysmenorrhoea suffer a high frequency of additional 
symptoms both within and outside the pelvis that contribute to their lived experience of 
dysmenorrhoea.  
 
Hypothesis 2: That the reported symptom profile can differentiate between women with or 
without a laparoscopically proven diagnosis of endometriosis.  
 
Hypothesis 3:  That the presence of endometriosis is a common, but non-essential, feature of 
DRPPS. 
 
Hypothesis 4: That a history of distressing sexual events is associated with an alteration in the 
symptom profile in women with dysmenorrhoea-related pelvic pain. 
 
 
2.4 MANUSCRIPT AND STATEMENT OF AUTHORSHIP 
 
The following manuscript was published in the Journal of Pain Research on 13th December 
2018. All authors gave final approval of the version to be published, and agree to be 
accountable for all aspects of the work: 
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THE CO-MORBIDITIES OF DYSMENORRHEA: A CLINICAL SURVEY COMPARING 
SYMPTOM PROFILE IN WOMEN WITH AND WITHOUT ENDOMETRIOSIS 
 
All authors gave final approval of the version to be published, and agree to be accountable for 











been estimated to cost the Australian economy over US$6 
billion per year.8 Dysmenorrhea in isolation, whether as a 
symptom of endometriosis or when associated with chronic 
pelvic pain, is clearly a condition with important educational, 
employment, quality of life, financial, and health economic 
implications.
Developing effective clinical guidelines for the manage-
ment of dysmenorrhea, endometriosis, and chronic pelvic 
pain is complicated due to their overlapping symptomatol-
ogy, a lack of biomarkers, and the requirement that women 
undergo laparoscopic surgery to determine whether endome-
triosis lesions are present.9 In addition, confounding factors, 
potentially including a past history of sexually distressing 
events, may modify the pain experience.10
While several studies have linked a laparoscopic diag-
nosis of endometriosis with a wide range of additional 
symptoms at a rate higher than the general population,9,11–15 
few papers have investigated the frequency of these symp-
toms in women presenting with dysmenorrhea in clinical 
practice. In addition, they have not determined whether a 
specific symptom profile is associated with the presence of 
endometriosis lesions.
This study investigates the prevalence of 14 symptoms 
in women with dysmenorrhea who were referred to a pelvic 
pain and endometriosis unit with ready access to laparoscopic 
surgery. It compares the symptom profile of women with and 
without a laparoscopic diagnosis of endometriosis, and the 
severity of symptoms in women with and without a history 
of distressing sexual events. Three specific hypotheses were 
investigated:
1. That the prevalence of additional symptoms is high in 
women with dysmenorrhea,
2. That a specific symptom profile may indicate the presence 
of endometriosis lesions, and
3. That experience of distressing sexual events may alter 
the symptom profile of women with dysmenorrhea.
This study provides an insight into both the pain experience 
and the symptom profile of women presenting to gynecolo-
gists and laparoscopic surgeons in real-life clinical practice.
Patients and methods
study design
This is a cross-sectional analytical study.
Participants
The target population consisted of girls and women over 16 
years of age, with dysmenorrhea rated as more than 3 on a 
0–10 numerical scale, and with sufficient written English 
language skills to complete a symptom questionnaire. All 
participants were given an informed opportunity, to give 
or withhold consent for the use of their de-identified health 
information for research purposes, by marking one of two 
boxes on the questionnaire (see the section “Test methods” 
for details). Figure 1 shows the CONSORT flow diagram 
for study inclusion.
Permission to study the symptoms of those women who 
had indicated their consent on the questionnaire was approved 
by the Royal Adelaide Hospital Ethics Committee, HREC 
Reference No: R20170604. The study was conducted in 
accordance with the Declaration of Helsinki.
Test methods
The symptom questionnaire (displayed in Appendix 1) was 
posted to all new patients (301 women) referred to a pelvic 
pain and endometriosis unit, with ready access to laparo-
scopic surgery for the period January 1, 2015 to June 30, 
2016. The questionnaire was developed by a pain specialist 
gynecologist (SFE) to assist with patient management. It 
was refined over 18 years to ensure ease of use by patients, 
minimize unanswered questions, and facilitate a full clinical 
assessment of relevant symptoms by the clinician.
The dysmenorrhea-associated symptoms investigated 
included stabbing pains in the pelvis, bowel symptoms, food 
intolerances, bladder symptoms, headaches, pain with sexual 
activity, vulval pain, fatigue, poor sleep, nausea, sweating, 
dizziness, anxiety, and low mood. The presence of anxiety or 
low mood was assessed using a Depression Anxiety Stress 
Scale-21 questionnaire.16
Additional questions recorded patient age, parity, use of 
hormonal treatments for menstrual symptoms, days of pain 
per month, duration of dysmenorrhea, and whether there was 
a history of distressing sexual events, including sexual assault.
Six months following the closure of study enrolment, 
notes for each patient were retrieved and reviewed by the 
principal investigator, who was blinded to patient symptoms. 
Each de-identified patient was allocated to groups according 
to whether a diagnosis of endometriosis had been confirmed 
(Endo+), excluded (Endo–), or could not be determined as no 
laparoscopy had been performed (No Lap). Endometriosis was 
considered confirmed when endometriotic lesions had been 
confidently observed during laparoscopy at any time in their 
life, or where endometriomas were confidently visualized on 
ultrasound at the time of clinical assessment. An ultrasound 
diagnosis of endometrioma has known high specificity for 






























































   
                                 







Details of patient numbers overall and in each group are 
provided in Figure 1. Of 301 women who completed the 
questionnaire, informed consent was provided by 255 women 
and declined by 25 women. Twenty-one women neglected to 
complete the request for consent and were deemed to have 
declined. Where the patient was under the age of 18 years, 
inclusion required the presence of a parent during the medical 
consultation to confirm consent.
From this cohort of 255 women, 168 patients suffered dys-
menorrhea. Eighty-seven women were excluded from the study 
as their pain from dysmenorrhea was rated as less than 3 on a 
numerical 0–10 score (n=83), or written English language skills 
were poor (n=4), and consent could not reasonably be obtained.
From this cohort of 168 women, those patients with 
endometriosis confirmed (Endo+, n=101), endometriosis 
excluded (Endo–, n=22), and where a diagnosis could neither 
be confirmed nor excluded (No Lap, n=45), were identified. 
Of those women with endometriosis confirmed, 16% were 
classified as stage 1–2 and 84% were classified as stage 
3–4, using the revised American Society for Reproductive 
Medicine Classification.18
The cohort of 101 women with endometriosis confirmed 
was then divided into those patients using hormonal therapies 
(Endo+ Hx+, n=56) and those patients not using hormonal 
therapies (Endo+ Hx−, n=45). The hormonal therapies 
utilized by participants included the oral contraceptive pill 
(n=33), a levonorgestrel-loaded intra-uterine contraceptive 
device (LIUCD, n=16), an oral contraceptive pill with LIUCD 
in combination (n=3), an etonorgestrel implant (n=6), depot 
medroxyprogesterone acetate (n=1), oral norethisterone 
(n=2), and oral estradiol (n=1).
From the cohort of 56 women with endometriosis con-
firmed who were using hormonal therapies, those women 
currently using hormonal treatments were further divided 
into those women whose hormonal therapy included a 
LIUCD (Endo+ Hx+ LIUCD+, n=17), and those women 
on hormonal therapy that did not include a LIUCD (Endo+ 
Hx+ LIUCD–, n=39).
Results were collated for eight patient groupings:
1. All women with dysmenorrhea (All Dys, n=168)
2. Women with endometriosis confirmed (Endo+, n=101)
3. Women with endometriosis excluded (Endo–, n=22)
4. Women with endometriosis confirmed who were current 
users of hormonal therapy (Endo+ Hx+, n=56)
5. Women with endometriosis confirmed who were non-
users of hormonal therapy (Endo+ Hx–, n=45)

















Number of symptoms per woman with dysmenorrhea
6. Women with endometriosis confirmed who were using 
hormonal therapy that included a  LIUCD (Endo+ Hx+ 
LIUCD+, n=17)
7. Women with endometriosis confirmed who were using 
hormonal therapy without a LIUCD (Endo+ Hx+ 
LIUCD–, n=39)
8. Women on whom no laparoscopy had been performed 
(No Lap, n=45)
additional symptoms present per woman 
with dysmenorrhea
Figure 2 displays the number of additional symptoms experi-
enced per woman across the whole group with dysmenorrhea. 
Dysmenorrhea was the sole symptom in 0.6% of women, and 
2.4% of women reported that all 14 symptoms were present. 
The mean number of additional symptoms was 8.5.
Demographic, pain, and menstrual data by 
endometriosis diagnosis
Patient groups All Dys, Endo+, Endo–, and No Lap were 
broadly similar with regard to age, age of menarche, age when 
dysmenorrhea commenced, frequency of previous pregnancy, 
and parity (Table 1). The age of participants ranged from 13 
to 50 years with a mean age of 29.2 years (SD 8.4 years). 
Across all women, the mean severity of dysmenorrhea was 
7.9 on a 0–10 numerical scale with an SD of 1.7.
Compared to women without endometriosis (Endo–), 
women with a confirmed diagnosis of endometriosis (Endo+) 
showed no statistically significant differences for severity 






























































   
                                 






The comorbidities of dysmenorrhea
demographic, pain, and menstrual data in women with endo-
metriosis according to use or non-use of hormonal therapies 
including a LIUCD.
Compared to women with endometriosis who were 
non-users of hormonal therapy (Endo+ Hx−), women with 
endometriosis who were current users of hormonal therapies 
(Endo+ Hx+) reported significantly more days of dysmen-
orrhea per month (P=0.037), more days of pelvic pain per 
month (P=0.027), were more likely to have had a previous 
pregnancy (P=0.021), and were more likely to be parous 
(P=0.026).
Compared to women with endometriosis using hormonal 
therapies that excluded a LIUCD (Endo+ Hx+ LIUCD–), 
women with endometriosis using hormonal therapies that 
included a LIUCD (Endo+ Hx+ LIUCD+) reported sig-
nificantly more days of dysmenorrhea per month (P=0.05).
Symptom profile by use of hormonal 
therapies in women with confirmed 
endometriosis
A comparison was undertaken between women with endo-
metriosis who used (Endo+ Hx+) or did not use (Endo+ 
Hx−) hormonal therapy, to determine if hormonal treat-
ment was associated with a change in symptoms (Table 4). 
The frequency of individual symptoms was similar in both 
groups apart from an increase in sweating among those not 
receiving hormonal therapy (P=0.009). Figure 4 displays 
the symptom profile in women with endometriosis by use 
of hormonal therapy.
A further comparison was undertaken between women 
with endometriosis using hormonal therapy that included a 
LIUCD (Endo+ Hx+ LIUCD+), and women with endome-
triosis using hormonal therapy without a LIUCD (Endo+ Hx+ 
LIUCD–). Those women using a LIUCD trended to a higher 
frequency of stabbing pains in the pelvis (82.4% vs 63.2%, 
P=0.155) and sweating (58.8% vs 38.5%, P=0.159) than 
those women using hormonal therapies without a LIUCD, 
but these differences were not statistically significant.
Dysmenorrhea and stabbing pelvic pains
One hundred and six of the 166 women (63.9%) who 
answered the question about stabbing pains in the pelvic 
region reported that stabbing pains were present. Based on 
univariate logistic regression, variables associated with stab-
bing pain included: severity of dysmenorrhea (OR =1.60, 
95% CI =1.27–2.01, P<0.001), number of additional symp-
toms (OR =1.26, 95% CI =1.12–1.41, P<0.001), diagnosis 
of migraine (OR =2.30, 95% CI =0.97–5.46, P=0.058), 
number of days per month of dysmenorrhea (OR =1.15, 95% 
CI =1.04–1.28, P=0.007), and number of days per month 
Table 4 symptom prevalence across women with endometriosis, according to use or non-use of hormonal therapies, and use or non-





















Dysmenorrhea (%) 100 100 100 100 1 1
stabbing pain (%) 69.1 68.9 82.4 63.2 0.983 0.155
Bowel problems (%) 48.9 50 47.1 51.3 0.912 0.771
Food intolerances (%) 66.7 63.6 52.9 68.4 0.752 0.270
Bladder problems (%) 20.0 20.0 17.6 21.1 1.000 0.770
headaches (%) 55.6 60.7 64.7 59 0.601 0.686
sexual pain (%) 35.9 40 37.5 41.2 0.693 0.804
Vulval pain (%) 38.6 43.3 35.3 47.2 0.635 0.413
Fatigue (%) 68.9 83.9 88.2 82.1 0.073 0.562
Poor sleep (%) 55.6 60.7 70.6 56.4 0.601 0.318
nausea (%) 50 46.4 58.8 41 0.723 0.219
sweating (%) 20 44.6 58.8 38.5 0.009 0.159
Dizziness/faint (%) 62.2 62.5 52.9 66.7 0.977 0.329
anxiety (%) 57.8 55.4 52.9 56.4 0.807 0.810
low mood (%) 57.8 58.9 64.7 56.4 0.907 0.562
Notes: endo+ hx+, women with endometriosis confirmed on hormonal therapy; Endo+ hx+ liUcD+, women with endometriosis confirmed using hormonal therapy 
that included a liUcD; endo+ hx+ LIUCD–, women with endometriosis confirmed using hormonal therapy excluding a LIUCD; Endo+ hx–, women with endometriosis 
confirmed on no hormonal therapy; * chi-squared tests.






























































   
                                 





The comorbidities of dysmenorrhea






















Past history of distressing sexual events (n=20)














Days of pelvic pain per month
Past history of distressing sexual events (n=23)



















Past history of distressing sexual events (n=23)






























































   
                                 





with endometriosis is highly associated with the severity of 
dysmenorrhea, days per month of dysmenorrhea, days per 
month of pelvic pain, and diagnosis of migraine headache. 
And finally that a past history of distressing sexual events 
is associated with an increase in the severity and number of 
pain symptoms.
A woman’s experience of dysmenorrhea includes all 
symptoms experienced at menstruation, both pelvic and 
extra-pelvic. A major strength of this study is its symptom-
based applicability to the management of women presenting 
with dysmenorrhea and its associated symptoms, regardless 
of endometriosis status. While our group may represent a 
more complex subset of women with dysmenorrhea than 
is found in the general population, it is likely that they are 
similar to women referred to other gynecologists providing 
care for women with endometriosis and pelvic pain.
The lack of association between pain 
severity, presenting symptom profile and 
the presence of endometriotic lesions
Dysmenorrhea and pelvic pain have traditionally been associ-
ated with the presence of laparoscopically diagnosed endo-
metriosis lesions. While these conditions commonly coexist, 
the relationship between the clinical symptoms with which 
a girl or woman presents to her health practitioner (dysmen-
orrhea) and the medical condition that may or may not be 
found at laparoscopy (endometriosis) remains controversial. 
A literature review by Janssen et al4 considered laparoscopic 
outcomes in adolescent girls aged 10–21 years presenting 
with pain. They found endometriosis lesions to be present 
in 62% of adolescents overall, in 75% of girls with chronic 
pelvic pain resistant to treatment with the oral contraceptive 
pill and anti-inflammatory medications, in 70% of girls with 
dysmenorrhea alone, and in 49% of girls with chronic pelvic 
pain not necessarily resistant to treatment. Additional factors 
affecting the experience of dysmenorrhea appear likely. A 
consensus paper published in 2013 included majority but not 
universal support for a statement describing a “ philosophical 
shift to consideration of endometriosis and pelvic pain as 
a spectrum or continuum of disease”.9 It was recognized 
that this approach would avoid excluding women who lack 
laparoscopic confirmation of a diagnosis of endometriosis, 
yet have similar symptoms and associated diagnostic and 
therapeutic interventions.
Robust evidence demonstrates that the presence of endo-
metriosis lesions does not determine the severity of pelvic 
pain. In 656 women with chronic pelvic pain, Yosef et al 
found significant correlations between the severity of pain 
and the presence of dysmenorrhea, irritable bowel syndrome, 
painful bladder syndrome, pelvic muscle pain, or abdomi-
nal wall pain, but not with the presence of endometriotic 
lesions.19 As-Sanie et al used functional MRI to demonstrate 
that the experience of chronic pain was associated with 
anatomical changes in the brain rather than the presence of 
endometriosis lesions,20 and Vercellini et al confirmed the 
lack of association between the severity of laparoscopically-
staged endometriosis lesions and the severity of pain expe-
rienced.21 With regard to the reduction in quality of life and 
increase in anxiety and depression common in women with 
endometriosis,22 Facchin et al demonstrated that it is the 
presence of pain, rather than the presence of lesions, that is 
of importance.23 Women with asymptomatic endometriosis 
enjoyed the same quality of life and mental health outcomes 
as healthy controls. In our study, women with endometriosis 
excluded had a significantly higher frequency of blad-
der symptoms (50% vs 20%, P=0.005) than women with 
endometriosis confirmed. This may reflect the presence of 
coexisting painful bladder syndrome, a common cause of 
pelvic pain that clusters with other pelvic pain diagnoses.24 
By choosing to study women presenting with dysmenorrhea, 
rather than purely those with confirmed endometriosis, our 
findings further separate the pain of dysmenorrhea and the 
presence of endometriosis lesions. Our study also provides 
clinically relevant information to assist the management 
of women with dysmenorrhea where their endometriosis 
status is unknown.
Table 5 Dysmenorrhea score, days per month of pelvic pain, and number of symptoms in women with, and without, a history of 
distressing sexual events
Past history of distressing  
sexual events
No past history of distressing  
sexual events
Significance*
N Mean SD N Mean SD
Dysmenorrhea pain score 20 8.4 1.8 103 7.8 1.6 0.112
Pelvic pain days per month 23 22.0 8.4 112 18.1 9.0 0.055
number of symptoms 23 10.5 2.6 115 8.3 3.2 0.003






























































   
                                 




The comorbidities of dysmenorrhea
The association between pain symptoms 
and central sensitization
Two mechanisms consistently implicated with both the 
development of endometriotic lesions25 and a range of 
persistent visceral pain conditions26 are inflammation and 
activation of the innate immune system resulting in central 
pain sensitization. Inflammation elicits pain via inflamma-
tory mediators and peripheral sensitization of nociceptors.27 
Central sensitization may arise following continuous or 
recurrent nociceptive input from the periphery, resulting in 
enhanced excitability of spinal projection neurons in the spi-
nal cord and central nociceptor terminals within the brain.28 
Enhanced neurotransmission with long lasting molecular 
changes in both the spinal cord and brain may result in 
pain perception that no longer reflects, and is independent 
of, peripheral pain nociceptive signaling.26 Altered central 
processing of nociception in women with dysmenorrhea, 
both during menses and on pain-free days, as measured by 
serum cortisol, response to thermal stimuli, and functional 
MRI investigation, has been demonstrated by Vincent et al, 
Arendt-Nielssen et al, and Iacovides et al,29–31 with literature 
review by Payne et al.32 Central sensitization has the potential 
to affect both pelvic and extra-pelvic pain symptomatology.
With regard to pelvic symptoms, there is ample evidence 
for the convergence of sensory information from discrete 
pelvic organs of the gastrointestinal or genitourinary tract 
in the dorsal root ganglia, spinal cord, and brain,33,34 result-
ing in viscero-visceral hyperalgesia and the experience of 
multiple pain symptoms across pelvic organs. The women in 
our study demonstrated a high frequency of bowel (47.3%) 
and bladder (23.2%) symptoms. Both irritable bowel syn-
drome and painful bladder syndrome cluster in women with 
pelvic pain, and are associated with central sensitization and 
inflammation13,24,35
There is also evidence for the convergence of sensory 
information from visceral and somatic pelvic structures in the 
dorsal horn of the spinal cord. This results in visceral-somatic 
hyperalgesia and the experience of reflex muscle contraction 
and spasm associated with visceral pain as a manifestation 
of central sensitization.36–38 Our study demonstrated a high 
frequency of stabbing pain (63.9%), a symptom associated 
with musculoskeletal pain39 in women with dysmenorrhea. 
The presence of stabbing pelvic pain was highly associated 
with the severity of dysmenorrhea, days per month of dys-
menorrhea, and days per month of pelvic pain.
With regard to extra-pelvic symptoms, central pain 
mechanisms have been implicated in the experience of 
fatigue, poor sleep, fibromyalgia, and headache.40 The high 
frequency of chronic headache in our study is striking. 
About 80.9% of participants reported headache, with 21.1% 
reporting headaches on 15 or more days per month. In com-
parison, a population-based study in Italy found 42.8% of 
people reported headache in the previous year, and only 3.4% 
reported headache on 15 or more days per month.41 These 
findings are consistent with growing evidence for the role of 
central sensitization20 and extra-pelvic symptoms in the lived 
pain experience of women with dysmenorrhea.
endometriosis as a common comorbidity 
of pelvic pain syndrome (PPs)
Endometriosis and dysmenorrhea frequently coexist.4 
However, the high frequency of symptoms in our study, 
both within and outside the pelvis, regardless of endome-
triosis status, supports the view that endometriosis and 
pain may be associated, rather than etiologically linked, 
conditions. They may share a similar underlying mecha-
nism, yet represent distinct clinical entities within a larger 
syndrome of associated symptoms and conditions. Both 
endometriosis and dysmenorrhea would then be common, 
but non-essential features of female PPS, much as polycys-
tic ovaries are common, but non-essential, features of the 
systemic metabolic disorder, polycystic ovarian syndrome 
(PCOS).42
Further support for considering endometriosis and dys-
menorrhea as common features within female PPS comes 
from Clemens et al, who found similar pain symptoms in 
male PPS, where endometriosis and dysmenorrhea do not 
occur.43 Sutcliffe et al described similar clinical symptoms 
during pelvic pain flares in men and women with urologically 
based PPS, although flares were more frequent and of longer 
duration in women.44
The association between pain symptoms 
and use of hormonal therapies including a 
liUcD
A LIUCD is a long-acting, reversible contraceptive that 
releases 20 µg of levonorgestrel per day over 5 years of use. 
It offers effective contraception, reduced menstrual blood 
flow, reduced dysmenorrhea, and high levels of patient 
satisfaction in the general population,45,46 or women with 
adenomyosis,47 particularly in those women who have cho-
sen to continue using a LIUCD for more than 12 months.48 
However, a proportion of women request removal of the 
device in the first year of use, with the commonest reasons 






























































   
                                 





ing.49 In women with endometriosis, use of a LIUCD has the 
added benefit of reducing the recurrence of endometriosis 
lesions following laparoscopic surgery.50 However, despite 
these known benefits of a LIUCD, Lockhat et al51 found 
that only 68% of women continued to use a LIUCD at 12 
months post-insertion, with 11.8% of women requesting 
removal of the LIUCD due to “abdominal pain”. Our study 
found that women with endometriosis using hormonal thera-
pies reported significantly more days per month of pelvic 
pain, and that those using a LIUCD had a higher, but not 
statistically significant, increase in stabbing pains (82.4% 
vs 63.2%, P=0.155) when compared with non-users of 
hormonal therapies. This may reflect the referral of women 
with pain for whom these therapies had been tried but found 
unsuccessful, potentially in women with more severe central 
pain sensitization. Research to review whether the presence 
of stabbing pains may indicate a subgroup of women more 
likely to report persistent or unresolved pain following 
LIUCD insertion should be considered. Our study did not 
include sufficient patients to investigate the relative benefits 
of individual oral hormonal therapies or regimes, as has been 
proposed in other studies.52,53
The effect of previously distressing sexual 
events on symptom severity
Our finding that those women who reported a history of 
distressing sexual events suffered more pelvic pain supports 
similar findings by Yosef et al.19 Their study found that a 
history of sexual abuse was significantly associated with 
increased severity of pelvic pain. Ballina et al described 
enhanced recovery and reduced pain severity following 
sexual assault in women with opioid receptor polymorphisms, 
further linking pain mechanisms to pain severity.54 Schliep 
et al found no increase in the frequency of endometriosis in 
women with prior history of sexual assault.10
Despite our finding that a history of distressing sexual 
events was associated with more severe pain, the majority 
of our patients reported no sexual assault. The frequency of 
distressing sexual events (16.7%) is consistent with popula-
tion data described in the Australian Bureau of Statistics 
Personal Safety Survey55 (2016), where 18% of Australian 
women had experienced sexual violence since the age of 15 
years. With a 15% missing data rate for this question in the 
present study, it is possible that adverse sexual events were 
under-reported in our sample. However, by analyzing only 
those women who reported either “yes” or “no”, the potential 
for error has been minimized.
Translational significance for clinical 
practice
Our study investigated 14 dysmenorrhea-associated symptoms 
in a group of women presenting to a gynecology clinic with par-
ticular interest in endometriosis, dysmenorrhea, and pelvic pain. 
This has wide-ranging clinical applications. Firstly, our study 
shows that the full assessment of a woman with dysmenorrhea 
should proceed with the expectation that multiple symptoms, 
both within and outside the pelvis, are likely to be present. 
Secondly, we found that the presenting symptom profile was an 
unreliable indicator of the presence of endometriosis, as similar 
pain profiles were found in women both with and without endo-
metriosis lesions. Thirdly, our findings have implications for the 
training of health practitioners. The wide range of symptoms 
included within dysmenorrhea-associated PPS extends beyond 
the traditional teaching of individual medical and allied health 
care domains. There are consequently similarities between the 
changing management of PPS and the evolved management 
of PCOS. Comprehensive care of the pelvic and extra-pelvic 
symptoms of PCOS has moved beyond management of ovarian 
cysts to include the assessment of blood lipid and sugar profiles, 
the management of hirsuitism and acne, and lifestyle advice to 
manage obesity and reduce inactivity.
The high frequency of the covarying of migraine, stabbing 
pain, and dysmenorrhea supports further research investigat-
ing a potential common mechanism involving acquired cen-
tral pain sensitization for these conditions. A pilot study by 
Sator-Katzenschlager et al56 using amitriptyline or gabapentin 
in 56 women with chronic pelvic pain found a reduction in 
pain among both treatment groups. If proven, this would sup-
port the use of therapeutic interventions directed at central 
sensitization with effects on both pelvic and extra-pelvic 
symptoms in women with dysmenorrhea.
Conclusion
This study aims to extend our knowledge in an area that has 
been under-researched with regard to its impact on the well-
being of women, their families, and our society: the lived 
experience of women with dysmenorrhea.
While the lack of a control group in this study limits our 
ability to make firm conclusions, our findings indicate that 
additional symptoms are common in these women, and that 
the presence of endometriosis lesions cannot reliably be 
predicted by the presenting symptom profile. Of the symp-
toms investigated, the presence of stabbing pelvic pains and 
migraine headaches were most closely correlated with the 






























































   
                                 




The comorbidities of dysmenorrhea
extra-pelvic symptoms is consistent with central sensitiza-
tion as a component mechanism in female PPS. A history of 
distressing sexual events was associated with an increased 
number of pain symptoms, but was not more common than 
in the general population.
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The manuscript entitled “The co-morbidities of dysmenorrhoea: A clinical survey comparing 
symptom profile in women with and without endometriosis”, has increased our knowledge of 
the lived experience of women with dysmenorrhoea-related pelvic pain presenting to a 
gynaecologist for medical care.  
 
Hypothesis 1, that women with dysmenorrhoea report a high frequency of additional 
symptoms, both pelvic and extra-pelvic, was confirmed. We determined that women 
presenting to a gynaecologist with dysmenorrhoea-related pain suffered an average of eight 
symptoms in addition to dysmenorrhoea, and that these symptoms included both pelvic and 
extra-pelvic symptoms, consistent with the presence of a central pain mechanism. While the 
lack of a control group in this study limits our ability to make firm conclusions, our findings 
indicate that additional symptoms are common in these women. Of the symptoms 
investigated, the presence of stabbing pelvic pains, and migraine headaches was most closely 
correlated with the severity of dysmenorrhoea.  
 
Hypothesis 2, that the symptom profile may be used as a guide for clinicians to the presence 
or absence of endometriosis lesions was not supported. While the frequency of bladder 
symptoms was significantly higher in women without endometriosis, other symptoms were of 
similar frequency between the two groups.  
 
Hypothesis 3, that the presence of endometriosis is a common, but non-essential, feature of 
DRPPS was supported. Similar symptoms were found in women with and without a diagnosis 
of endometriosis. This finding supports a relationship of association rather than causation 
between the presence of endometriosis lesions and the presence of pain.  
 
Hypothesis 4, that a history of distressing sexual events would modify the symptom profile 
was confirmed. Those women affected reported an increase in pain severity, and an increase 
in the number of pain symptoms reported. However, a report of distressing sexual events was 
no more common among our study cohort than among the general population of young women 
in Australia. This suggests that while these events may worsen symptoms, they are not a 
major aetiological factor for the development of DRPP. 
 
Chronic pelvic pain has been variably associated with a history of sexual abuse in the pain 
literature, with the most consistent finding being an association with sexual abuse in childhood. 
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Rapkin et al. (1990) found that while the frequency of reported sexual assault was not 
significantly different between 31 adult women with chronic pelvic pain (19.4%), 32 women 
with chronic pain of alternate aetiology (16.4%), and 142 pain-free controls (12.5%), those 
women with chronic pelvic pain were more likely to report sexual abuse occurring during 
childhood (39.0% versus 18.4% and 9.4% respectively). Lampe et al. (2000) investigated 36 
women with chronic pelvic pain, 23 women with chronic low back pain, and 20 pain-free 
controls with similar findings. They found that while the frequency of reported sexual abuse 
did not vary significantly across groups, the women with pelvic pain reported a higher 
frequency of abuse before the age of 15 years.  
 
Our documentation of 14 symptoms commonly associated with dysmenorrhoea-related pelvic 
pain, regardless of the presence or absence of endometriosis lesions, further develops the 
clinical concept of Dysmenorrhoea-Related Pelvic Pain Syndrome. However, the mechanism 
by which inflammation develops remains unknown. Why is it that one in five girls develop 
severe dysmenorrhoea at or soon after menarche, while four in five do not?  Chapter 3 
investigates the potential of innate immune system activation to act as the common 






CHAPTER 3: DYSMENORRHOEA, THE INNATE IMMUNE 
SYSTEM AND A POSSIBLE NEW BIOMARKER 
 
To have great pain is to have certainty; to hear that another person has pain is to have 
doubt.  




Chapter 2 investigated a cohort of women with dysmenorrhoea-related pelvic pain, and found 
a high prevalence of additional symptoms, both pelvic and extra-pelvic. These findings are 
consistent with a systemic, rather than purely pelvic, mechanism for the presence of pain-
related symptoms. However, they do not inform the nature of the mechanism involved.  
 
As described in Sections 1.4.4 and 1.8.3, women with dysmenorrhoea, chronic pelvic pain 
and endometriosis show an increased inflammatory phenotype. They describe the strong 
association between inflammation and central pain mechanisms, and the increasing evidence 
of a role for Toll-Like Receptors (TLRs) in the genesis of inflammation. A series of research 
findings by Khan et al. (Khan et al., 2008, 2010, 2013, 2015) describe an increased expression 
of TLR4 activity, and an increased colonisation of the uterus by E.Coli, in the uterus of women 
with endometriosis when compared with healthy controls. They proposed a bacterial 
contamination theory for the development of endometriosis lesions. However, the implications 
of these findings for women with dysmenorrhoea, or CPP, remain unclear. Not all the women 
with E.coli colonisation within their study displayed endometriosis, and their research did not 
report the implications of TLR4 activation within the uterus on the reported experience of pain.  
 
Further research in this area would be facilitated by the identification of an effective biomarker 
for pain, and or, endometriosis. To date, a range of approaches have been used to investigate 
potential biomarkers for the presence of endometriosis with the aim of early diagnosis, and 
more effective targeting of laparoscopic surgical procedures. Nisenblat et al.(2016b) 
investigated a panel of blood cytokines and concluded that: 
 
Of the biomarkers that were subjected to meta-analysis, none consistently met the 
criteria for a triage diagnostic test. Nisenblat et al. (2016b) p2  
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A further study investigated 78 plasma microRNA markers and found 49 markers that were 
differentially expressed in women with endometriosis. While three microRNA markers (miR-
155, miR-574-3p and miR139-3p) could be independently validated, when combined together 
as a prognostic test (Nisenblat et al., 2019) these markers demonstrated a sensitivity and 
specificity for the presence of endometriosis of 83% and 51% respectively, which was 
considered insufficient to guide clinical practice. More recently, the potential for deletions in 
mitochondrial DNA (1.2 and 3.7kb) has been investigated by Creed et al. (2019), who found 
a sensitivity and specificity of 81.8% and 72.2% for the 1.2kb deletion, and 85.1% and 57.9% 
for the 3.7kb deletion, with a test combining the two markers currently under consideration for 
commercial development.  
 
Unfortunately, even where a highly sensitive and specific biomarker for the presence of 
endometriosis is determined, its use as a clinical biomarker for the presence of pain may be 
limited. The lack of a biomarker for the subjective symptom of pain has hampered the 
development and evaluation of pain therapies across a range of pain conditions. An effective 
biomarker would enhance the clinical assessment of pain and inform data enrichment of 
clinical trials designed to test the effectiveness of pain therapies. In a novel approach, recent 
studies at the University of Adelaide suggest that an increased responsiveness of 
mononuclear cells, with subsequent release of IL-1β, within the peripheral blood can provide 
an objective measurement of the presence of chronic pain (Kwok et al. 2013).  As outlined in 
Section 1.6.1. PBMCs are cells of the innate immune system within the peripheral blood that 
activate glial cells within the dorsal horn of the spinal cord, resulting in central pain 
sensitisation and the symptomatic experience of pain. Using pre-clinical models, Kwok et al. 
(2012, 2013) demonstrated that activation of PBMCs mirror changes within the brain and 
spinal cord. In subsequent studies using this model, Kwok et al. were able to accurately predict 
the presence of pain in 28 out 34 patients with chronic pain.  This finding suggests that the 
responsiveness of PBMCs to TLR2 or TLR4 stimulation has significant potential as an in vitro 
biomarker for the presence of chronic pain, and this approach warrants further investigation. 
Kwok’s cohort of patients was confounded by the inclusion of a heterogeneous population of 
males and females with varied chronic pain conditions, an average age of 46 years, multiple 
co-morbidities, and the concurrent use of potentially immune-modifying medications. In 
contrast, young women with dysmenorrhoea-related pelvic pain offer an opportunity to 
investigate the potential of Kwok’s test in a consistent cohort of young, otherwise healthy 
women without additional comorbidities or the use of confounding medications. If proven to 
be effective, such a biomarker could support the use and development of entirely new classes 
of medications for the management of this common and debilitating condition.  
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As described in section 1.5.2. the oral contraceptive pill is commonly used to manage 
dysmenorrhoea and has demonstrated efficacy in a proportion of women. The mechanism of 
benefit of the oral contraceptive (OC) is unknown. As discussed in section 1.7.4., the innate 
immune system, as mediated by TLRs is modified by the hormonal environment.  
 
 
Chapter 3 seeks to investigates the role of Toll-Like Receptors, specifically TLR 2 and TLR4, 
in women with dysmenorrhoea-related pelvic pain. We also seek to determine whether the 
pain-modulating effect of the oral contraceptive pill is mediated via TLRs. Chapter 3 utilises 






Chapter 3 has four aims: 
 
Aim 1:  To determine whether there is evidence of activation of the innate immune system, via 
Toll-Like Receptors 2 and 4, in young women with dysmenorrhoea-related pelvic pain.  
 
Aim 2: To investigate the potential of an in vitro test for the responsiveness of PBMCs to TLR 
stimulation as a pain biomarker in young women with dysmenorrhoea-related pelvic pain.  
 
Aim 3: To determine whether the effectiveness of this test as a biomarker for pain is affected 
by the presence or absence of pain at the time of sampling.  
 
Aim 4: To determine whether use of the oral contraceptive pill modifies the innate immune 




This chapter investigates four hypotheses: 
 
Hypothesis 1: That women with dysmenorrhoea-related pelvic pain exhibit activation of the 
innate immune system via Toll-Like Receptor mechanisms compared with pain-free controls. 
 
Hypothesis 2: That the responsiveness of PBMCs to TLR2 or TLR4 stimulation, as measured 
by release of the cytokine IL-1β, can act as a pain biomarker for dysmenorrhoea-related pelvic 
pain.  
 
Hypothesis 3: That IL-1β release from B s is higher on days where reported pain is severe 
than on days when pain is absent or mild. 
 
Hypothesis 4: That IL-1β release from B s is modified by the use or non-use of the oral 
contraceptive pill.  
 
This is the first study to investigate an in vitro immune relationship in young women with pain 
at an early stage of their chronic pain condition, and in response to a dynamic, natural pain 
stimulus – their own menstrual cycle.  
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This chapter introduces the manuscript entitled “Toll-Like Receptor Responsiveness of 
Peripheral Blood Mononuclear Cells in Young Women with Dysmenorrhea” which has been 
published in the Journal of Pain Research.  
    
3.4 MANUSCRIPT AND STATEMENT OF AUTHORSHIP 
 
The study was part-funded by the Australia New Zealand College of Anaesthetists (ANZCA) 
Research Foundation (Grant 15/013). Its contents are solely the responsibility of the authors 
and the funders had no role in the study design, data collection and analysis, decision to 
publish, or preparation of the manuscript. 
 
The following manuscript was published in the Journal of Pain Research on 9th March 2020:  
TOLL-LIKE RECEPTOR RESPONSIVENESS OF PERIPHERAL BLOOD MONONUCLEAR 
CELLS IN YOUNG WOMEN WITH DYSMENORRHOEA 
 
All authors gave final approval of the version to be published, and agree to be accountable for 






women.10–12 Hardi et al9 retrospectively reviewed 100
women with dysmenorrhea-predominant persistent pelvic
pain, and found that dysmenorrhea predated the development
of persistent pain by between 1 and 30 years.
Current medical management options include the oral
contraceptive pill (OC), non-steroidal anti–inflammatory
medications (NSAIDs), or progestogens. However, many
young women find these options to be ineffective, contra-
indicated or unacceptable.13 There is an unmet need for
new, effective treatments for dysmenorrhea.
Traditionally, dysmenorrhea in women has been classi-
fied as either primary, where no organic cause has been
identified, and secondary, where an associated condition,
such as endometriosis is present. However, despite the
recognized association and common co-existence of endo-
metriosis with dysmenorrhea, there is no reliable correla-
tion between the severity of endometriosis lesions and the
severity of pain.14 In previous work, our group has demon-
strated the strong association between dysmenorrhea and
a range of symptoms, both within and outside the pelvis,
that include: headache, fatigue, anxiety, low mood, bladder
or bowel symptoms, and nausea.15 These factors strongly
suggest the presence of additional elements affecting the
experience of dysmenorrhea. Compelling epidemiological,
clinical and experimental evidence in both human and
animal studies demonstrates that increased peripheral and
central nervous system (CNS; glial) immune system activ-
ity, via Toll-like receptors (TLRs), is involved in the
development of persistent pain conditions.16 In this
paper, we propose that immune pathology may also be
present in women affected by dysmenorrhea, whether or
not an associated condition such as endometriosis is pre-
sent, and that activation of the immune system in these
women occurs via TLRs. Therefore, the innate immune
reactivity of an individual’s peripheral blood immune cells
may provide insights into the mechanism behind their
disease state.
TLRs are a family of receptors found on the surface
membrane of cells of the innate immune system, such as
macrophages, glia and astrocytes. They recognize molecu-
lar patterns typically associated with microbial pathogens
and facilitate an immune response with the release of cyto-
kines, including interleukin-1beta (IL-1β), both peripher-
ally and in the spinal cord. Lipopolysaccharide (LPS), also
known as endotoxin, is a component of the cell wall of
gram-negative bacteria, which elicits robust immune
responses in animals via TLR4 receptors. PAM3CSK4
(PAM) is a synthetic lipopeptide that elicits strong immune
responses via TLR2 receptors. Altered TLR inflammatory
responses have been demonstrated in visceral medical con-
ditions characterized by persistent pain, such as inflamma-
tory bowel disease and painful bladder syndrome.17,18
Macrophages are cells of the innate immune system that
originate from peripheral blood monocytes and are present
in almost all tissues. These cells alter their physiology,
infiltrate tissues and secrete cytokines including IL-1β19,20
in response to inflammatory mediators.
We hypothesize that peripheral blood mononuclear cells
(PBMCs) from women with severe dysmenorrhea exhibit
enhanced IL-1β release following stimulation of either TLR4
or TLR2 receptors when compared with normal (control)
womenwithminimal, or no, dysmenorrhea.Where confirmed,
this offers the potential for the responsiveness of PBMCs to
TLR stimulation to be used as a biomarker for pain in future
research of dysmenorrhea treatment options.We also hypothe-
size that TLR responsiveness is modulated by use of the OC,




This is an observational clinical and laboratory study, with
samples taken from women at two stages of their menstrual
cycle. This studywas approved by the HumanResearch Ethics
Committee of the Royal Adelaide Hospital, Adelaide, South
Australia. HREC/14/RAH/63. RAH Approval No. 140217.
The study was conducted in accordance with the Declaration
of Helsinki.21
Participants
The target population consisted of girls and women aged
between 16 and 35 years of age. Potential participants were
invited to complete a Survey Monkey Questionnaire when
they responded to recruitment notices displayed to the gen-
eral public or following an invitation to enroll through
a private medical clinic, Pelvic Pain SA, Adelaide,
Australia. After selection based on the eligibility criteria,
participants were provided with a study information sheet.
Study exclusion criteria (Table 1) ensured that women pos-
sessing factors that might influence inflammation, TLR
receptor response, the immune system, or the severity of
dysmenorrhea were excluded from the study. Eligible parti-
cipants from the general public were offered the opportunity
of an initial phone interview to provide further information
about the study, to obtain consent for further participation in
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the study, and to arrange a screening assessment visit with the
Principal Investigator (PI). Figure 1 shows the Enrolment
Flow Chart for study inclusion.
Three hundred and sixty women completed the online
questionnaire, with 105 women choosing to provide their
contact details for consideration for study inclusion. Phone
interview assessment by the Principal Investigator further
excluded 44 women based on the presence of exclusion
criteria. Sixty-one women recruited from the general public
and five additional women recruited through Pelvic Pain SA,
Adelaide, Australia proceeded to the Screening Visit, where
they underwent a full clinical assessment, and the appropriate
study group allocation was accurately determined.
Participants below the age of 18 were interviewed in the
presence of their parent or guardian, who co-signed the
consent form with the participant. One participant was
excluded due to previous pregnancy. Thus, a total of 65
women were enrolled in the study. Nine women were
excluded during the study due to a high pre-test level of
C-reactive protein (1), use of marijuana (1), irregular men-
strual cycles (3), non-attendance for testing (2), insufficiently
severe pain (1), and the development of an unrelated neuro-
logical illness (1). Fifty-six women satisfied all inclusion and
exclusion criteria and completed the testing procedures.
Group Allocation
Participants were allocated to seven clinical groups at the
Screening Visit (Table 2; groups 2A and B combined).
Group allocation was determined by the self-reported pre-
sence or absence of severe dysmenorrhea, the use or non-
use of the OC, and the self-reported presence of pelvic
pain for more, or less, than 15 days per month, as reported
at the Screening Visit. Controls were women with self-
reported dysmenorrhea of between 0 and 3 on an 11-point
numerical scale (NRS)22 using anchor points of 0 and 10,
where 0 represented no pain and 10 represented the most
severe pain imaginable on the worst day of their menstrual
period (Groups 1 and 2). Controls who were OC users
(Group 2) were further divided into women who were
pain-free prior to use of the OC (Group 2A), and women
who had self-reported dysmenorrhea of between 4 and 10
prior to OC use (Group 2B). However, as study results for
Group 2A and Group 2B were found to be similar, these
groups were combined to form an enlarged Group 2, as
illustrated in Table 2.
Dysmenorrhea-based pelvic pain participants (Groups 3, 4,
5 and 6) had self-reported dysmenorrhea of 7–10 on an
11-point NRS on the worst day of their menstrual period. As
the number of days affected by pain varied throughout the
severe dysmenorrhea cohort, participants with dysmenorrhea
were further divided into those with pelvic pain for less than
15 days permonth (Groups 3 and 4), and thosewith pelvic pain
for more than 15 days per month (Groups 5 and 6). This
provided an estimate of the severity of life impact of their
dysmenorrhea-based pelvic pain condition. Dysmenorrhea-
based pelvic pain participants (Groups 3,4,5 and 6) were
further divided based on OC use (non-OC users in Groups 3
and 5; OC users in Groups 4 and 6).
Study Visit Schedule
Participants were assessed on two occasions during a single
menstrual cycle: the menstrual phase (Day 1–2 of their
menstrual cycle), a phase associated with high pain in
women with dysmenorrhea; and the mid-follicular phase
(Day 7–10 of their menstrual cycle), a time associated with
low pain in women with dysmenorrhea. At Study Visit 1,
participants attended the Pain and Anaesthesia Research
Clinic (PARC) of the Royal Adelaide Hospital, Adelaide,
Australia on either day 1 or 2 of their menstrual cycle.
Table 1 Study Exclusion Criteria
Dysmenorrhoea on Day 1 2 reported as 4 6 on a 10-point scale
Menstrual cycle length less than 26 or more than 30 days
Irregular menstrual cycles
Previous pregnancy
Use of reproductive hormones (apart from OC)
Use of levonorgestrel-releasing intrauterine device
Use of thyroxine, insulin or corticosteroids
BMI less than 16 or more than 30
Inflammatory process, surgical procedure or infection in previous 4
weeks
Renal, hepatic, cardiac or auto-immune disease
Use of immunosuppressant medications
Use of medications affecting TLR responsiveness, including
amitriptyline and minocycline
Use of analgesics including anti inflammatory drugs, opioids or
paracetamol for 5 drug half-lives prior to testing
Use of alcohol for 24 hrs prior to testing
Use of opioids or marijuana for 30 days prior to testing
Inability to read or comprehend written information provided
Dovepress Evans et al




acid (EDTA), and PBMCs isolated using Optiprep (Sigma-
Aldrich, Castle Hill, NSW, Australia) as directed by the
manufacturer, using the mixer flotation method.
Quantification of PBMC Responsiveness to TLR
Stimulation
To test our hypotheses, we utilized the laboratory techni-
que devised by Kwok et al to measure IL-1β release from
PBMCs following TLR stimulation.23,24 Two analyses
were undertaken: one using the TLR4 agonist LPS, and
the other using the TLR2 agonist PAM.
Isolated cells were diluted to 1 x 106 cells·mL 1 in
enriched RPMI 1640 (10% (v/v) fetal calf serum and 1%
(v/v) penicillin), and plated into 96 well plates (Nunc,
Roskilde, Denmark) using 100 µL per well. Sufficient cells
were obtained from all participants, and plasma was not col-
lected. As no reference range for LPS or PAM concentration is
available for this group, TLR responsiveness was assessed
across a range of concentrations. Triplicate wells were treated
with a dosage curve of TLR agonists: LPS; 12.5 pg·mL 1 to
10 µg·mL; 1 and PAM 12.5 pg·mL 1 to 1 µg·mL 1 (Sigma-
Aldrich, Castle Hill, NSW, Australia). Control wells contained
no TLR agonist. Plates were incubated for 20 hrs at 37 °C and
5% CO2 in a humidified environment (Thermoline Scientific,
Sydney, Australia). IL-1β levels were determined using
a commercially available ELISA kit (IL-1β ELISA; BD
Bioscience, Australia) according to themanufacturer’s instruc-
tions. The absorbance was quantified on a BMG Polarstar
microplate reader (BMG Labtechnologies, Offenburg,
Germany) at 450 nm. The manufacturer’s limit of quantifica-
tion of 0.8 pg·mL 1 was used, with any readings below this
removed from further analysis.
Method for Statistical Analysis
To determine the responsiveness of PBMCs to LPS stimula-
tion, represented by the EC50, concentration-response curves
were fitted to an Emax model using the Hill equation
25 and
a non-linear mixed-effects model approach. The slope para-
meter was fixed to 1 to reduce the number of parameters to be
estimated. The model used was of the form:
E ¼ E0 þ
Emax #C
EC50 þ C
where E0 is the response Y at baseline (absence of dose),
Emax is the asymptotic maximum dose effect (maximum
effect attributable to the drug), and EC50 is the concentra-
tion which produces 50% of the maximal effect.
Individual Emax models were fitted for each subject at
each timepoint (Day 1–2 or Day 7–10). Before model
fitting, individual plots of the concentration-response data
collected were used to estimate the EC50, Emax and Emin
for each subject at each timepoint, to assess the applic-
ability of an Emax model. As several participants demon-
strated a maximum response at well below the maximum
concentration tested, potentially associated with reduced
cell stability at higher concentrations of LPS, only con-
centrations up to the observed maximum response were
used in model fitting. For doses above the maximum
response, the maximum response observed was imputed
to force a plateau and facilitate model fit. All model fitting
and all analyses were performed using Statistical Analysis
Software (SAS v 9.4). Starting values were set with Max
representing the maximum response observed for that par-
ticipant at that timepoint, and Min representing the mini-
mum response for that participant at that timepoint. From
the model, estimated values for EC50, Emax and Emin were
obtained for each subject at each timepoint. The results for
EC50 were analyzed using a mixed model for repeated
measures with EC50 as the outcome variable and day
(1–2 or 7–10), OC use (yes or no) and pain (no pain,
Table 2 Summary of Group Allocation Criteria and Demographics




















1 Controls: No OC 8 - - - 23.6 23.9 1.25 0.25
2 Controls: OC 15 - - + 21.9 22.3 0.92 0.31
3 Dysmenorrhea: No OC 7 + - - 25.7 23.1 6.4 0.4
4 Dysmenorrhea: OC 8 + - + 21.3 22.4 5.75 0.25
5 Pelvic Pain: No OC 8 + + - 22.6 22.2 6.9 1.25
6 Pelvic Pain: OC 9 + + + 22.9 20.4 6.9 3.9
Notes:+ = present, - = absent.
Abbreviation:OC, oral contraception.
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dysmenorrhea <15 days per month, dysmenorrhea >15
days per month) as factors in the model.
The main effects from the model provide information
on the differences in PBMC responsiveness according to
the presence of pain (irrespective of OC use or menstrual
phase), differences in PBMC responsiveness according to
OC use (irrespective of the presence of pain or menstrual
phase) and differences in PBMC responsiveness according
to menstrual phase (irrespective of the presence of pain or
OC use). Participant was included as a repeated term using
a compound symmetry covariance structure. From the
model the differences in responsiveness of PBMCs to
LPS stimulation were determined, according to the six
clinical groups described in Table 2.
During the analysis, variation in the days per month of
pain was noted within groups 3, 4, 5 and 6 between that
reported at the Screening Visit and that reported at pre-
sentation on study test days. For this reason, further ana-
lysis was undertaken combining Groups 3 and 5 (pain; no
OC use) and Groups 4 and 6 (pain; OC use) together to
include participants experiencing pain regardless of the
number of pain days per month. This analysis allowed us
to consider the effect of three individual factors within the
entire participant group: the presence or absence of pain
(Pain vs No Pain), the use or non-use of the OC (OC vs No
OC), and the menstrual phase of testing (Day 1–2 vs Day
7–10). From the model the differences in Least Squares
(LS) mean values for comparisons of interest were
obtained with 95% confidence limits and relevant
P-values by factor, as shown in Figure 4.
The model was a reasonable fit, with a few outlier
results noted. Outliers were identified through two meth-
ods. Using Method 1, the raw mean and standard deviation
were obtained, and values outside mean ± 2 standard
deviations were flagged as outliers. Using Method 2,
once the model was fitted, the residuals were obtained
together with their standard error. Any value outside ± 2
was flagged as an outlier. The mixed model was then re-
run excluding any value identified by either method as an
outlier. The overall results were not substantially changed,
and further statistical analysis was continued using the full
data set with outliers included.
Results
All participants were aged between 16 and 35 years, had
regular menstrual cycles, no previous pregnancies, nor-
mal body mass index (BMI) and were in good general
health, apart from the presence of dysmenorrhea-
predominant pelvic pain. As described in Table 2, and
using one-way ANOVA and Kruskal–Wallis post hoc
analyses, no significant differences were found for the
age (p=0.52), height (p=0.52) or weight (p=0.68) of the
women in each group. There were no significant differ-
ences in BMI (p=0.38) or age (p=0.60) between those
with and without pain, and there were no significant
differences in BMI (p=0.21) or age (p=0.11) between
users and non-users of the OC. The average menstrual
pain score for each group recorded at the time of testing
was noted to be less than the maximal pain score pre-
dicted by participants during group allocation at the
screening visit.
Table 2 summarizes the group allocation criteria and
demographics.
IL-1β Release Following Stimulation with
PAM and LPS
All participants exhibited minimal IL-1β release in the non-
stimulated state. Both TLR4 agonist LPS, and TLR2 agonist
PAM3CSK4, induced elevations in IL-1β in the isolated
PBMCs from all participants. Inspection of the data showed
that the effect size following PAM stimulationwas smaller and
more variable than the effect size following LPS stimulation
(Figures 2 and 3). The IL-1β response to LPS stimulation
followed a biphasic distribution across the logarithmic con-
centration range of 12.5 pg·mL 1 to 10 µg·mL 1 (Figure 2).
A similar direction of response was seen in PBMCs stimulated
with PAM across the logarithmic concentration range of
12.5 pg·mL 1 to 1 µg·mL 1 (Figure 3) but the response
followed a monophasic distribution with wide variability. In
view of the smaller effect size and higher variability following
PAM stimulation, only LPS responses are analysed further.
Analysis of EC50
The Least Squares (LS) mean values for EC50 and Emax for
the variables Pain, OC use and Day of testing were
obtained from the mixed model. Emax values were vari-
able, consistent with suspected non-specific cellular toxi-
city at high LPS concentrations. As it is the responsiveness
of PBMCs to LPS stimulation that we are investigating,
rather than the absolute Il-1β levels, further analysis con-
siders the LS means for EC50 rather than Emax. EC50 is the
outcome variable we have used to compare the respon-
siveness of PBMCs to TLR4 stimulation with LPS
between participants.
The LS mean values for EC50 by factor with p value are
displayed in Table 3 and plotted in Figure 4. The difference
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Discussion
To our knowledge, this data is the first to demonstrate an
increase in systemic immune responsiveness in young
women with dysmenorrhea-related pelvic pain to TLR
agonists. This is a preliminary study with potentially wide-
ranging clinical implications. Our initial hypothesis, that
there would be a “pain response” to severe dysmenorrhea,
as evidenced by a dynamic, increased responsiveness of
PBMCs following TLR stimulation at the time of painful
menstruation, was confirmed. However, the association
was less than that demonstrated by Kwok et al23 in an
older, undifferentiated cohort of both male and female
chronic pain patients. While the direction of response for
both TLR2 and TLR4 stimulation was similar, the effect
size was greater with TLR4 stimulation.
Our research demonstrated a significant difference
between the responsiveness of PBMCs to TLR4 stimu-
lation (Table 3, p=0.042) in women with and without
dysmenorrhea-related pelvic pain. The mechanism
behind the upregulation of the innate immune system
in these women with pain may involve factors that
increase exposure of the uterus or peritoneal cavity to
TLR stimulation, or that impair the immune response to
normal TLR stimulation.
Recurrent Retrograde Menstruation with
Exposure of the Peritoneal Cavity to
Endometrial Immune Cells and
Microorganisms as a TLR Stimulus to the
Innate Immune System
Exposure of the peritoneal cavity to menstrual blood and
debris via the process of retrograde menstruation through the
fallopian tubes has already been demonstrated in 76–90% of
women.26 During the late secretory phase of the menstrual
cycle, an influx of immune cells, including macrophages,
arrives in the endometrium following the normal, pre-
menstrual fall in progesterone. Menstrual fluid that reaches
the peritoneal cavity includes blood, shed endometrial cells,
immune cells and bacteria, including the gram-negative
bacilli with cell walls comprised of LPS.27 As such, retro-
grade menstruation provides multiple opportunities for inter-
action with the innate immune system.28 Menstrual stromal
cells have been identified in lymph nodes draining the uterus
during menstruation providing further evidence of immune
clearance of endometrial cells in menstrual fluid.29 Our
research demonstrated an increased responsiveness of the
innate immune system independent of the day of testing
(Table 3, p=0.22). This supports the presence of immune
activation across the menstrual cycle, rather than purely in
the presence of severe pain. These findings are consistent
with the clinical studies by Slater, Vincent, Payne, Granot
and As-Sanie30–34 who have demonstrated a reduced pain
stimuli threshold in women with dysmenorrhea, present
throughout the menstrual cycle, at both pelvic and extra-
pelvic sites, as measured by pressure pain threshold or
functional MRI change.
Figure 4 Least Squares means for EC50 with 95% confidence limits by factor using
mixed model.
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An Impaired Immune Response with
Reduced Clearing of Menstrual Debris
from the Peritoneal Cavity as a Stimulus
to the Innate Immune System
While all women with an intact uterus menstruate, and
many exhibit retrograde menstruation, not all women suffer
severe dysmenorrhea. A healthy immune response may be
required to clear the pelvis of menstrual debris promptly,
and an impaired immune response may be associated with
reduced clearing of menstrual debris. Persistent chronic
inflammation associated with residual menstrual tissue
could be a mechanism for increased pain. Such an impaired
response would provide prolonged stimulation of TLRs,
Figure 5 Forest Plot for difference in LS means for EC50 with 95% confidence limits by factor.
Table 3 Least Squares Means for EC50 (with 95% Confidence Limits) and Significance (*) by Factor, Derived from Mixed Model Comparing
Participants with Pain/No Pain, OC Use/Non OC Use, Day 1–2/Day 7–10 in Controls WhoWere Non OC Users, and Day 1–2/Day 7–10 in
All Participants
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with potential for enhanced immune system activation. Our
finding that there was no significant difference between
TLR4 responsiveness in the menstrual compared with the
mid-follicular phase across our entire participant cohort
(Figure 5, Line 3) suggests that the process of menstruation
itself is not the sole contributor to TLR responsiveness. This
finding was further investigated within the group of pain-
free controls who were non-OC users (Group 1). There was
no significant difference between the responsiveness of
PBMCs in the menstrual compared with the mid-follicular
phase (Table 3, p=0.16) of pain-free controls who were non-
OC users.
Recurrent Stimulation of the Innate
Immune System, via TLRs as a Potential
Driver of Peripheral and Central Pain
Sensitization
It has been proposed that recurrent, monthly, painful
menstruation may lead to the development of persistent
pain states.23 Our study provides evidence that this
effect may act in part via TLR4 mediated mechanisms.
Preclinical models have demonstrated that glia assume
a pro-inflammatory reactive state following activation by
TLRs, and that TLR4 mediated inflammation contributes
to central pain amplification via the dorsal horn of the
spinal cord.35 The established ability of TLR antagonists
to significantly reduce experimentally induced neuro-
pathic pain in an animal model further supports these
findings.36 In human studies, dysmenorrhea appears to
be a central factor in the development of viscero-
visceral hyperalgesia, and pain co-morbidities including
migraine.15,37-39 Multiple studies have shown that even
small peripheral immune challenges have a profound
effect on pain enhancement, even in healthy
subjects.40–42 Doses of LPS as low as 0.4 ng·kg 1
delivered intravenously (IV) can provoke immune
enhancement of pain responsiveness, which is below
the threshold for a clinical response in healthy adults.
This dose is also below the FDA approved level of LPS
contamination (1 ng·kg 1) in drug preparations and
intravenous fluids. Our data, demonstrating an underly-
ing sensitivity of PBMCs to TLR4 stimulation in
women with dysmenorrhea-related pelvic pain provides
a plausible mechanism by which cyclical exposure to
menstruation engendering recurrent innate immune sti-
mulation may predispose some women to chronic pelvic
pain.
The Oral Contraceptive as Treatment for
Dysmenorrhea
Despite its widespread use for the clinical management of
dysmenorrhea, the exact mechanism by which the OC
reduces pain in some, but not all women with dysmenor-
rhea remains uncertain. Our hypothesis that use of the OC
would modulate the responsiveness of PBMCs in women
with dysmenorrhea was not supported. Furthermore, we
found no significant differences in IL-1β release between
women who were users or non-users of the OC (Table 3,
p=0.98). It appears that the benefits some women derive
from OC treatment for the management of dysmenorrhea
is via pathways other than TLR-mediated immune system
modulation. Alternatively, it may be that the OC nor-
malizes the increased responsiveness of PBMCs to pain,
masking the underlying pain pathology.
While our research found no significant difference
between the responsiveness of PBMCs to TLR stimulation
inwomenwhowere users or non-users of theOC, this requires
further research. It is known that the sensitivity of TLR4
receptors is increased by estrogen35,43. The OC is widely
used by young women for a range of hormonal management
and contraceptive purposes apart from dysmenorrhea, and an
improved understanding of its immune effects would have
wide-ranging implications for clinical practice. It is important
to note that the women using the OC in our investigation were
not selected on the basis of clinical benefit of OC use for pain.
This limits the conclusions that can be drawn from our data.
TLR Stimulation of PBMCs as a Blood
Biomarker for Pain in Women with
Dysmenorrhea
While the evidence linking TLRmediated neuro-inflammation
and chronic pain in animal models is compelling,35,44 its rele-
vance to human pain conditions has been lacking, largely due
to the inaccessibility of the human central nervous system
(CNS) and the lack of a reliable, effective, human biomarker
for pain or immune activation. Pain in humans has thus been
a subjective experience, conventionally assessed by patient
reports or rating scales. This lack of suitable biomarker ham-
pers the development of new pain management options. It
reduces our ability to predict which women are most at risk
of pain progression, our ability to monitor the response to pain
therapies and it confounds patient stratification for enriched
clinical trials.
However, given the research findings byKwok et al24 that
the TLR response from PBMCs does indeed mirror similar
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changes in the spinal cord, the demonstration by Kwok et al
and Schrepf et al17,23 that the technique we have used can
indeed differentiate a human cohort of either chronic pain or
bladder pain patients from controls, and our own research
findings, we believe that the measurement of innate immune
responsiveness has the potential to be a useful biomarker for
pain in women with dysmenorrhea. Unlike our study, Kwok
et al24 and Schrepf et al17 found the response to TLR2
stimulation to be a better discriminator of persistent pain
status than the response to TLR4 stimulation. However, the
participant cohort in Kwok and Schrepf’s studies included
confounding diagnostic variables, such as co-morbid medical
conditions, drug or hormone use, male patients, and pain
conditions outside the pelvis. For the potential of this test
as a biomarker for pain to be realized, longitudinal interven-
tion studies, ideally placebo controlled, using the biomarker
would be required. This testing can be performed indepen-
dently of the menstrual cycle stage, simplifying future trans-
lational clinical trial development. However, the wide
variability between individual responses, and the time and
resource intensive requirements of the laboratory procedure
we have used, limit its practical use. While repeating the
study with larger numbers of participants may further refine
the research findings, we do not believe that this should be
undertaken. Advances in TLR testing using single point
analysis provide improved convenience over our research
protocols, despite their lack of ability to measure dynamic
PBMC responsiveness in individual patients. Our study has
demonstrated that testing can be performed independently of
the menstrual cycle stage, simplifying future translational
clinical trial development.
The Association Between Dysmenorrhea,
Endometriosis and the Innate Immune
System
Despite our focus on the role of the innate immune system
and the primary care presentation of dysmenorrhea, it is
recognised that a proportion of our study participants with
pain may have endometriosis. Endometriosis was found in
62% of 880 adolescents undergoing laparoscopy for severe
dysmenorrhea in a meta-analysis of 15 studies.45 However,
dysmenorrhea may occur without endometriosis, endome-
triosis may be present without pain, and pain may persist
despite complete surgical excision of endometriotic
lesions, showing that the association between endometrio-
sis and dysmenorrhea should not be assumed to imply
causality.14,46
Endometriosis is recognized as an inflammatory condi-
tion, with an increase in IL-1β release both at a local and
systemic level.47,48 Increased E. Coli colony formation with
increased endotoxin (LPS) levels has been demonstrated in
both menstrual blood and the peritoneal fluid of women with
endometriosis, with endometrial cell growth enhanced by
LPS administration.27 These findings prompted Khan et al
to propose the “Bacterial contamination theory” for the
development of endometriosis lesions, whereby contamina-
tion of menstrual fluid by E. Coli elicits peritoneal inflamma-
tion and predisposes to the development of endometriosis
lesions.49 The prolonged presence of endometrial cells in the
peritoneal cavity following menstruation has been demon-
strated in women with endometriosis, and ascribed to either
deficient cell-mediated immunity,50,51 or enhanced endome-
trial cell survival. Our research has investigated TLR activa-
tion from a pain, rather than an endometriosis lesion
perspective. Despite this, it is possible that similar mechan-
isms, potentially involving impairment of the innate immune
system and TLR activation, may predispose an individual to
both conditions.
Study Strengths and Weaknesses
A strength of this study is the stringent exclusion criteria
used, the lack of clinical co-morbidities, and the lack of
confounding medications in this young, otherwise healthy,
patient group. Another strength is the sampling at two
stages of the menstrual cycle in each participant. This
enables estimates of within-subject variability to be distin-
guished from between-subject and assay variability. Our
study’s demonstration that testing can be done during both
the menstrual and mid-follicular phases of the menstrual
cycle further enhances the applicability of this test to
research and clinical practice.
Our study is an observational study with small group sizes,
rather than an interventional study with large numbers of
participants. Therefore, firm conclusions cannot be made.
However, our study design was suitable given the exploratory
nature of our research. As our participants were not rando-
mized for OC usage, there is potential for selection bias.
Future studies may choose to stratify groups according to
participant-reported benefit or non-benefit of the OC for pain
symptoms.
Conclusion
To our knowledge, this is the first study to demonstrate an ex
vivo immune relationship in young women with dysmenor-
rhea-related pelvic pain. This response was at an early stage
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of their pain condition, and in a participant cohort free of
confounding medical conditions or medications.
Our study found a significantly increased responsiveness
of peripheral blood mononuclear cells to toll-like receptor
stimulation using lipopolysaccharide (p=0.042). No differ-
ence was found in PBMC responsiveness in women who
were users or non-users of the OC (p=0.98). We propose that
the mechanism of increased pain responsiveness in young
women with dysmenorrhea results from a TLR-mediated
activation of the immune system, after impaired clearing
and prolonged exposure of the peritoneal cavity to menstrual
and bacterial debris. This research provides a basis for the
consideration and future development of novel treatments
for dysmenorrhea and persistent pelvic pain.
Our study makes substantial progress in expanding our
knowledge of the biological basis of dysmenorrhea-related
pelvic pain, a field that has been under-researched when
compared to its impact on individual women and society.
This study identifies key parameters and therapeutic targets
for further research and drug development in this area of
unquestioned need.
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Hypothesis 1, that young women with severe dysmenorrhoea have enhanced IL-1β release 
from peripheral blood mononuclear cells following stimulation of TLR 2 and 4 receptors using 
the TLR4 agonist lipopolysaccharide (LPS) and the TLR2 agonist Pam3CSK4, when 
compared with normal (control) women with minimal dysmenorrhoea was confirmed. Unlike 
the studies of Kwok and Schrepf (Kwok et al., 2013; Schrepf et al., 2015) our research found 
TLR4 to be a better discriminator for pain than TLR2. The studies by Kwok and Schrepf were 
confounded by medications, diverse pain diagnoses, and medical co-morbidities, while our 
study enrolled a young, more homogeneous population.   
 
Hypothesis 2, that the responsiveness of PBMCs to TLR2 or TLR4 stimulation, as measured 
by the release of IL-1β release, has potential as a biomarker for the presence of 
dysmenorrhoea-related pelvic pain was confirmed. However, while further studies using this 
technique and a larger sample size may elicit further information, the technique we used is 
labour intensive and operator dependent. It is likely that simpler, bedside, reproducible tests 
for immune activation will replace it, and be easier to use as a guide for clinical management.   
 
Hypothesis 3, that increased immune responsiveness of PBMCs to TLR stimulation would be 
present only on days of high pain was not supported. Women with severe pain showed 
increased TLR4 responsiveness on both high and low pain days. This finding offers the 
potential for simplification of specimen timing in future trials. 
 
Hypothesis 4, that the responsiveness of PBMCs to TLR stimulation would be modulated by 
use of the oral contraceptive pill was not supported. Despite its widespread use for 
dysmenorrhoea, our findings suggest that the OC reduces dysmenorrhoea-related pelvic pain 
through mechanisms independent of the innate immune system.  
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CHAPTER 4: IS HIGH SENSITIVITY C-REACTIVE PROTEIN 
MEASUREMENT IN BLOOD A RELIABLE PROXY FOR INNATE 





As discussed in Chapter 3, the discovery and validation of a blood biomarker for 
dysmenorrhoea-related pelvic pain would simplify the evaluation and development of novel 
pelvic pain treatments. A potential simple marker for activation of the immune system is high-
sensitivity C-Reactive Protein (hsCRP). Chapter 4 investigates the potential for hsCRP to act 
as a biomarker for pain and immune activation in our cohort of women with dysmenorrhoea. 
 
C-Reactive Protein is an acute phase protein of the innate immune system found in blood 
plasma, whose concentration rises in response to inflammation or infection (Gabay & Kushner, 
1999; M. Harrison, 2015). CRP is produced in the liver and rises in response to an increase 
in IL-6 secretion by macrophages or T-cells. The main biologic function of CRP is to recognise 
pathogens and damaged cells within the body and to facilitate their removal by recruiting 
phagocytic cells and the complement system. (Volanakis, 2001) A substantially raised CRP is 
found in women with acute pelvic inflammatory disease, where a bacterial infection of the 
peritoneal cavity induces a substantial host response. However, a raised CRP is non-specific, 
and has been associated with a range of both gynaecological (Hemilä et al., 1987), and 
systemic inflammatory conditions including inflammatory bowel disease (Vermeire et al., 
2004), and rheumatoid arthritis (Amos et al., 1977). Ma et al studied monocytes in the 
peripheral blood of women with dysmenorrhoea, and found an up-regulation of genes coding 
for pro-inflammatory cytokines, with these changes present throughout the menstrual cycle 
(Ma et al., 2013).  
 
In response to infection, or acute inflammation, CRP levels rise above the commonly reported 
normal level of <5 mg/L, usually to an order of magnitude of difference (Lourenço et al., 2014).  
High levels such as these are easily recognised as abnormal. However, over recent years, 
there has been increasing interest in the relevance of mildly elevated CRP levels, potentially 
as a marker for low-grade inflammation and increased risk of inflammatory disease states. 
This interest has been facilitated by the development of a high-sensitivity test for CRP (hsCRP) 
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able to measure and distinguish levels below 5mg/L. High sensitivity testing has determined 
that a normal level of CRP in healthy individuals is <1mg/L, and shown an association between 
a CRP level of 1-3 mg/L and a range of systemic inflammatory conditions (Dhingra et al., 
2008). In this study, based on the Framingham Offspring Study of 3782 participants (mean 
age 55 years; 52% women) free of cardiovascular disease, the prevalence of inflammatory 
conditions among women rose from 46.5% where hsCRP<1mg/L, to 51.7% where hsCRP 1-
3mg/L, to 56.0% where hsCRP 3-10mg/L, and to 70.1% where hsCRP >10mg/L. The level of 
hsCRP has already been utilised within a Norwegian Risk Factor Composite score, 
incorporating body mass index, fibrinogen, C-reactive protein, and triglycerides to predict the 
presence of chronic pain (Sibille et al., 2016).  
 
Recently, Gold et al investigated 2939 women aged between 42 and 52 years, to determine 
whether an increased hsCRP level could be used as a biomarker for women reporting a range 
of premenstrual symptoms, including abdominal cramps and back pain.  (Gold et al., 2016) 
Their research found that an hs R  level  mg  was significantly positively associated with 
abdominal cramps or back pain with an adjusted odds ratio of 1.40 (95% CI 1.09-1.80). While 
this study suggests a possible relationship between hsCRP and pain, research by Mu et al 
investigating a relationship between hsCRP and the presence of endometriosis was not 
supportive. Mu et al. (2018) measured the levels of a range of inflammatory blood markers, 
including IL-β, -6, TNF-α receptor 1 and 2, and hsCRP in 350 women (average age 42 years) 
with endometriosis, and 694 healthy female controls. While they found a correlation between 
the levels of IL-β and endometriosis, they found no correlation between levels of hs R  levels 
and the presence of endometriosis. However, both the study by Mu et al. and the study by 
Gold et al. investigated middle-aged and older women, without documenting the phase of their 
menstrual cycle at blood sampling. For this reason, the potential of hsCRP to act as a 




Chapter 4 investigates the potential of hsCRP to act as a simple, rapid and reproducible 
biomarker for the degree of inflammation, or the severity of pain by further investigating the 
cohort of young women, with and without dysmenorrhoea-related pelvic pain, described in 
Chapter 3. It has 2 aims: 
 
Aim 1: To investigate the potential for the blood measurement of hsCRP to act as a biomarker 
for the severity of dysmenorrhoea-related pelvic pain within an outpatient clinical setting.   
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Aim 2: To investigate whether blood levels of hsCRP correlate with the number of days of 




This chapter investigates two hypotheses: 
 
Hypothesis 1: That increasing levels of hsCRP correlate with an increasing DPelvicPM, and 
can thus act as a biomarker for the lived experience of pain.  
 
Hypothesis 2: That increasing levels of hsCRP correlate with an increased responsiveness of 
PBMCs to TLR4 stimulation, as measured by the EC50 for release of IL-1β from B s, in 





This cohort comprises 56 women stratified into groups according to the presence of pain, 
measurement of the DPelvicPM, and stratification based on the use or non-use of the oral 
contraceptive pill.  
 
High-sensitivity CRP measurement was undertaken on blood samples taken on Day 1-2 of 
the menstrual cycle, and on Day 7-10 of the menstrual cycle, as per the protocol outlined in 
the published article, Evans SF, Kwok YH, Solterbeck A, Liu J, Hutchinson MR, Hull ML, & 
Rolan PE. (2020). Toll-Like Receptor Responsiveness of Peripheral Blood Mononuclear Cells 
in Young Women with Dysmenorrhea. Journal of Pain Research, 13, 503–516.  
 
Blood analysis for hsCRP was performed through Healthscope Laboratories.  
 
4.5 RESULTS (UNPUBLISHED) 
 
Multiple comparisons were made between the level of hsCRP and variables including clinical 
group allocation, day of testing, DPelvicPM, use or non-use of the OC, and the responsiveness 
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of PBMCs to LPS stimulation as measured by the EC50 for release. Comparisons made and 
figures generated were formed using GraphPad Prism.  
 
A comparison between the level of hsCRP in women who are users, and non-users, of the 
OC 
A two-tailed unpaired t-test was used to investigate the levels of hsCRP among the entire 
participant cohort divided into users and non-users of the OC. Levels of hsCRP were 
significantly higher among OC than non-users on both Day 1-2 (p=0.027) and Day 7-10 




Figure 4.1: Comparison of hsCRP levels for each individual either taking (blue) or not taking 








Further analysis was undertaken to compare hsCRP with clinical grouping according to the 
presence or absence of pain, whether pain was present for more than 15 or less than 15 days 
per month, and OC use (Figure 4.2). Using a one-way ANOVA with Tukey’s post hoc test, 
there was no significant difference found when comparing the mean of any group, to the mean 
of every other group, at either timepoint. A difference was noted between OC and non-OC 









A comparison between the level of hsCRP and DPelvicPM  
A two-tailed, non-parametric Spearman’s correlation computing r for X, versus every Y 
dataset, and linear regression analysis was used to investigate the relationship between 
hsCRP levels and DPelvicPM (Figure 4.3). No statistically significance difference was found 
when comparing the relationship between DPelvicPM and hsCRP levels on Day 1-2 (no OC; 
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A two-tailed, non-parametric Spearman’s correlation, computing r for X versus every Y dataset 
and linear regression was used to investigate the relationship between hsCRP and EC50 for 
participants with pain, without pain, or the combined participant cohort (Figure 4.4). No 
statistical significance was found when comparing the relationship between EC50 and hsCRP 
levels on days 1-2 (pain; r= 0.06761, p = 0.7131, no pain; r = -0.08455, p = 0.7013, combined; 
r = -0.008018, p = 0.9537) or days 7-10 (pain; r= 0.03677, p = 0.8417, no pain; r = -0.3806, p 
= 0.0732, combined; r = -0.1397, p = 0.3092) of their menstural cycle. While the correlation 
between CRP levels and EC50 was not found to be significant, there was a trend towards 
significance in women without pain on Day 7-10 (p=0.0732). This trend describes an increased 
EC50, where a lower responsiveness of PBMCs to TLR4 stimulation represents reduced 
activation of the innate immune system, in women with lower levels of hsCRP.  
 
Figure 4.4: CRP levels for each individual either experiencing (purple) or not experiencing 
(green) pain during their menstral cycle versus EC50. Solid lines represent the linear 





Hypothesis 1, that increasing levels of hsCRP correlate with an increasing DPelvicPM and 
can thus act as a clinical biomarker for the lived experience of pain was not confirmed. This 
finding is in contrast to the findings of Gold et al. (2016), who found a relationship between 
premenstrual symptoms and hsCRP in an older cohort of patients aged between 42 and 52 
years, but is consistent with the findings of Mu et al. (2018) who found no correlation between 
the levels of hsCRP and the presence of endometriosis. 
 
Hypothesis 2, that increasing levels of hsCRP correlate with an increased responsiveness of 
PBMCs to TLR stimulation (lower EC50) in young women with dysmenorrhoea-related pelvic 
pain, was not confirmed. Studies into the regulation of CRP have established that interleukin-
6 (IL-6) is the  principal inducer of the CRP gene, while IL-1β, glucocorticoids and complement 
activation products synergise this effect (Ganter et al., 1989; Majello et al., 1990). As IL-6 is 
an important component of the inflammatory cascade, our research suggests that additional 
non-inflammatory mechanisms play a role in hsCRP levels.   
 
Our study found that levels of hsCRP are increased by use of the OC in this cohort of young 
women with or without dysmenorrhoea-related pelvic pain. This finding is consistent with 
current literature. Buchbinder et al. (2008) measured hsCRP levels in a group of 412 
unselected female blood donors, and found that the 97th percentile for CRP levels was 7.52 
mg/L for non-users of the OC, and 11.95 mg/L in OC users. Donors were not stratified 
according to the reason for use, or non-use, of the OC.  Divani et al. (2015) investigated the 
effect of OC use in 59 young women using a panel of inflammatory markers, including hsCRP, 
monocyte chemotactic protein-1, soluble tumor necrosis factor (sTNF), interleukin-6 (IL-6), 
and soluble CD40 ligand. This study found significantly more women with levels of hsCRP>3 
among OC users (p < 0.0001), compared to nonusers. However, their small sample size was 
unable to determine a relationship between hsCRP and other inflammatory markers. 
 
A study of 389 post-menopausal women who were either users, or non-users, of hormone 
replacement therapy (HRT), found that while use of hormonal replacement therapy was 
associated with an increase in CRP, it was also associated with reduced levels of other 
inflammatory markers, including vascular cell adhesion molecule-1 plasma E-selectin (17.8 vs 
14.8 ng/mL, p<0.01), interleukin-6 (1.51 vs 1.29 pg/mL, p<0.01), and s-thrombomodulin 
plasma (4.8 to 4.3 ng/mL p<0.01). They concluded that the discrepancy between increased 
plasma levels of hsCRP, and reduced plasma levels of other inflammatory markers, suggests 
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that the increased hsCRP found in HRT users is due to metabolic hepatic activation, rather 
than an acute-phase response (Silvestri et al., 2003).  
 
Women use the OC for a wide range of purposes: contraception, menstrual suppression, acne 
management, and the treatment of pain. It is possible that the increased hsCRP in women 




The higher levels of hsCRP among women using the combined oral contraceptive pill, already 
reported within the literature, was confirmed. Our research does not support the use of hsCRP 
as a biomarker for pain in this group of young women with dysmenorrhoea-related pelvic pain. 
In addition, our research does not support the use of hsCRP as a biomarker for inflammation 
in this group.   
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CHAPTER 5: DOES THE HORMONAL ENVIRONMENT AFFECT 
THE INNATE IMMUNE SYSTEM OR THE LIVED EXPERIENCE OF 
PAIN? 
 
It's so extraordinary that we female humans should be linked to the moon and the 
tides. It'd sound like science fiction if you made it up.  Mysterious planetary forces 
making us bleed. 




Chapter 2 found a high prevalence of additional symptoms, both within and outside the pelvis, 
in young women with dysmenorrhoea-related pelvic pain, suggestive of a systemic aetiology. 
Chapter 3 found evidence that increased activation of the innate immune system may provide 
a mechanism for this effect. Sections 1.5 and 1.6 described the interplay between hormonal 
factors, pain and the immune system.  
 
This chapter further interrogates the cohort of young women investigated in Chapter 3. It seeks 
to assess whether levels of sex steroid hormones, or cortisol, are associated with activation 
of the innate immune system, as measured by the responsiveness of PBMCs to TLR4 
stimulation. It also seeks to assess whether levels of sex steroid hormones, or cortisol, are 
associated with variation in the lived experience of pain symptoms, as measured by the days 
per month of pelvic pain (DPelvicPM), the days per month of period pain (DPeriodPM), or the 
days per month of headache (DHeadachePM). In particular it investigates whether the levels 
of androgens, including testosterone, in women may either protect or predispose an individual 
to pain symptoms. 
 
The evidence that hormonal levels influence pain perception in women has been outlined 
previously (Section 1.5). This is consistent with research within the University of Adelaide  that  
found a relationship between estradiol levels and TLR4 activation in female rodents (Nicotra 
et al., 2014).  This chapter extends this investigation to human females with DRPP. It also 
further investigates the relationship between androgen levels and TLR4 activation in females 
with DRPP, an area not yet researched. If the optimal hormonal environment for pain reduction 
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without increased activation of the immune system can be determined, this would have direct 
translational importance to the clinical management of women with pain.  
 
The accurate assessment of androgen levels in women is hampered by the relatively low 
levels of androgens circulating in women, when compared to men for whom the tests were 
formulated. The most sensitive laboratory method for androgen assessment is liquid 
chromatography mass spectrometry (LC-MS) (Rosner et al., 2010). These tests are labour-
intensive and therefore of limited use in primary health, where radioimmunoassay or direct 
chemiluminescent immunoassay techniques are commonly used. Our research uses high 
sensitivity liquid chromatography, mass spectrometry (LC-MS) across a range of 11 steroid 
hormones, and cortisol, analysed as a single batch, across two phases of the menstrual cycle. 
The clinical variables chosen (DPelvicPM, DPeriodPM and DHeadachePM) are quantifiable, 
and easily assessed during clinical assessment. They do not require laboratory testing, and 
are therefore appropriate for the low-resource, primary care, setting. As not all migraine 
headaches are classic in symptomatology, and the accurate diagnosis of migraine was not 




Chapter 5 seeks to investigates whether the hormonal environment is associated with the 
subjective experience of pain symptoms, or the responsiveness of PBMCs to LPS stimulation.  
It has three aims: 
 
Aim 1: To further clinical understanding of the effect of the steroid hormone blood profile on 
the subjective experience of dysmenorrhoea-related pelvic pain at two stages of the menstrual 
cycle. This information has direct translational application to the choice of hormonal therapies 
offered by clinicians to girls and women with pain.  
 
Aim 2: To further clinical understanding of the relationship between the steroid hormone blood 
profile, and the degree of immune activation at two stages of the menstrual cycle.  
 
Aim 3: To determine which measurement of androgen activity correlates best with the 







This chapter investigates three hypotheses: 
 
Hypothesis 1: That the hormonal profile of an individual is associated with the days per month 
of pain experienced. 
 
Hypothesis 2: That the hormonal profile of an individual is associated with the responsiveness 
of PBMCs to TLR4 stimulation, as measured by the EC50 for IL-1β release. 
 
Hypothesis 3: That the Free Androgen Index (FAI) provides a simple and useful test for 
assessing androgen activity in women. 
 
This chapter introduces the manuscript entitled “The Relationship between Androgens and 
Days per Month of Period Pain, Pelvic Pain, Headache, and TLR4 responsiveness of 
Peripheral Blood Mononuclear Cells in Young Women with Dysmenorrhoea” which has been 
submitted for publication in the Journal of Pain Research.  
 
5.4 MANUSCRIPT AND STATEMENT OF AUTHORSHIP 
 
The study was part funded by a grant from the Anaesthesia and Pain Medicine Foundation of 
the Australia and New Zealand College of Anaesthetists. 
 
The following manuscript was accepted for publication to the Journal of Pain Research on 
12th January 2021:  
 
The Relationship between Androgens and Days per Month of 
Period Pain, Pelvic Pain, Headache, and TLR4 responsiveness of 
Peripheral Blood Mononuclear Cells in Young Women with 
Dysmenorrhoea 
 
All authors gave final approval of the version to be published, and agree to be accountable 
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Purpose: Women bear a disproportionate burden of persistent pain conditions when 
compared to men. To determine whether the hormonal environment affects the clinical 
experience of pain, as measured by the days per month of pelvic pain (DPelvicPM), period 
pain (DPeriodPM), headache (DHeadachePM) or the in vitro EC50 for Interleukin-1β –1β) 
release following TLR4 stimulation with Lipopolysaccharide from Peripheral Blood 
Mononuclear Cells (PBMCs). Findings were stratified according to use or non-use of the oral 
contraceptive pill.  
 
Patients and methods: Fifty-six women aged 16-35 years, with minimal or severe 
dysmenorrhea, and use or non-use of the OC, were enrolled. Blood was collected on two 
occasions in a single menstrual cycle: Day 1-2 and Day 7-10. Hormonal analysis for 
testosterone, dehydrotestosterone, dehydroepiandrosterone, ndrostenedione, α-
ndrostanediol, β-androstanediol, estradiol, estrone, 1 α-hydroxyprogesterone, 
progesterone, cortisol and sex-hormone binding globulin was undertaken using ultra-sensitive 
Liquid Chromatography Mass Spectrometry (LC-MS).  PBMCs were exposed to 
lipopolysaccharide (LPS) and the resulting Interleukin-1β output was determined.  
 
Results: Non-users of the OC showed a strongly inverse correlation between a reducing free 
androgen index (FAI) and increasing DPelvicPM (p=0.0032), DPeriodPM (p=0.013), 
DHeadachePM (p=0.041) on Day 1-2. Non-users of the OC showed a significant increase in 
DPelvicPM (p=0.049) with increasing estradiol on on Day 7-10. Modestly significant 
associations were found between reduced androgens and potentiated LPS-induced IL–1β 
(lower EC50). 
 
Conclusion: This is the first study to investigate the relationship between the hormonal 
environment and activation of the immune system in young women with dysmenorrhoea-
related pain conditions. Low androgen levels were consistently associated with increased 
pain. Translational implications for the findings are discussed.  
 
Keywords: Pain, testosterone, oral contraceptive pill, dysmenorrhoea, pelvic pain, IL-1β 
 
Funding: The study was part funded by the Australia New Zealand College of Anaesthetists 





Women bear a disproportionate burden of pain compared with men across the majority of pain 
conditions (1), and ample evidence suggests a role for both the hormonal and immune 
environment in the development of female pain. Before puberty, the prevalence of chronic 
pain conditions is approximately equal in boys and girls (2).  However, girls are over-
represented by the age of 12-14 years, with the presence of persistent pain correlating more 
closely with the stage of pubertal development than with age (3). A major contributor to the 
disparity in chronic pain between girls and boys is the presence of dysmenorrhea and 
abdominal pain (4).  Dysmenorrhea frequently predates (5), and is believed to be an etiological 
factor in, the development of chronic pelvic pain in women (6).  
 
Compelling epidemiological, clinical and experimental evidence in both human and animal 
studies demonstrates that increased peripheral and central nervous system immune system 
activity, via Toll-Like Receptors (TLRs), is involved in the initiation and maintenance of chronic 
pain conditions (7–9). Our group has already demonstrated that immune pathology, including 
an increase in TLR4 responsiveness, is present in women affected by dysmenorrhea-related 
pelvic pain (10). 
 
Toll-like receptors are pattern-recognition receptors on the surface of cells which recognise 
molecular patterns typically associated with microbial pathogens, and which respond by the 
release of cytokines including Interleukin-1β (IL-1β) that promote inflammation. 
Lipopolysaccharide (LPS) within the cell wall of gram-negative bacteria is a potent agonist of 
TLR4, an antigen on immune cells including mononuclear cells in the peripheral blood, and 
glial cells within the brain and spinal cord. Altered TLR inflammatory responses have already 
been demonstrated in visceral medical conditions characterized by persistent pain, such as 
inflammatory bowel disease and painful bladder syndrome (11,12).  
 
In our previously published work (10), peripheral blood from women with dysmenorrhea-
related pelvic pain showed significantly enhanced IL-1β release from peripheral blood 
mononuclear cells (PBMCs) following in vitro TLR4 stimulation with lipopolysaccharide, when 
compared with pain-free controls. The present study further investigates this cohort of women 
to determine whether the hormonal environment affects the degree of TLR4-induced immune 
activation, or the experience of pelvic pain.  
 
In this study, Immune system TLR4-dependent reactivity is measured by determining the dose 
of LPS required to achieve 50% of maximal IL-1β release response E 50) from peripheral 
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blood mononuclear cells (PBMCs). Correlations between the levels of individual steroid 
hormones and cortisol with the DPeriodPM, the DPelvicPM, and the days of headache per 
month (DHeadachePM), allow an objective assessment of the relationship between hormone 
levels and the subjective experience of pain. Correlations between the levels of individual 
steroid hormones with the EC50 allow an assessment of the relationship between hormone 
levels and the degree of immune system activation. The self-reported number of days of period 
(DPeriodPM) or pelvic pain per month (DPelvicPM), is used as an indicator of pelvic pain 
severity.  
 
We investigate the hypothesis that androgens may be protective against the development of 
chronic pain conditions in women, and discuss the potential role of androgens as a treatment 





This is an observational clinical and laboratory study further extending analysis of the patient 
cohort reported by Evans et al.,(10) and approved by the Human Research Ethics Committee 
of the Royal Adelaide Hospital, Adelaide, South Australia. HREC/14/RAH/63. RAH Approval 
No. 140217. The study was conducted in accordance with the Declaration of Helsinki (13). All 
participants below the age of 18 were interviewed in the presence of a parent or guardian.  
 
Participants 
The target population consisted of girls and women aged between 16 and 35 years with either 
minimal, or severe, dysmenorrhea. Participants with minimal dysmenorrhea had self-reported 
pain of between 0-3 on an 11-point numerical scale (14) on the worst day of their menstrual 
period. At the screening visit, participants with severe dysmenorrhea had self-reported pain of 
between 7-10 on the 11-point numerical scale on the worst day of their menstrual period. 
Participants were further separated according to use or non-use of the oral contraceptive pill 
(OC). Potential participants were identified either when they responded to recruitment notices 
displayed to the general public, which provided a link to an anonymous Survey Monkey 
questionnaire, or through a private clinic, Pelvic Pain SA. Eligible participants from the general 
public were offered the opportunity of an initial phone interview to provide further information 
about the study, to obtain consent for further participation in the study, and to arrange a 
screening assessment visit with the Principal Investigator (PI). Figure 1 shows the Enrolment 




Globulin (SHBG) (Healthscope Laboratories, Adelaide, Australia) to allow later calculation of 
the Free Androgen Index (FAI) and Free Estrogen Index (FEI); and an extended hormonal 
profile analysed as a single batch, using ultra-sensitive Liquid Chromatography Mass 
Spectrometry (LC-MS) (Anzac Research Institute, Sydney, Australia). The hormonal 
analysis included measurement of testosterone (T), dihydrotestosterone (DHT), 
dehydroepiandrosterone (DHEA), androstenedione (adione), α-androstanediol (3αdiol), β-
androstanediol βdiol), estradiol E2), estrone E1), 1 α-hydroxyprogesterone (17OHP4), 
progesterone (P4) and cortisol (C). Measurements for T, DHT, DHEA, adione, 3αdiol, βdiol, 
17OHP4, P4 and C are measured in ng/ml. Measurements for E2 and E1 are in pg/ml. Our 
use of high-sensitivity liquid chromatography mass spectrometry (LCMS) steroid hormonal 
assays overcomes difficulties in androgen research in women associated with the low levels 
of androgens present in women compared to men. Hormonal analysis on both Day 1-2 
(menstrual phase) and Day 7-10 (mid follicular phase) of a single menstrual cycle allows 
estimates of within-subject variability to be distinguished from between-subject and assay 
variability.  
 
The IL-1β release from PMBCs across a range of concentrations of lipopolysaccharide 
stimulation of TLR4 receptors was used as a measure of TLR4 immune activation (Figure 2), 
and was determined using the technique developed by Kwok (15,16) and published in detail 





Figure 2. IL-1β release ean ± SEM) following LPS (TLR4) stimulation (12.5pg·mL to 
10µg·mL) of PBMC’s obtained from controls: no OC (red circle, solid line), controls: OC (blue 
square, solid line), dysmenorrhea: no OC (red triangle, dotted line), dysmenorrhea: OC (blue 
upside down triangle, dotted line), pelvic pain: no OC (red diamond, dashed line), and pelvic 
pain: OC (blue cross, dashed line). A four-parameter logistic dose-response curve has been 

















Determination of EC50 
Immune system TLR4-dependent reactivity is measured by determining the dose of LPS 
required to achieve a 50% of maximal IL-1β release response E 50) from peripheral blood 
mononuclear cells (PBMCs). Statistical modelling and a non-linear mixed-effects model 
approach was used to estimate the EC50 for each subject, at each testing timepoint (10). 
Concentration - response curves to LPS stimulation were fitted to an Emax model using the 
Hill equation (17), with the slope parameter fixed to 1 to reduce the number of parameters to 
be estimated. The model used was of the form: 




where E0 is the response Y at baseline (absence of dose), Emax is the asymptotic maximum 
dose effect (maximum effect attributable to the drug) and EC50 is the concentration which 
produces 50% of the maximal effect. Individual Emax models were fitted for each subject at 
each timepoint (Day 1-2 or Day 7-10).  
All model fitting and all analyses were performed using Statistical Analysis Software (SAS v 
9.4). Starting values were set with Max representing the maximum response observed for 
that participant at that timepoint, and Min representing the minimum response for that 
participant at that timepoint. From the model the differences in LS means for contrasts of 
interest were obtained with 95% confidence limits and relevant P-values by factor. The 
statistical analysis used is further described in our previous paper by Evans et al. (10). 
A lower EC50 represents increased responsiveness of PBMCs to stimulation with LPS, a proxy 
measurement for increased immune system activation. A higher EC50 represents reduced 
responsiveness of PBMCs and reduced negative regulatory pressure and/or controls.  
 
Determination of Free Androgen Index and Free Estrogen Index 
The FAI was determined according to the formula: FAI = 100*testosterone/shbg 
The FEI was determined according to the formula: FEI = 100*estradiol/shbg 
 
Statistical Comparisons 
Two-tailed non-parametric Spearman’s correlations were undertaken to determine the p-value 
and Spearman’s Rank Correlation Coefficient (r).  Correlations were made between the levels 
of individual hormones, cortisol, the FAI, and the FEI, with the days per month of pelvic pain 
(DPelvicPM), period pain, (DPeriodPM), headache (DHeadachePM), and the EC50  for IL-1β 
release from PBMCs (Tables 1, 2, 3 and 4). Results were reported according to the use or 





Three hundred and sixty women completed the online Survey Monkey questionnaire. 
Following application of the exclusion criteria, 65 women were enrolled in the study. Nine 
women were excluded during the study due to a high pre-test level of C-reactive protein (1), 
use of marijuana (1), irregular menstrual cycles (3), non-attendance for testing (2), 
insufficiently severe pain (1), and development of an unrelated neurological illness (1). Fifty-
six women aged between 16 and 35 years, with regular menstrual cycles, no previous 
pregnancy, normal body mass index (BMI) and good general health, apart from the presence 
of dysmenorrhea-related pelvic pain, completed the study. There were no differences in age 
(p=0.52), height (p=0.52) or weight (p=0.68) of the women in each group (one-way ANOVA 
and Kruskal-Wallis analysis). 
 
Comparisons between hormonal levels and variables 
Multiple correlations were made between hormone levels, pain indices (DPelvicPM, 
DPeriodPM, DHeadachePM) and the EC50 for LPS-induced IL-1β release (EC50) 
 
 
Comparison between hormonal levels and Days of Pelvic Pain per Month (DPelvicPM) 
Day 1-2: Women who were non-users of the OC showed a significant inverse correlation 
between the DPelvicPM and levels of androstenedione (p=0.036), DHEA (p=0.0018) and FAI 
(p=0.0032) (Table 1, Figure 3). The combined cohort of all participants showed a significant 
inverse correlation between the DPelvicPM and levels of testosterone (p=0.021), DHEA 
(p=0.019) and FAI (p=0.0026).  
 
Day 7-10: Women who were non-users of the OC showed a significant inverse correlation 
between DPelvicPM and the FAI (p=0.0058). Women who were users of the OC showed a 
significant positive correlation between DPelvicPM and levels of estradiol (p=0.049) or the FEI 
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Comparison of hormone and cortisol levels between users or non-users of the OC  
A one-way ANOVA with Tukey’s post hoc test was used to compare hormone levels in women 
who were users or non-users of the OC on both Day 1-2 and Day 7-10 (Table 5). In women 
who use the OC, the pill taken on Day 1-2 contains lactose only (lactose pill days). The pill 
taken on Day 7-10 contains ethinylestradiol in combination with a synthetic progestogen 
(hormone pill days).  
 
Day 1-2: (lactose pill days) Use of the OC was associated with a significantly higher level of 
SHBG (p=0.0001) and cortisol (p=0.0001). Use of the OC was associated with a significantly 
lower level of DHEA (p=0.0043) and FAI (p=0.0013). There was no significant difference in 
testosterone, estradiol, or FEI. 
 
Day 7-10: (hormone pill days) Use of the OC was associated with a significantly higher level 
of SHBG (p=0.0001) and cortisol (p=0.0001). Use of the OC was associated with a 
significantly lower level of androstenedione (p=0.0019), DHEA (0.0281) and FAI (p=0.0001).  
There was no significant difference in testosterone, estradiol or FEI.  
 
The following hormones were present at levels too low for statistical analysis: estrone, 
progesterone, 17-hydroxyprogesterone, 3bdiol and estrone. Levels of DHT and 3alpha-
androstanediol were not significantly associated with alteration in either symptoms or the EC50.  
 
When considering these results overall, lower levels of androgenic hormones, and particularly 
the calculated Free Androgen Index, were inversely associated with increasing DPelvicPM, 
DPeriodPM, and DHeadachePM. Higher estradiol levels on Day 7-10 (pill days), particularly 
in OC users, were associated with an increase in the DPelvicPM, but not the DPeriodPM, 
DHeadachePM. or EC50. Weak associations were found between lower levels of androgen 
activity, and a lower EC50 consistent with a mildy enhanced immune responsiveness. Strong 
associations were found between cortisol levels and EC50 on Day 7-10 (pill days), with 






The association between hormone levels and pain symptoms 
Multiple lines of evidence (18,19) describe the excess of chronic pain conditions in females 
when compared to males. Pain research to date has predominantly considered ways in which 
the relative estrogen dominance in females may predispose females to chronic pain, as 
opposed to the ways in which the relative androgen dominance in males may protect males 
from these conditions. The physiological and potentially therapeutic roles of androgens in 
females has been under-researched. Our research found a highly significant inverse 
relationship between androgen levels, particularly a low FAI, and increasing pain symptoms, 
particularly in non-users of the OC. Oral contraceptive use results in both the suppression of 
testosterone production by the ovaries, and the induction of SHBG by the liver, with a 
consequently lower FAI (Figure 3).  
 
Multiple mechanisms of action in both the periphery and the central nervous system support 
an inverse relationship between testosterone levels and pain. Studies of male-to-female 
transgender patients show an increase in chronic pain conditions following hormonal transition 
from an androgenic to an estrogenic hormonal environment (20,21), while female-to-male 
transgender patients show an improvement in pre-existing pain conditions following the 
administration of testosterone. Our research found a highly significant association between 
androgen levels and pain symptoms, particularly in women who were non-users of the OC, 
where the ovarian production of testosterone is unsuppressed and the production of SHBG 
within the liver is not enhanced.  
 
In patients with Rheumatoid Arthritis, an inflammatory condition associated with reduced 
androgen levels in both males and females, there is increased production of proinflammatory 
cytokines within synovial cells (22). Within these cells, increased levels of IL-1β, tumour 
necrosis factor (TNF-α) and Interleukin-6 (IL-6) enhance the activity of aromatase (23), 
resulting in the increased conversion of testosterone to estradiol, increased levels of estrogen, 
and reduced levels of androgens (22,24–26). The disease-modifying effects of anti-TNF 
medications in patients with RA may act through the local enhancement of androgen activity 
(27).  
 
Previous human studies have demonstrated the central nature of dysmenorrhea-related pelvic 
pain, its relationship to viscero-visceral hyperalgesia, and its association with pain co-
morbidities including migraine (28–31). Within the dorsal horn of the spinal cord, it has been 
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proposed that androgens act in concert with estrogen to increase endogenous opioids 
following a nociceptive stimulus (32). White and Robinson proposed that a low testosterone 
level fails to induce sufficient endogenous opioids to dampen pain signals (33). Fibromyalgia, 
a centrally-mediated pain condition, is associated with reduced levels of androgens, and a 
strong association has been found between the days where symptoms were severe, and the 
days where testosterone levels were low (34). At the neuronal level, dihydrotestosterone, a 
metabolite of testosterone, provides neuroprotection against microglial inflammatory 
responses via suppression of TLR4, and inhibition of TNF-alpha and IL-1β production (35).  
Within the brain, Vincent et al. (36) found reduced activation of brain centres associated with 
descending pain inhibition, including the ventral rostral medulla, in healthy women with low 
androgen levels undergoing a cold thermal pain stimulus, despite no variation in the 
temperature required to induce pain.  
 
In contrast with the robust association with androgenic activity, our research found a modest 
correlation between estradiol levels on Day 7-10 and pain symptoms. Our findings are 
consistent with established clinical practice, where lower estrogen OCs or estrogen 
suppression is prescribed to reduce the frequency or volume of menstrual bleeding (37). The 
oral contraceptive pill has known effectiveness at the level of the uterus: reducing menstrual 
flow (38), and reducing prostaglandin release (39,40). It is yet to be determined whether the 
OC-induced androgen suppression and SHBG induction may have unintended negative 
effects on the development of central pain sensitization.  
 
The association between hormone levels and EC50 of LPS-induced IL-1β release from PBMCs 
Activation of the innate immune system via TLR4 is known to be involved in the initiation and 
maintenance of chronic pain (8,9,41,42), with activation showing as increased responsiveness 
of immune cells to TLR stimulation. Our group has already demonstrated an increased 
responsiveness of PBMCs to TLR4 activation with LPS within this group of women with 
dysmenorrhea-related pelvic pain, compared to pain-free controls (10). Our finding of a 
modest association between reduced androgen activity and a lower LPS-induced IL-1β EC50 
(increased immune activation) suggests that activation of the immune system via TLR4 
comprises one factor affecting pain symptoms, but that immune mechanisms outside the 
hormonal environment are also involved. It also suggests that the ability of hormonal 
manipulation to manage chronic pelvic pain is limited. Our study found no significant effect of 
estrogens on EC50.  This is consistent with the research of Bouman et al. (43) who found that 
neither estradiol nor progesterone influenced the release of cytokines from monocytes in 
humans. However, they did not assess the effect of androgens. 
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The association between cortisol and EC50 of LPS-induced IL-1β release from PBMCs 
Our finding of a highly significant association between increased levels of cortisol (a 
suppressor of inflammation) and an increased EC50 of LPS-induced IL-1β release (reduced 
activation of the innate immune system) in non-users of the OC is consistent with an 
inflammation-based model of chronic pain. The divergent effect in OC users, where higher 
levels of cortisol were associated with a lower EC50 of LPS-induced IL-1β release (increased 
activation of the innate immune system) is a potential cause for concern to health care 
providers, owing to the known association between immune activation and chronic pain. Our 
findings are consistent with those of Vincent et al. (44) who described a significantly lower 
mean level of cortisol in women with dysmenorrhea where all participants were non-users of 
the OC, suggesting an impairment of the immune response.  Use of the OC has already been 
associated with a reduced cortisol response to cold-pressor testing and emotional memory 
responses (45–47).  
 
Measurement of the FAI within clinical practice 
The majority of testosterone within the circulation is protein-bound to either SHBG or albumin, 
leaving a relatively small percentage of testosterone in its unbound, bioavailable state. While 
there are multiple cellular mechanisms involved, it is the unbound testosterone fraction which 
contributes maximally to its clinical effects. The Free Androgen Index (FAI) provides a simple 
and easily calculated estimate of androgen activity, requiring only a measurement of total 
testosterone and SHBG. FAI results are less reliable as an indicator of testosterone activity in 
populations where SHBG levels are below 30nmol/l, such as in males or women with 
Polycystic Ovarian Syndrome, obesity, or insulin resistance (48). For these reasons, the 
Calculated Free Testosterone (cFT) is preferred in some laboratories. The cFT incorporates 
albumin levels, and utilises the more complex Vermeulen Equation (49), to provide an 
estimate which more closely matches the results obtained by dynamic equilibrium testing in 
these groups. Our research excluded women with a BMI > 30, and women with irregular 




Our key research finding of an inverse association between androgen levels and pain 
symptoms, both within and outside the pelvis, offers a new approach to the management of 
pain in women. Multiple androgen-enhancing options are already available. Progestogen-only 
contraceptive users avoid the estrogen-induced rise in SHBG associated with combined OCs, 
and Máximo et al. (50) demonstrated that women using progestogen-only contraception have 
a higher pain threshold than women using the combined OC. Intrauterine contraceptive 
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devices maintain natural ovarian testosterone production by avoiding ovarian suppression, 
and their estrogen-induced rise in SHBG. When considering the further development of OC 
formulations, an optimal OC for a woman with pain might comprise an estrogen with minimal 
induction of SHBG, and a progestogen with minimal anti-androgen activity. Conservation of 
the ovaries at the time of hysterectomy maintains gonadal production of testosterone in 
women where post-surgical testosterone replacement is not anticipated (51).  
 
Testosterone therapy is recommended to reduce pain perception and fatigue in women with 
opioid-induced androgen deficiency (OPIAD) (52), and White et al. reduced tender points and 
stiffness in women with fibromyalgia by using testosterone gel (33). However, the role of 
androgen replacement in the absence of opioid use in women with low androgen levels and 
chronic pain is less established. Where levels of estrogen or progestogen are low, these are 
replaced to conserve bone density and prevent endometrial hyperplasia. The supplementation 
of testosterone to prevent fatigue, improve sexual function, or reduce chronic pain, anxiety 
and low mood, has been under-utilised. In women using hormonal replacement, the estrogen-
induced rise in SHBG may further reduce androgen activity through increased testosterone 
binding. Our study also raises potential concerns regarding the profound suppression of 
androgens associated with the use of gonadotrophin releasing hormone agonist or antagonist 
medications over prolonged periods of time in women with pain. 
 
Optimal testosterone levels for the reduction of pain have yet to be determined. Huang et al. 
(53) researched the effect of increasing doses of testosterone over 24 weeks in 
hysterectomized and oophorectomized women compared to placebo. They observed a 
significant dose response relationship between free testosterone levels and the Psychological 
General Well-Being Index (PGWBI) score, lean body mass, and stair climbing power when 
compared to placebo, but only where supra-physiological levels were achieved. Fasting 
glucose, lipid profile and liver function tests remained unchanged from baseline following 
testosterone administration, and did not differ according to dose. Their study considers the 
use of testosterone as a pharmacological treatment, rather than a physiological replacement. 
The future development of selective androgen receptor modulators (SARMs) offers the 
potential of androgen effect without the potential side effect of virilization. 
 
Our study raises substantial further research questions relating to the use of testosterone 
therapy to reduce pain or enhance quality-of-life in women with current endometriosis lesions. 
The aromatase-mediated conversion of testosterone to estradiol within endometriosis lesions 
has the potential to promote lesion growth. The optimal testosterone regime for these women, 
and the potential for testosterone to be used in combination with an aromatase inhibitor 
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medication to prevent the conversion of testosterone to estrogen (54), has yet to be fully 
explored.  
  
Our study has notable strengths, including the stringent exclusion criteria used, the lack of 
clinical co-morbidities or confounding medications in this young, healthy patient group, and 
the accurate measurement of steroid hormones at low levels, using liquid chromatography 
mass spectrometry methods in a single batch. Another strength is the sampling at 2 stages of 
a single menstrual cycle in each participant. A potential study weakness is the use of blood 
hormonal assays rather than tissue hormonal assays. As shown in the synovial fluid of patients 
with rheumatoid arthritis (55), or the intralesional fluid in women with endometriosis lesions, 
the enzyme aromatase allows a local hormonal concentration of estradiol that may be many 
times greater than blood levels (56). Another weakness is the heterogeneity of participants 
within the oral contraceptive group. This group includes participants using a range of different 





Our study provides new insights into the way the hormonal environment affects the experience 
of pain in women, using clinical variables that are readily determined in a primary care setting: 
the DPelvicPM, the DPeriodPM, and the DHeadachePM.  Of the tests undertaken in our cohort 
of young women with normal BMI and regular menstrual cycles, the FAI proved to be a 
consistent indicator of difference. 
Our findings support the concept that the female predominance of chronic pain relates more 
to the protection men receive from higher testosterone levels, than the risk women incur from 
higher estradiol levels. The potential for use of the OC to reduce menstrual symptoms, yet 
increase immune activation, with increased potential for the development of chronic pain, 
requires further research. If confirmed, this has widespread implications for the management 
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The research outlined in Chapter 5 supports a role for the hormonal environment, particularly 
androgens, in the subjective experience of pain.  
 
Hypothesis 1, that the hormonal profile of an individual is associated with variation in the days 
per month of pain experienced was confirmed. These findings were predominantly in women 
who were non-users of the OC, and thus experiencing their own natural ovarian hormonal 
cycles. They were also predominantly with regard to androgen, rather than estrogen activity. 
An increased number of DPelvicPM was inversely correlated with levels of androstenedione, 
DHEA and FAI on Day 1-2, and the FAI on Day 7-10. An increased number of DPeriodPM 
was inversely correlated with levels of androstenedione, DHEA and FAI on Day 1-2, and FAI 
on Day 7-10 in non-users of the OC. An increased number of DHeadachePM was inversely 
correlated with the FAI on Day 1-2 in users of the OC, and in the larger combined group on 
both Day 1-2 and Day 7-10.  These findings provide a potential novel management option for 
the reduction of pain symptoms in women: androgen supplementation.  
 
Our findings of an increase in pain symptoms with lower androgen levels is consistent with the 
study by Aloisi et al. (2007) which investigated pain symptoms in 47 male-to-female, and 26 
female-to-male, transgender patients 12 months following gender reassignment. Aloisi 
assessed the frequency of pain symptoms within individuals under both estrogen-dominant 
and androgen-dominant hormonal conditions. Fourteen of the 47 male-to-female participants 
(30%) reported the presence of a painful condition, which was not present prior to the initiation 
of estrogen hormonal therapy.  Sixteen of the 26 female-to-male participants (61%) reported 
a painful condition prior to the initiation of testosterone therapy, with 11 of these participants 
reporting an improvement in pain following hormonal transition to an androgen-dominant 
hormonal environment.  
 
Testosterone supplementation for the clinical management of fibromyalgia, a centrally-
mediated condition associated with widespread pain, has been investigated by White and 
Robinson (2015). They have proposed a potential mechanism for the association between low 
levels of androgens and pain symptoms. In healthy individuals, the release of Substance P by 
nociceptive neurons is increased following either a painful or stressful experience, resulting in 
reduced serotonin levels and impaired wellbeing. The raised Substance P stimulates 
aromatase within the central nervous system, with increased conversion of testosterone to 
estrogen, an estrogen-mediated upregulation of endogenous opioids, and a reduction in 
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symptoms (Figure 5.1.a). In patients with fibromyalgia, reduced levels of testosterone provide 
insufficient substrate for aromatase following the release of Substance P, resulting in 
inadequate levels of estradiol, reduced production of endogenous opioids, and the clinical 




Figure 5.1.a and 5.1.b: Hypothesised signaling pathway for testosterone in relation to 
nociception in the CNS (White & Robinson, 2015) 
 
The finding that testosterone supplementation can be utilised in the management of opioid 
overuse (O’Rourke & Wosnitzer, 2016; Smith & Elliott, 2012) further supports a central 
mechanism for testosterone effect, and an interaction with opioid mechanisms. Individuals 
who use regular opioids show lower basal testosterone levels than non-users (Abs et al., 2000; 
Finch, Roberts, Price, Hadlow, & Pullan, 2000; Malik, Khan, Jabbar, & Iqbal, 1992; Rasheed, 
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& Tareen, 1995), although whether low androgen levels precede, or follow, the use of regular 
opioids remains unclear.  
 
Hypothesis 2, that the hormonal profile of an individual is associated with changes in the 
responsiveness of PBMCs to TLR4 stimulation, as measured by the EC50 for IL-1β release 
remains inconclusive. A modest positive correlation between the EC50 and levels of 
androstenedione on Day 1-2 and testosterone on Day 7-10 was found in the combined group 
of participants. However, the lack of a clear outcome suggests that multiple mechanisms affect 
immune responsiveness. Androstenedione is a weak androgen, and a precursor for both 
estrone and testosterone. Our finding of complex results with unclear implications when 
considering the effect of steroid hormones on the innate immune response is consistent with 
the experience of other researchers. Hewagama et al. (2008), described both estrogen- and 
androgen-response elements on the promotor segments of innate immunity genes, including 
those affecting female T-cells suggesting a role for hormonal mechanisms in pain. However, 
Asai et al. (2001) found that females have fewer TLR4 receptors on PBMCs than males, and 
a lower level of TNF-α secretion following LPS stimulation, seemingly inconsistent with the 
known female preponderance in pain conditions. While this may suggest reduced activation 
of the immune system in females, Klein et al. (2016b) found higher CD4+ T cell counts, 
CD4/CD8 ratios and macrophage phagocytic activity in females than males. Bouman et al. 
(2005) proposed that estradiol has multiple and opposing effects on human immune cells: low 
doses increase the production of pro-inflammatory cytokines and induce a pro-inflammatory 
phenotype, whereas high concentrations reduce inflammatory cytokines and induce a low 
inflammatory phenotype. Asai (2001) postulated that estradiol modulates cytokine secretion 
in females, and that the mechanism behind the higher prevalence of pain in women involves 
non-circulatory mechanisms.  
 
Androgens have been clearly shown to reduce immune activation and reduce the production 
of cytokines in rodent studies. Rettew et al. (2008) demonstrated a reduction in TLR4 
expression, and reduced sensitivity to TLR4 stimulation in the macrophages of mice treated 
with testosterone. Benten et al. (2004) demonstrated that this testosterone-induced, down-
regulation of LPS signalling occurs via nongenomic Ca2+ signalling, providing a further 
complexity in the relationship between testosterone, TLR mechanisms and immunity. Yang et 
al. (2020) showed that DHT (a potent metabolite of testosterone) inhibited the production of 
prostaglandin E2 through the suppression of cyclo-oxygenase 2. DHT also inhibited the 
TLR4/NF-κB signaling pathway with a reduction in the production of proinflammatory factors 
including PGE2, TNF-α and -1β from microglial cells in the central nervous system. This 
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immune suppression with subsequent reduction in the formation of PGE2 provides a potential 
mechanism for our finding of an inverse relationship between the FAI and DPeriodPM.  
 
Hypothesis 3, that the FAI provides a clinically useful measure of androgen activity, inversely 
correlated with the presence of pain symptoms, was confirmed. The FAI is a simple laboratory 
test, suitable for clinical use in primary care provided that the SHBG level is above 30, and 
obesity is absent. Current clinical management of dysmenorrhoea and pelvic pain relies 
heavily on the manipulation of the steroid hormone profile to suppress menstruation from an 
early age (Harada et al., 2008; Larsson et al., 1992; Lindh & Milsom, 2013; Milsom et al., 
1990). This results in suppression of the FAI via a reduction in testosterone and an increase 
in SHBG. From the perspective of a patient, this effect may enhance their perceived benefits. 
For example, the suppression of androgens is associated with a reduction in acne, and a 
reduction in unwanted body hair (Fraser & Kovacs, 2003). However, while hormonal 
suppression of menstruation is effective at reducing the number of menses experienced, or 
the heaviness of menstrual flow, there exists the possibility that by reducing androgen activity, 
an individual may increase their risk of developing chronic pain conditions, including CPP.  
 
From the perspective of a primary care clinician, the knowledge that low androgen levels may 
contribute to an increase in pain symptoms is of immediate translational clinical importance. 
As outlined within the published article, multiple options currently exist to either maintain 







CHAPTER 6: ACTIVATION OF THE INNATE IMMUNE SYSTEM 
VIA TOLL-LIKE RECEPTOR4 AS A UNIFYING HYPOTHESIS 
FOR DYSMENORRHOEA, CHRONIC PELVIC PAIN AND 
ENDOMETRIOSIS 
 
“One of the greatest pains to human nature is the pain of a new idea” 
Walter Bagehot, Physics and Politics, 1869 
 
In view of the shared features of association with menstruation, co-occurrence in time and 
symptomatology, and activation of TLR4 and the innate immune system, this thesis puts 
forward a new theory for the relationship between dysmenorrhoea, CPP and endometriosis. 
It is proposed that these conditions be considered as three phenotypic variants, arising from 
a common underlying mechanism (Figure 6.1). Our research proposes that this underlying 
mechanism involves the activation of Toll-Like Receptors within the uterus, with symptoms 
presenting clinically once hormone levels rise at puberty.  
 
With regard to dysmenorrhoea, it is proposed that pre-menarchal activation of TLR4 primes 
an individual to experience dysmenorrhoea once menstruation begins, through the TLR4-
mediated stimulation of cyclo-oxygenase-2 and consequent PGE2 production. PGE2 results 
in increased myometrial contraction with an increase in menstrual pain. A pre-menarchal 
timing for the activation of TLR4 is consistent with the onset of dysmenorrhoea soon after 
menstruation begins, and the pain symptoms experienced by a proportion of girls before 
menarche. 
 
With regard to CPP, it is proposed that intrauterine TLR4 activation within the uterus results 
in an increase in local cytokines, including IL-1β, IL-6 and TNF-α. This has two effects. Firstly, 
local cytokines sensitise nociceptors associated with sensory afferent neural pathways as 
described in Figure 1.21. This results in the activation of spinal glia and the transition from 
dysmenorrhoea to CPP, and is consistent with the research by Kwok et al (2014) in a rodent 
model. The shared spinal segments involved and the potential for antidromic inflammatory 
processes provide an explanation for the clustering of bowel and bladder symptoms with 
dysmenorrhoea described in Chapter 2. The activation of glial cells within the spinal cord 
provides a potential explanation for the presence of systemic symptoms such as headache, 






Secondly, local cytokines within the uterus activate circulating immune cells, including 
PBMCs, increasing their responsiveness to further TLR4 stimulation. This is consistent with 
our findings in Chapter 3. The free flow of activated immune cells from the circulation to the 
brain and spinal cord further enhances sensitisation of the central nervous system. Regular 
menstrual cycles result in repeated episodes of immune activation, and the progression from 
dysmenorrhoea to CPP. This is consistent with the research by Hardi et al., describing the 
transition from dysmenorrhoea to CPP in women over time. Factors known to modify the 
immune response, including higher levels of androgens, modify the pain experience of 
individuals, as outlined in Chapter 5.  
 
With regard to the formation of endometriosis lesions, it is proposed that a TLR4-mediated 
impairment of macrophage function results in the reduced clearance of menstrual debris 
following retrograde menstruation. This facilitates endometriosis lesion formation. Lesion 
development may be further enhanced by the antidromic spread of central inflammatory 
processes via neuronal pathways. A pre-menarchal timing for the activation of TLR4 is 
consistent with Marsh and Laufer’s (2005) finding of endometriosis lesions in a proportion of 
pre-pubertal girls with pain.  
 
Although not addressed in this thesis, TLR4 activation within the uterus with the consequent 
increase in local inflammation, may also contribute to the known association between the 
presence of endometriosis, and an increased risk of infertility and miscarriage (Pallacks et al., 
2017). 
 
The Unifying Theory offers a distinct change from the current concept of endometriosis lesions 
as the major causative factor for pain symptoms (Figure 6.2), which is rejected by the findings 
of this thesis. From a clinical perspective, endometriosis lesions become a common, but non-
essential, feature of Dysmenorrhoea-Related Pelvic Pain Syndrome (DRPPS), and DRPPS 
assumes an umbrella role for the cluster of symptoms and conditions commonly experienced 
by women with DRPP. In this way the relationship between endometriosis and DRPPS may 
be likened to the relationship between polycystic ovaries and Polycystic Ovarian Syndrome 
(PCOS). While polycystic ovaries were initially considered to be a purely ovarian condition 
(Evans & Riley, 1958), PCOS now includes symptoms as diverse as hyperlipidaemia, insulin 
resistance, hirsuitism, and acne. The symptoms of PCOS cluster together, and polycystic 
ovaries are frequently found, but the presence of cystic ovaries is no longer essential for the 
diagnosis (Kauffman et al., 2008). 
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Our theory easily encompasses the wide range of symptoms found in clinical practice, and 
therefore has direct, translational, clinical relevance. It explains the situation where pelvic pain 
is severe, yet endometriosis lesions are minimal or absent, where pain is minimal, yet 
endometriosis lesions are widespread, and where pain persists following the surgical removal 
of endometriosis lesions. Individuals may vary in their phenotypic presentation depending on 
the relative contribution of each of the three pathways described (Figure 6.1).  
 
Evolution reduces the frequency of disadvantageous genetic human traits, particularly those 
with potential to reduce fertility, such as endometriosis. That these conditions remain frequent 
in women throughout the world, suggests that a genetic predisposition to these conditions 
confers certain survival benefits. A reduced mortality from infectious disease, including post-
partum sepsis, associated with an enhanced immune response, offers such an advantage. 
However, this survival advantage comes at the price of increased auto-immune disease and 
increased chronic pain. In previous generations, the disadvantages of enhanced intrauterine 
activation of the immune system were modified by a later menarche, early and multiple 
pregnancies, and thus fewer lifetime menses. Additional environmental factors associated with 
the modern era, offer an additional mechanism for increased TLR4 stimulation.   
 
This thesis has taken the first steps towards developing and investigating a novel and 






CHAPTER 7. FUTURE DIRECTIONS 
 
 
This thesis has progressed the evidence for an entirely new theory for the relationship between 
dysmenorrhoea, chronic pelvic pain and endometriosis. It has taken the first steps towards 
establishing a role for TLR4 in the initiation and experience of dysmenorrhoea and CPP.  
 
7.1 RECOMMENDED TOPICS FOR FUTURE STUDY 
 
Female visceral pain remains an under-researched area with regard to its human impact. 
Multiple potential further lines of research arose while conducting this research. The following 
topics comprise areas of particular interest for future research.  
 
7.1.1 DETERMINATION OF THE AGE AT WHICH PRIMING OF THE INNATE IMMUNE 
SYSTEM OCCURS IN FEMALES.   
 
Early life events are known to affect the developing brain (Stolp et al., 2005). An association 
between exposure to adverse early life events, including infections, and the subsequent 
development of neuropsychiatric conditions, including pain, anxiety and depression, has been 
demonstrated in animal and human models (Benmhammed et al., 2019; Giridharan et al., 
2019; Kannampalli et al., 2017; Liu et al., 2017; Palma et al., 2016; Schwarz et al., 2011). 
There exists the potential for early life events, potentially even pre-birth, to predispose to 
dysmenorrhoea, chronic pelvic pain or endometriosis, by providing a priming event that 
sensitises the individual to future pain when an appropriate stimulus such as the onset of 
menstruation occurs.  
 
7.1.2 THE ROLE OF GENETIC TLR4 POLYMORPHISMS IN PREDISPOSING FEMALES 
TO DYSMENORRHOEA, CPP OR ENDOMETRIOSIS. 
  
TLR polymorphisms are common around the world. Genetic variants are already associated 
with reduced steroid responsiveness (Kim et al., 2020), and a range of other medical 
conditions (Ferwerda et al., 2008; Figueroa et al., 2012; Koval et al., 2018; Pirahmadi et al., 
2013; Sharma et al., 2016; Sharma et al., 2019; Singh et al., 2015; Vijay, 2018; Witte et al., 
2014). An association between TLR4 polymorphism with endometriosis has been 
demonstrated (Latha et al., 2011), but the relationship with dysmenorrhoea and CPP 
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remains to be determined. Where an association between TLR4 polymorphisms and female 
visceral pain is found, do these polymorphisms affect uterine immune activation, the 
responsiveness PBMCs to LPS stimulation, or the activation of spinal glial cells? 
 
7.1.3 THE ROLE OF OTHER TOLL-LIKE RECEPTORS IN FEMALE PAIN 
 
Each Toll-Like Receptor responds to a unique ligand, as described in Figure 1.15. TLR4, the 
classical TLR researched in human pathology, is but one of the TLRs capable of immune 
activation in humans. Recent research has showcased the potential importance of non-TLR4 
mechanisms. For example, plasmacytoid dendritic cells produce Type 1 Interferons (IFN-α β) 
following the activation of TLR7 and TLR9 by viral nucleic acid (Seillet et al., 2012b). A viral 
ligand, present at an early life stage, is a potential contender for immune priming in girls. Seillet 
demonstrated an increased TLR7 response in female mice when compared to male mice, and 
in post-menopausal women treated with estradiol, demonstrating both gendered and 
hormonal influences worthy of further investigation. Inhibitors of TLR8 reduce TNF-α 
production within the synovial cells of patients with rheumatoid arthritis (Sacre et al., 2008).  
  
7.1.4 THE ROLE OF DENDRITIC CELLS WITHIN THE UTERUS AS ANTIGEN-
PRESENTING CELLS 
 
Intrauterine immune activation relies on the effective presentation of microbial elements to T-
cells. Dendritic cells are a component of the innate immune system, and well placed to 
efficiently enhance the immune stimulus, through their ability to attach to bacterial particles, 
and presented them appropriately to T cells (Ueno et al., 2007). An understanding of the 
intrauterine factors affecting dendritic cell function offers potential for the development of 
novel, intrauterine, translational, immune-modulating treatment options.  
 
7.1.5 THE ROLE OF EOSINOPHILS IN FEMALE INFLAMMATORY PAIN 
 
All TLRs, except TLR8, are expressed to a variable degree by eosinophils (Kvarnhammar & 
Cardell, 2012), and bronchial asthma is more frequent among women with endometriosis 
(Sinaii et al., 2002; Smorgick et al., 2013). Recent evidence has determined that TLR4 
activation of eosinophils promotes an inflammatory phenotype (Yoon et al., 2019), providing 
an alternative TLR-mediated mechanism for female pain, and a further translational 
mechanism for novel immune-modifying therapies.  
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7.1.6 THE RELATIVE ROLE OF CIRCULATORY IMMUNE CELL ACTIVATION, VERSUS 
INTRAUTERINE SENSORY NEURON ACTIVATION IN TLR-MEDIATED FEMALE 
VISCERAL PAIN.  
 
Our research investigated the immune response of PBMCs. However, the activation of 
spinal glia may also occur through the TLR4-mediated activation of sensory afferent 
neurons. As shown in Figure 1.11 and Figure 1.21, sensory afferents from the uterus 
converge on the dorsal horn. This provides a mechanism for spinal glial activation that 
bypasses the circulation. Research to determine the relative importance of these activation 
mechanisms in female visceral pain would allow targeting of translational treatment options.  
 
7.1.7 FURTHER ELUCIDATION OF THE OPTIMAL HORMONAL ENVIRONMENT TO 
PREVENT THE TRANSITION FROM DYSMENORRHOEA TO CPP, AND THE 
DEVELOPMENT OF ENDOMETRIOSIS IN GIRLS 
 
Our research has found a significant association between reduced androgen activity, as 
measured by the FAI, and increased pain symptoms. Consistent with current literature, the 
most commonly used treatment for dysmenorrhoea, the OC, influences the FAI through an 
increase in SHBG, and influences androgen levels directly through ovarian and adrenal 
suppression. As such, use of the OC in young women may have both advantages, (reduced 
frequency of menses when used continuously) and disadvantages (increased innate immune 
activation, and the potential for increased prevalence of chronic pain). A longitudinal 
observational study following girls from puberty, or before, and determining the treatments 
undertaken, and the frequency of later chronic pelvic pain, would be optimal. That such 
studies, for a condition affecting 1 in 5 women, have not already been undertaken is testament 
to the lack of research attention that this area of health care has received.  
 
7.1.8 ENVIRONMENTAL FACTORS, INCLUDING DIET AND ENVIRONMENTAL TOXINS, 
THAT INFLUENCE IMMUNE ACTIVATION IN FEMALES.  
 
Section 1.6.3 outlined dietary and environmental factors that may influence immune 
activation. Many of these factors are a feature of modern life. Martinez-Garcia et al. 
demonstrated that fasting and dietary lipids affect the expression of TLR2 and TLR4 on 
circulating white blood cells, and the release of IL-1β following  stimulation (Martínez-
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García et al., 2020). Our research did not prescribe specific dietary preparation prior to blood 
sampling, potentially affecting research results. Future studies would benefit from recording 
the fasting status, and pre-test diet of participants. The determination of lifestyle factors 
affecting TLR expression, also provide a potential avenue for the reduction of inflammation 
in primary care, or low-resource settings.  
 
7.1.9 THE RELATIONSHIP BETWEEN CLINICAL SYMPTOM PHENOTYPES, TLR4 
RESPONSE AND HORMONE LEVELS 
 
Further investigation of this relationship would provide additional guidance to health 




7.2 CONCLUDING STATEMENT 
 
With little research into chronic pelvic pain (CPP) worldwide, current management occurs in a 
vacuum of knowledge few areas of medicine would accept. Such research neglect provides 
multiple opportunities for innovation in diagnosis and clinical management. This thesis has 
provided new insight into the under-researched condition, dysmenorrhoea-related pelvic pain. 
It has proposed a novel theory that is consistent with the full range of symptoms and 
presentations found in clinical practice.  
 
The development of the Unifying Theory began with investigating the lived experience of 
women affected by DRPP, and investigating the range of symptoms reported. This confirmed 
the inconsistent association between specific symptoms and a lifetime diagnosis of 
endometriosis, and introduced the concept of Dysmenorrhoea-Related Pelvic Pain Syndrome. 
This suggested the existance of a systemic, rather than purely pelvic, mechanism for pain.  
 
Evidence for activation of TLR4 and the innate immune system as a mechanism for the 
systemic syndrome was then sought, with the finding of increased responsiveness of PBMCs 
to TLR4 stimulation in women with pain, when compared. This built on the preclinical research 
by Kwok et al. (2012, 2014) demonstrating that an increased responsiveness of PBMCs 
mirrored TLR4-mediated activation of glia within the spinal cord.  
 
Chapter 5 demonstrated that a factor known to modify immune activation (higher levels of 
androgens), moderated pain symptoms experienced by women with DRPPS.  
 
This thesis opens a new door to potential clinical management options for women with pain.  
With an at-risk patient population (teens with severe dysmenorrhoea) easily identified at an 
early stage of their pain condition, novel treatments that target inflammation in young women 
have the potential for the secondary prevention of CPP. As such, immune modulation offers 
the potential for CPP to become one of the few areas of human chronic pain where prevention 
is a realistic goal. If this can be achieved, the improved management of dysmenorrhoea-
related pelvic pain has the potential to alter quality-of-life outcomes for women, and health 
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